Therapeutic RNA and therapeutic RNA-loaded nanoparticle compositions, methods of manufacture, and use
Non-viral nanoparticle compositions encapsulating RNA molecules with modified nucleotides and viral proteins address cytotoxicity and immunogenicity issues, facilitating efficient therapeutic protein delivery.
Patent Information
- Application Number
- PCT/US2026/026901
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Existing RNA virus-based therapeutic platforms face challenges such as cytotoxicity, poor replicative efficiency in non-permissive cells, and immunogenicity, limiting their broader adoption for therapeutic protein delivery.
Development of non-viral nanoparticle compositions encapsulating naked RNA molecules, including positive-sense RNA encoding RNA-dependent RNA polymerase L protein and accessory nucleoprotein N and phosphoprotein P, along with therapeutic polypeptides, utilizing ribosome recruitment elements and modified nucleotides to enhance stability and translation efficiency.
The compositions achieve sustained expression of therapeutic proteins with minimal cellular cytotoxicity and reduced immunogenicity, enabling effective therapeutic delivery.
Smart Images

Figure US2026026901_12112026_PF_FP_ABST
Abstract
Description
[0001] ISB-153.01WO Attorney Reference No. 9929-113741-02 THERAPEUTIC RNA AND THERAPEUTIC RNA-LOADED NANOPARTICLE COMPOSITIONS, METHODS OF MANUFACTURE, AND USE
[0002] CROSS REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of priority to U. S. Provisional Patent Application No.
[0004] 63 / 801,295, filed on May 7, 2025, the entire contents of which are hereby incorporated by reference.
[0005] FIELD
[0006] The field relates to therapeutic RNA and therapeutic RNA-loaded nanoparticle compositions, methods of manufacture, and use.
[0007] SEQUENCE LISTING INCORPORATION
[0008] The Sequence Listing is submitted as an XML file in the form of the file named “9929-113741-02_Sequence_Listing” (570,607 bytes), which was created on May 6, 2026, which is incorporated by reference herein.
[0009] BACKGROUND RNA viruses are classified based on the polarity of their RNA genomes (Lauber & Gorbalenya, 2012). Positive-sense RNA viruses have genomes that can serve directly as mRNA and be immediately translated by the host cell machinery. In contrast, negative-sense RNA viruses require transcription into complementary positive-sense RNA before translation can occur.
[0010] Among the diverse RNA viruses explored for therapeutic applications, influenza virus, Newcastle Disease Virus (NDV), and alphaviruses represent well-established model systems. Influenza virus is a negative-sense, segmented RNA virus of the Orthomyxoviridae family that causes seasonal respiratory illness in humans and animals. NDV is a highly contagious, nonsegmented, negative-sense RNA virus from the Paramyxoviridae family that affects a wide variety of bird species, both domestic and wild. Alphaviruses, in contrast, belong to die Togaviridae family and are positive-sense singlestranded RNA viruses known for causing a variety of diseases in humans and animals, often transmitted by mosquitoes. All three have been explored for vaccine and dierapeutic applications, as have several others (US 5,166,057; US 7,442,379 B2; Whalen, 1998; Pekos et al., 1999; Romer-Oberdorfer et al., 1999; Singh et al., 1999; Nakaya et al., 2001; Schnell et al., 2001; and Zhao et al., 2003).
[0011] For example, US Patent 5,166,057 to Leonia disclosed die co-transfection of influenza virus widi recombinant negative-strand RNA corresponding to an engineered viral segment, complexed with viral proteins (including PB1, PB2, PA, and NP). Co-infection with influenza was used to drive replication and expression of a foreign gene such as chloramphenicol acetyltransferase (CAT) from die recombinant ribonucleoprotein complexes.ISB-153.01WO Attorney Reference No. 9929-113741-02 Similarly, US Patent 7,442,379 B2 to Garcia-Sastre reported on the construction of a recombinant NDV vaccine from full-length cDNA clones of the NDV genome with a vaccine antigen gene inserted into the backbone. The clones were co-transfected into permissive cells along with helper plasmids encoding the viral proteins needed for replication and transcription to produce infectious viral particles.
[0012] Beyond vaccine applications, NDV has also been explored as an oncolytic agent due to its selective replication in tumor cells and its ability to stimulate anti-tumor immunity across a variety of cancer types (Garcia-Sastre et al., 2011; Chinsomboon et al., 2014; Najmuddin et al., 2023; Chen et al., 2024; and Li et al., 2025). For instance, the effectiveness of NDV against tumors and safety in normal tissue have been demonstrated in several clinical studies. Cassel et al. (1965) injected adenovirus and NDV directly into uterine carcinoma, resulting in partial necrosis and sloughing, but followed by regrowth. Cassel et al. (1983) reported on the postsurgical management of stage II malignant melanoma treated with a NDV oncolysate. Pecora et al. (2002) examined intravenous administration of NDV in patients with advanced solid cancers. Freeman et al. (2006) disclosed intravenous delivery of NDV oncolytic virus for treatment of recurrent glioblastoma multiforme.
[0013] Unfortunately, treatments with natural strains of NDV typically wane over time. This has prompted in part modifications of the NDV genome to encode foreign therapeutics to improve its drug properties. Vigil et al. (2007 and 2008), Zhao H, et al. (2008), Zamarin D., et al. (2009 and 2012), and Harper, J., et al., (2020) variously reported on recombinant fusogenic NDV vectors expressing IFNy, GM-CSF, IL-2, IL- 12, or TNFa for use in cancer therapy. Huberts et al. (2025) disclosed a NDV variant with reduced neutralization and enhanced oncolytic activity against pancreatic cancer cell lines. Zhong et al. (2025) reported an interventional clinical trial using a recombinant NDV expressing tire porcine al,3GT gene (NDV-GT) in 20 patients with relapsed or refractory metastatic cancer. Similar to the methods used for NDV vaccines, reverse genetics were used to construct full-length cDNA clones followed by co-transfection with helper plasmids into T7 -expressing cell lines to produce infectious viral particles that are then purified for injection.
[0014] Although not inherently oncolytic, alphaviruses have been extensively studied as platforms for vaccines and therapeutics. Self-amplifying RNA and trans-amplifying RNA technologies, derived from alphaviruses such as Venezuelan equine encephalitis virus (VEEV), Semliki Forest virus (SFV), and Sindbis virus (SINV), have been developed for transient expression of therapeutic proteins (Geall et al., 2012; Blakney et al., 2021; and Yildiz et al., 2024). These approaches utilized the alphaviral RNA-dependent RNA polymerase (RdRp, composed of nSPl-4) to amplify and transcribe subgenomic RNA encoding the gene of interest (Yildiz et al., 2024). In the self-amplifying RNA format, nonstructural and structural elements were combined within a single RNA molecule, with the structural open reading frame replaced by the therapeutic gene. In contrast, a trans-amplifying RNA system was used to separate these functions by expressing the RdRp from one RNA and placing the therapeutic gene under the subgenomic promoter on another (Yildiz et al., 2024).ISB-153.01WO Attorney Reference No. 9929-113741-02 Recent efforts to enhance performance of self-amplifying and trans-amplifying RNAs have further included modifications employed in non-amplifying mRNA systems such as the COVID vaccine, but with mixed results. These include 5’ capping with ribonucleotide analogs and the incorporation of modified nucleosides such as pseudouridine. For example, capping the 5’ end of mRNAs prior to transfection with synthetic cap analogs, such as anti-reverse cap analogs (ARCAs) or CleanCap®, can significantly improve protein expression post-transfection (Henderson et al., 2021; and Thess et al., 2015). In contrast, 5-methylcytidine (m5C) and 5-methyluridine (m5U) were reported to be sufficiently compatible with a replicon derived from VEEV alphavirus to mediate protein translation, while those containing Nl-methylpseudouridine in place of uridine showed no detectable expression (Azizi, H., et al., 2024).
[0015] Despite their promise, alphaviral RdRp is intrinsically cytotoxic, inducing substantial cell death-up to 70% within 72 hours post-transfection (Beissert et al., 2017). Elevated intracellular levels of RdRp also correlate with suppression of host cell translation, reducing the yield of recombinant protein (Vanluchene et al., 2023). Furthermore, alphavirus RdRp is highly immunogenic, eliciting strong humoral responses that limit tire feasibility of repeated administration (Bloom et al., 2021).
[0016] While both negative- and positive-sense RNA systems have been applied in vaccine and cancer settings, challenges such as inherent cytotoxicity, poor replicative efficiency in non-permissive cells, immunogenicity, and technical production constraints have limited their broader adoption as platforms for therapeutic protein delivery. The present disclosure addresses these and other needs.
[0017] SUMMARY
[0018] Provided are compositions containing naked RNA molecules and non-viral nanoparticles loaded with the RNA, methods of manufacture, and use.
[0019] In some embodiments, the nanoparticle compositions generally include non-viral nanoparticle delivery vehicle encapsulating naked RNA, the naked RNA comprising:
[0020] (a) positive-sense RNA encoding RNA-dependent RNA polymerase L protein (RdRp L) and accessory nucleoprotein N and phosphoprotein P derived from nonsegmented negative-sense RNA virus and under control of a ribosome recruitment element; and
[0021] (b) positive- or negative-sense RNA encoding one or more non-viral therapeutic polypeptides under control of one or more subgenomic promoters for the RdRp L;
[0022] wherein the RdRp L, N, and P proteins and the one or more non-viral therapeutic polypeptides are each individually encoded on the same or different RNA molecule, with the proviso that when on the same molecule, the RNA is positive-sense and contained in the same non-viral nanoparticle delivery vehicle.
[0023] In some embodiments, the naked RNA compositions include:ISB-153.01WO Attorney Reference No. 9929-113741-02 (a) positive-sense RNA encoding RdRp L protein and accessory nucleoprotein N and phosphoprotein P derived from nonsegmented negative-sense RNA virus and under control of a ribosome recruitment element; and
[0024] (b) positive- or negative-sense RNA encoding one or more non- viral polypeptides under control of one or more subgenomic promoters for the RdRp L;
[0025] wherein the RdRp L, N, and P proteins and the one or more non-viral polypeptides are each individually encoded on the same or different RNA molecule, with the proviso that when on the same molecule, the RNA is positive-sense; and
[0026] wherein the naked RNA includes 5’ and 3’ ends, and one or more additional features comprising, or selected from:
[0027] (i) one or more pseudo-ribonucleotides, such as pseudouridine, Nl-methyl- pseudouridine, 5-methoxyuridine, 5-methylcytidine, 5-hydroxymethylcytidine, or methyluridine, incorporated in the RNA;
[0028] (ii) one or more ribosome skipping elements operably linking one or more genes encoding the N, P, and RdRp L proteins, and optionally, Hie non-viral therapeutic polypeptide;
[0029] (iii) an internal ribosomal entry site (IRES) element or a m7G-ribonucleotide or analog capping group at the 5’ end of the positive-sense RNA, and optionally, an exonuclease resistant group, such as one or more hairpins or a poly-A tail, at the 3’ end of the positive-sense RNA; or (iv) any combination of (i), (ii) and (iii).
[0030] In some embodiments, the compositions include a positive-sense RNA molecule encoding a viral RdRp derived from either positive-sense or negative-sense RNA virus, wherein tire RNA molecule encoding the RdRp comprises a 5’ end, a 3’ end, or both a 5 ’end and a 3' end modified with one or more exonuclease-resistant hairpins.
[0031] In some embodiments, tire compositions include an RNA molecule having 5’ and 3’ ends, the RNA molecule comprising:
[0032] (a) a 2 ’,3 ’-cyclic phosphate at the 3’ end of the RNA; and
[0033] (b) one or more pseudo-ribonucleotides incorporated into tire RNA, such as pseudouridine, Nl-methyl-pseudouridine, 5-methoxyuridine, 5-methylcytidine, 5-hydroxymethylcytidine, or methyluridine.
[0034] In some embodiments, the methods of RNA manufacture include:
[0035] (a) providing a DNA template comprising a sequence encoding a nonsegmented negative-sense RNA virus-derived trans-amplifying RNA (taRNA) and operably linked to a T7 RNA polymerase promoter of Class II;ISB-153.01WO Attorney Reference No. 9929-113741-02 (b) linearizing the DNA template; and
[0036] (c) synthesizing the taRNA by in vitro transcription using the T7 RNA polymerase in the presence of modified nucleotides comprising Nl-methylpseudouridine (ml'P),
[0037] thereby producing a taRNA suitable for expression in a host cell.
[0038] In some embodiments, a method of treatment is provided, comprising:
[0039] administering to a subject in need thereof a therapeutic composition of the disclosure.
[0040] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1: Illustration of tire natural viral replication cycle of nonsegmented negative-sense RNA viruses.
[0041] FIG.2: Illustration of tire natural nonsegmented negative-sense viral replication complex. FIG.3: Shows delivery and production of an antibody using non-viral nanoparticles encapsulating recombinant trans-amplified or self-amplified RNA constructs of the disclosure.
[0042] FIGS. 4A-4B: Shows recombinant nonsegmented negative-sense trans-amplified RNA construct systems of the disclosure, utilizing two transcripts.
[0043] FIGS. 5A-5B: Shows recombinant nonsegmented negative-sense trans-amplified RNA construct systems of the disclosure, utilizing three transcripts.
[0044] FIGS. 6A-6B: Shows examples of recombinant nonsegmented negative-sense trans-amplified RNA construct systems of the disclosure for producing one or more therapeutic proteins.
[0045] FIGS. 7A-7C: Shows recombinant nonsegmented positive-sense self-amplified RNA construct systems of the disclosure.
[0046] FIG.8: Shows delivery and production of a single-chain fragment variable (scFv) therapeutic protein using non-viral nanoparticles encapsulating a recombinant trans-amplified propagating, nonsegmented negative-sense viral RNA construct system of the disclosure.
[0047] FIG.9: Shows delivery and production of a scFv therapeutic protein using non-viral nanoparticles encapsulating a recombinant self-amplified propagating, nonsegmented positive-sense viral RNA construct system of the disclosure.
[0048] FIGS. 10A-10B: Shows recombinant propagating, nonsegmented negative-sense trans-amplified viral RNA (FIG. 10A) and positive-sense self-amplified viral RNA (FIG. 10B) construct systems of the disclosure.ISB-153.01WO Attorney Reference No. 9929-113741-02 FIGS. 11A-11C: Shows examples of recombinant propagating, nonsegmented negative-sense trans-amplified viral RNA genome construct systems of the disclosure that target different cancers.
[0049] FIG. 12: Representative multi-transcript expression of mEGFP and mCherry in HEK293 cells transfected with negative-sense taRNA (SEQ ID NO.48) and 5’ capped positive-sense RdRp and accessory mRNA transcripts (SEQ ID NO. 65 and SEQ ID NO. 66) using Lipofectamine MessengerMax (Thermo Scientific). All transcripts utilized had complete N1 -methylpseudouridine substitution in place of uridine. Cells were plated and transfected in a 96-well optical plate with lOOng of total RNA transfected. Images pictured were taken at approximately 44 hours post-transfection on a Sartorius Incucyte. Left image: mEGFP fluorescence. Right image: mCherry fluorescence.
[0050] FIG. 13: Expression kinetics of mEGFP in HEK293 cells, following transfection with negativesense taRNA encoding mEGFP (SEQ ID NO. 48) and 5’ capped positive-sense RdRp and accessory mRNA transcripts (SEQ ID NO. 65 and SEQ ID NO. 66) using Lipofectamine MessengerMax (Thermo Scientific). All transcripts utilized had complete N1 -methylpseudouridine substitution in place of uridine. Images taken at 4 h intervals on a Sartorius Incucyte live-cell imager, and analyzed for total green object fluorescence intensity over background fluorescence signal, measured as RFU. Loss of imager focus on cells was observed at hours 60 and 128, and resulting inaccurate data points were removed from the graph. X-axis indicates hours post-transfection. Y-axis indicates total normalized GFP object fluorescence in RFU.
[0051] FIG. 14: Comparative fluorescent microscopy images of suspension HEK293 cells electroporated with negative-sense taRNA encoding tagBFP2 (SEQ ID NO. 48), positive-sense, hairpin-terminated IRES-driven N-T2A-V-T2A-P mRNA (SEQ ID NO. 68), and positive-sense 5’ capped L mRNA (SEQ ID NO. 66). All transcripts utilized had complete N1 -methylpseudouridine substitution in place of uridine. Pictured is fluorescence in the tagBFP2 channel, with brightness indicating relative fluorescence intensity in transfected cells. Left image: untransfected cells. Right image: transfected cells.
[0052] FIGS. 15A-15B: Flow cytometry analysis of HEK293 cells transfected with negative-sense taRNA encoding mEGFP, tagBFP2, and mCherry (SEQ ID NO. 48) and positive-sense 5’ capped RdRp and accessory mRNA (SEQ ID NO. 65 and SEQ ID NO. 66) using TransIT-mRNA (Mirus Biosciences), analyzed at day 4 following transfection. All transcripts utilized had complete Nl-methylpseudouridine substitution in place of uridine. Dead cells were gated out from analysis by Live-or-Dye-750 / 777 aminereactive staining (Biotium Sciences). FIG. 15A shows mEGFP vs tagBFP2 fluorescence, respectively encoded in 1st and 2nd taRNA subgenomic positions. FIG. 15B shows mEGFP vs mCherry fluorescence, respectively encoded in 1st and 3rd taRNA subgenomic positions.
[0053] FIG. 16: Representative fluorescent microscopy image and flow cytometry analysis taken at about 44 hours post-transfection with negative-sense taRNA encoding mEGFP (SEQ ID NO. 1) and 5’ capped positive-sense RdRp and accessory mRNA transcripts (SEQ ID NO. 65 and SEQ ID NO. 66) using Expifectamine (Thermo Scientific) in serum-free, suspension Expi293F shake-cultures. AllISB-153.01WO Attorney Reference No. 9929-113741-02 transcripts utilized had complete N1 -methylpseudouridine substitution in place of uridine. Approximately a 3-10% transfection efficiency was achieved with Expifectamine, as measured by GFP+ expression, both by Sartorius Incucyte automated microscopy analysis (5-10%) and by flow cytometry (3-4%). “MFI” indicates median fluorescence intensity of non-transfected cell subpopulation. At 44h, differential taRNA-mediated cell death in the transfected subpopulation versus the non-transfected subpopulation appeared minimal at about 4-5% as measured by Live-or-Dye-750 / 777 apoptotic dye (Biotium Sciences) in flow cytometry.
[0054] FIG. 17: Stain-free (BioRad Technologies) SDS PAGE gel analysis demonstrating expression of secreted Epogen (erythropoietin) in serum-free, suspension Expi293F cell shake-cultures transfected with negative-sense taRNA encoding Epogen (erythropoietin) (SEQ ID NO. 9) modified with a 6x His-tag and 5’ capped positive-sense RdRp and accessory mRNA transcripts (SEQ ID NO. 65 and SEQ ID NO. 66) using Expifectamine (Thermo Scientific). Cell culture supernatants were harvested at 72h and subsequently His-tag purified using Cobalt HisPure resin (Thermo Scientific). Negative-control supernatant from non-transfected Expi293F culture was simultaneously His-tag purified. Eluted protein and negative control samples were subjected to SDS-PAGE under reducing and non-reducing conditions. Stain-free gel was UV-activated and imaged on a BioRad ChemiDoc. A unique protein band of the expected glycosylated erythropoietin molecular weight (-37-40 kDa for Epogen) was observed in tire transfected sample lanes, indicating successful expression of tire recombinant protein. Molecular weight markers are indicated alongside the gel. “NR” indicates a non-reduced sample, and “R" indicates a reduced sample.
[0055] FIG. 18: Kinetic mEGFP expression curves measured over 168 hours post-transfection by Incucyte S3 imaging in 293T, Caco2, HepG2, and C2C12 cells transfected with SM102 lipid nanoparticles co-encapsulating NDV mEGFP taRNA, NP(NDV)-V(Measles)-P(NDV) mRNA, and NDV Strain Bl L mRNA at a 1:2:1 mass ratio.
[0056] FIGS. 19A-19B: Expression and activity of NDV taRNA variants. FIG.19A depicts kinetic mEGFP expression curves over 168 hours by Incucyte S3 imaging in 293T cells transfected with NDV mEGFP taRNA variants differing in uridine modification (100% Nl-methylpseudouridine, 85% Nl-methylpseudouridine + 15% uridine, or 100% uridine) and 5’ end group (5’ppp, 5' m7G CapO, 5’ m7G Capl, or 5’OH) in combination with NP(NDV)-V(Measles)-P(NDV) mRNA and NDV Strain Ulster L mRNA at a 1:2:1 mass ratio. FIG.19B depicts firefly luciferase luminescence signal-to-noise ratios from cell lysates of 293T and C2C12 cells transfected with SM102 lipid nanoparticles co-encapsulating NDV FLuc taRNA (5’ppp or 5’ m7G Capl), NP(NDV)-V(PIV5[N100D])-P(NDV) mRNA, and NDV Strain Ulster L mRNA at a 1:2: 1 mass ratio.
[0057] FIG.20: Kinetic mEGFP expression curves measured over 168 hours post-transfection by Incucyte S3 imaging in 293T cells transfected with NDV mEGFP taRNA variants harboring different self-cleaving ribozymes on the 3’ end of the taRNA (3’ antigenomic HDV, 3’ genomic HDV, 3’ minimalISB-153.01WO Attorney Reference No. 9929-113741-02 HDV67, and 3’ Twister) co-delivered with NP(NDV)-V(Measles)-P(NDV) mRNA and NDV Strain Ulster L mRNA at a 1:2:1 mass ratio.
[0058] FIG.21: Kinetic mEGFP expression curves measured over 240 hours post-transfection by Incucyte S3 imaging in 293T cells transfected with PIV5 mEGFP taRNA, NP(PIV5)-V(PIV5)-P(PIV5) mRNA, and PIV5 L mRNA at a 1:2: 1 mass ratio.
[0059] FIG.22: Production of therapeutic proteins from NDV taRNA in Expi293 cell culture depicting a stain-free gel of Protein G spin-column-purified adalimumab produced from Adalimumab NDV taRNA co-delivered with NP(NDV)-V(Measles)-P(NDV) mRNA and NDV Strain Ulster L mRNA at a 1:2:1 mass ratio, under reducing and non-reducing conditions and across successive column elutions.
[0060] FIGS. 23A-23B: Effect of T7 promoter selection on taRNA expression. FIG.23A depicts kinetic mEGFP expression curves over 168 hours in 293T cells transfected with NDV mEGFP taRNA synthesized from templates encoding either a modified phi2.5 (Class II) or a phi6.5 (Class III) T7 promoter. FIG.23B depicts analogous kinetic mEGFP expression curves over 240 hours in 293T cells transfected with PIV5 mEGFP taRNA synthesized from the same two promoter variants.
[0061] FIG.24: Characterization of an SM102 lipid nanoparticle co-encapsulating NDV FLuc taRNA, NP(NDV)-V(PIV5[N100D])-P(NDV) mRNA, and NDV Strain Ulster L mRNA, with the figure depicting an Agilent Tapestation electropherogram of the encapsulated RNA species at the expected sizes and 1:2:1 mass ratio.
[0062] FIGS. 25A-25C: Representative IVIS Spectrum bioluminescence imaging and quantitative analysis of mice following intramuscular (IM) administration of 5’m7G (Capl) and 5’ppp Flue (noncapped) taRNA-LNP formulations. FIG.25A depicts mice dosed IM with 5’ppp (non-capped) Flue taRNA, and FIG.25B depicts mice dosed IM with 5’m7G (Capl) Flue taRNA. Representative images were acquired over multiple days and color scaled for comparison as follows: FIG. 25 A (5’ppp) Color Scale: Log scale for Day 1 and Day 2 (Min: 5E4, Max: 1E6); for Day 3-14 (Min: 2E4, Max: 1E6); and FIG. 25B (5’ m7G (Capl)) Color Scale: Log scale for Day 1-14 (Min: 2E4, Max: 1E6). FIG.25C shows mean photon flux values within a defined region of interest (ROI), with bars indicating the range of individual mouse values and background luminescence from control animals indicated by dashed ( — ) line.
[0063] FIG.26: Representative bioluminescence imaging of rats following oral administration of freeze-dried lipid nanoparticle (LNP) formulations, as compared to control rats. Imaging was performed using an IVIS Spectrum system at multiple time points post-intraperitoneal injection of AkaLumine-HCl (TokeOni®), with animals positioned to capture different emission angles (subpanels i and j). Images were acquired on days 1 through 4 post-gavage under standardized conditions, with color scaling matched across images to enable comparison of signal intensity. Rat Color Range: Log-Scale for all days Min: 1.97e3 and Max: 4.00e4.ISB-153.01WO Attorney Reference No. 9929-113741-02
[0064] SEQUENCES
[0065] Any nucleic acid and amino acid sequences listed herein are shown using standard letter abbreviations for nucleotide bases and amino acids, as defined in 37 C. F. R. § 1.822. In at least some cases, only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
[0066] SEQ ID NOs. for amino acid sequences are listed in Table 1 and Table 2. SEQ ID NOs. for nucleic acid sequences are listed in Table 3 and Table 4. Tables 5-13 provide the detailed amino acid and RNA sequences, and Tables 14-20 provide additional associated information according to the SEQ ID NOs.
[0067] DETAILED DESCRIPTION
[0068] As summarized above, the present disclosure includes non-viral nanoparticle compositions encapsulating naked RNA derived from nonsegmented negative sense RNA virus encoding virus-derived RdRp L, N and P proteins and one or more non-viral therapeutic polypeptides. Upon cellular uptake and translation, the polypeptides induce a therapeutic effect. Self-amplifying and self-propagating compositions encoding a wide range of different therapeutics in various formats are exemplified.
[0069] Methods of manufacture and use are also provided.
[0070] The disclosure is exemplified by self-amplifying RNA (saRNA) and trans-amplifying RNA (taRNA) construct systems delivered as naked RNA molecules encapsulated in non-viral, synthetic nanoparticles. The saRNA and taRNAs utilize a replicon architecture derived from nonsegmented negative-sense viruses exemplified by Newcastle Disease (NDV) virus. Self-propagating naked RNA constructs encapsulated in non-viral nanoparticles are also provided. The exemplified constructs exhibit at least one week of sustained expression, minimal cellular cytotoxicity, a modular interferon suppression system, compatibility with Nl-pseudomethyluridine, and the ability to produce multiple independent protein transcripts and proteins from several subgenomic open reading frame (ORFs) in a single parent transcript.
[0071] Before the present invention is described in greater detail, a brief overview of the natural viral replication cycle of nonsegmented negative-sense RNA viruses is provided first. This overview of tire natural viral cycle is then followed by a detailed description of specific terms, compositions, methods of use, utility and advantages, examples, claims, abstract, and figures of the disclosure.
[0072] I. Natural nonsegmented negative-sense RNA virus
[0073] The natural viral replication cycle of nonsegmented negative-sense RNA viruses is illustrated in FIG. 1. As shown, virus particles are comprised of a pre-formed ribonucleoprotein replication complex, encapsulated within a matrix protein (M) core and presenting transmembrane-anchored hemagglutinin-ISB-153.01WO Attorney Reference No. 9929-113741-02 neuraminidase (H) and fusion protein (F) on its outer lipid-envelope. The replication complex consists of the nonsegmented negative- sense viral genome RNA associated with viral nucleoprotein (N), viral phosphoprotein (P), and viral RNA-dependent RNA polymerase (RdRp L). Viral H protein promotes binding with sialic acid presented on the target cell surface, resulting in endocytic uptake into the cell. During this process, viral F protein promotes fusion of the viral lipid envelope with the cellular endosome, resulting in release of the viral cargo into the cellular cytoplasm. The pre-formed replication complex thereafter begins subgenomic transcription of the structural and non-structural viral proteins required for viral replication inside the cell, a process driven by the interaction of viral RdRp L with nucleoprotein-encapsulated negative-sense RNA via the phosphoprotein scaffold. This subgenomic transcription process generates 5’ m7G-capped and polyadenylated, positive-sense mRNA transcripts encoding each of the viral proteins. Simultaneously, viral RdRp performs full-length transcription of an antigenomic (positive-sense) copy of tire viral genome. This intermediate positive-sense antigenome RNA subsequently serves as a transcription template for generation of new copies of negative-sense full-length genomic RNA. Newly-translated N, P, and L proteins associate with tire newly-replicated genomic RNA to form ribonucleoproteiii replication complexes. These replication complexes associate with viral matrix protein on the cytoplasmic side of the cellular plasma membrane. Viral matrix protein concurrently associates with newly translated and cell-surface exported H and F proteins, generating focal sites of viral budding. Fully-budded virus particles complete maturation and become replication-competent virus. During tire process of infection, viral interferon-suppressor (V) protein is also translated, which acts to inhibit the action of viral RNA-sensing and interferon pathway effectors such as STAT1 / 2, MAVS, and MDA5.
[0074] Referring now to FIG. 2, this figure illustrates the natural nonsegmented negative-sense viral replication complex in more detail. As can be seen, the mature virus particle contains a ribonucleoprotein replication complex consisting of a nonsegmented negative-sense RNA genome, encapsulated by viral nucleoprotein N that binds ribonucleotides in multiples of six bases. Scaffolded to the N proteins are viral phosphoproteins P, acting as a functional link between the nucleoprotein and the viral RdRp L protein. All three proteins are present in the pre-formed replication complex released from the virus into the host cell. Upon entry into the cell, viral RdRp recognizes successive viral sub-genomic promoters and performs transcription of each subgenomic ORF, producing m7G-capped and polyadenylated, positive sense mRNA encoding the non-structural viral replication proteins (N, P, V, and L) and viral structural proteins (M, F, and H). Viral V protein is produced from the P ORF by RdRp-mediated RNA editing to generate an alternate frameshift isoform. In certain members of the Paramyxoviridae family such as the Respirovirus genus, multiple translational start sites in the P ORF generate an alternate interferon suppressor C protein. In parallel, viral RdRp L binds to the 3’ genomic promoter and performs antigenomic transcription to produce non-capped, positive-sense full-length viral antigenomic RNA.
[0075] Thereafter, this positive-sense, anti-genomic template undergoes RdRp-mediated genomic transcription using its 3’ antigenomic promoter to produce full-length negative-sense, viral genomic RNA. Viral N, P,ISB-153.01WO Attorney Reference No. 9929-113741-02 and L proteins associate with the viral genomic RNA to form the ribonucleoprotein replication complex. The replication complex associates with the viral structural proteins, resulting in virus assembly and budding of a new virus particle.
[0076] IL Terms
[0077] Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Lewin’s Genes X, ed. Krebs et al., Jones and Bartlett Publishers, 2009 (ISBN 0763766321); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Publishers, 1994 (ISBN 0632021829); Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, 10 published by Wiley, John & Sons, Inc., 1995 (ISBN 0471186341); George P. Redei, Encyclopedic Dictionary of Genetics, Genomics, Proteomics and Informatics, 3rd Edition, Springer, 2008 (ISBN: 1402067534); and other similar references.
[0078] Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise.
[0079] “Comprising A or B” means including A, or B, or A and B. It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.
[0080] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
[0081] In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:
[0082] Antigenomic promoter: A regulatory nucleic acid sequence that initiates the transcription of the genome, which is the complementary strand to the viral antigenome. In certain RNA viruses such as paramyxoviruses, rhabdoviruses, and filoviruses, the genome is single-stranded negative-sense RNA (-RNA). The antigenomic promoter of a negative-sense RNA virus is located on the 3’ end of the antigenomic RNA (+RNA) and facilitates synthesis of a full-length negative-sense RNA (-RNA) strand.
[0083] Bispecifics: Refers to an artificial protein having both targeting and effector components. Unlike natural antibodies, which typically recognize only one antigen, bispecifics are engineered to bind two distinct molecules at once, often a first molecule on a tumor or infected cell and a second molecule on a cytotoxic effector cell such as a T cell. This dual binding capability establishes a bridge between targetISB-153.01WO Attorney Reference No. 9929-113741-02 cells and functional molecules that allows bispecifics to recruit immune cells to the target cells and destroy the target cells more effectively.
[0084] Alpha-Beta T cell receptor (AB-TCR): A heterodimeric receptor complex naturally found on the surface of antigen-specific T-cells, which binds to major histocompatibility complex (MHC)-loaded antigens presented on other cells. Contain variable amino acid sequences in the complementary-determining regions (CDRs), produced by V-D-J genomic recombination, to permit antigen-specific binding.
[0085] 5’ cap or capping group: A chemical modification of, or addition of a ribonucleotide analog to, the 5’ end of an RNA transcript that enhances stability and translation efficiency. Examples include, but are not limited to: 3’-7-methylguanosine-(5’)triphosphate (“m7G,” “m7G-ppp”), 3’-O-methyl-7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyl-N6-methyladenosine-(5’)phosphate-gu anosine (abbreviated herein as “3’-O-Me-m7G(5’)ppp(5’)2’-O-Me-m6A(5’)p(5’)G” or “CleanCap®M6 analog” (e.g., CleanCap®M6 analog (N-7453), from TriLink BioTechnologies); 3’-O-methyl-7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyl-adenosine-(5’)phosphate-(5’)-guanosine (abbreviated herein as “3’-O-Me-m7G(5’)ppp(5’)2’-O-Me-A(5')p(5’)G” or “CleanCap®AG 3’OMe analog” (e.g., CleanCap®AG 3’OMe analog (N-7413), from TriLink BioTechnologies); 7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyladenosine-(5’)phosphate-(5’)-guanosine (abbreviated herein as “m7G(5’)ppp(5’)2’-O-Me-A(5’)p(5’)G” or “CleanCap®AG analog” (CleanCap®AG analog (N-7113) from TriLink BioTechnologies); 7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyladenosine-(5’)phosphate-(5’)-uricil (abbreviated herein as “m7G(5’)ppp(5’)2’-O-Me-A(5’)p(5’)U” or “CleanCap®AU analog” (e.g., CleanCap®AU analog (N-7413), from TriLink BioTechnologies); or 7-methylguanosine-(5’)triphosphate-(5’)-adenosine-(5’)phosphate-(5’)-cytosine (abbreviated herein as “m7G(5')ppp(5’)A(5')p(5’)C,” “m7GpppAC,” or sometimes as “m7G-AC”), or m7G-AC analogs thereof, such as 7-methylguanosine-(5 ’ )triphosphate-(5 ’ )-2’ -O-methyladenosine-(5 ’ )phosphate-(5 ’ )-cytosine (abbreviated herein as “m7G(5’)ppp(5’)2’-O-Me-A(5’)p(5’)C” or “m7G-om2AC”), 3’-O-methyl-7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyl-adenosine-(5’)phosphate-(5’)-cytosine (abbreviated herein as “3’-O-Me-m7G(5’)ppp(5’)2’-O-Me-A(5’)p(5’)C”), or 3’-O-methyl-7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyl-N6-methyladenosine-(5’)phosphate-cytosine (abbreviated herein as “3’-O-Me-m7G(5’)ppp(5’)2’-O-Me-m6A(5’)p(5’)C”). The cap can be added naturally in vivo for many RNA viral genomes or through an ex vivo manufacturing process to enhance stability and translation efficiency of the RNA, including but not limited to, enzymatic co-transcriptional capping with m7G cap or analogs, or post-transcriptional capping with vaccinia or faustovirus capping enzyme, chemical capping by solid-phase synthesis, or a combination of enzymatic and chemical capping. The 5’ cap serves multiple functions, including protecting viral RNA from degradation by host exonucleases, facilitating ribosome binding, and, in some cases, aiding in the evasion of host antiviral responses. In the native system, the 5’ cap is typically a methylated guanosine nucleotide (m7GpppN) added by enzymes that are either encoded by the virus itself or hijacked from the host cell. For example,ISB-153.01WO Attorney Reference No. 9929-113741-02 some viruses acquire their 5’ cap through a process called “cap-snatching,” where they steal cap sequences from host mRNAs. Negative-sense RNA viruses, which do not directly use their genome as mRNA, must first generate a positive-sense RNA copy for translation. This process is carried out by the viral RNA-dependent RNA polymerase (RdRp), which also adds the 5’ cap to newly synthesized viral mRNAs to ensure proper translation. Newcastle disease virus (NDV), is an example. NDV, like all nonsegmented negative-sense RNA viruses, has a non-capped and non-polyadenylated negative-sense genome. Since NDV cannot be directly translated, its L protein (viral RdRp) transcribes the genome into positive-sense, capped and polyadenylated mRNAs, enabling efficient protein synthesis. While the NDV genome itself lacks a cap, its viral L protein possesses methyltransferase and capping activities to modify its product transcripts. Instead of capping, the genomic RNA is encapsulated by the nucleoprotein (N protein), which protects it and ensures efficient replication and transcription.
[0086] Eukaryotic 5’-untranslated region (5’-UTR): The untranslated sequence located upstream of the gene-coding region and downstream of tire m7G-cap in eukaryotic mRNA. Interacts with various host factors to regulate protein translation efficiency.
[0087] Eukaryotic 3’-untranslated region (3’-UTR): The untranslated sequence located downstream of the gene-coding region and upstream of the polyadenylation sequence in eukaryotic mRNA. Interacts with various host factors to regulate protein translation efficiency.
[0088] Gamma-Delta T cell receptor (GD-TCR): Refers to the subset of T-Cell Receptor (TCR) proteins expressed on gamma-delta (y8) T cells. The GD-TCR proteins include gamma and delta subunits expressed as a heterodimer on tire surface of a T cell that binds an antigen. Examples include the GD-TCRs VylVSl, Vy2V32, Vy6V31, and Vy9V32. The Vy9V82 TCRs are expressed on yS T cells primarily found in the blood and recognize cells infected with foreign substances like bacteria and viruses. The Vyl V31 TCRs are expressed on y3 T cells often found in tire skin and mucosal tissues, where they play a role in barrier defense. The Vy2V32 TCRs are expressed on yS T cells in various tissues and involved in both innate and adaptive immune responses. The Vy6V31 TCRs are primarily expressed on y3 T cells found in the gut and associated with mucosal immunity. In some embodiments, a bispecific heterodimer of the disclosure includes as the GD-TCR component a Vy9V32 TCR (i.e., gamma variable chain 9 (Vy9) / delta variable chain 2 (V32) TCR) in combination with a CD3 epitope as the immune cell recruiter component. Variants of GD-TCRS are also known, such as the Vy9V32 TCR variants Vy9V32 TCR(Cap / CPa|3), Vy9V32 TCR(Cyl) and Vy9V32 TCR(Cy2).
[0089] Genomic promoter: Regulatory nucleic acid sequence that directs the full-length transcription of antigenomic RNA in certain viruses. In negative-sense RNA (-RNA) viruses, the genomic promoter sequence is present on tire 3’ end of the full-length genomic RNA (-RNA) and permits transcription of full-length antigenomic RNA (+RNA), which is used as an intermediate template during viral replication.
[0090] Hexamer rule: Requirement applying to many nonsegmented negative- sense RNA viruses, and most particularly to the Paramyxoviridae family. The viral genomic RNA length must be divisible by aISB-153.01WO Attorney Reference No. 9929-113741-02 multiple of 6 ribonucleotides to accommodate complete encapsulation by the 6-mer binding viral nucleoprotein. In addition, viral RNA regulatory elements (leaders, promoters, and trailers) must be encapsulated by nucleoprotein in the correct hexamer phasing to maintain functionality. Failure to keep hexamer-divisible length or phasing results in deficient RdRp-mediated replication and transcription.
[0091] Immune cell recruiter: Refers to the binding domain of a bispecific that engages an immune cell to initiate an immune response. Sometimes referred to as an "effector" group. The immune cell recruiter component of the bispecific is designed to engage with receptors on immune cells, such as the T cell receptor (TCR) or co-stimulatory molecules, leading to the activation and proliferation of immune cells. Examples of immune cell recruiters in bispecifics of specific interest include epitopes for the immune cell receptors CD3, CD16 and one or more human compliments such as C3. For example, a CD3 immune cell recruiter or epitope binds to the CD3 molecule on T cells, which is part of the TCR complex, triggering T cell activation. A CD16 immune cell recruiter or epitope binds to CD16, a low-affinity receptor for IgG (FcR III) expressed on natural killer (NK) cells, monocytes, and neutrophils. C3, when activated, generates fragments C3a, C3b and C5a that can attract immune cells such as neutrophils and macrophages to tire site of infection or inflammation for clearing pathogens and debris.
[0092] Internal ribosomal entry sites (IRESs): Specialized RNA sequences that allow capindependent translation initiation, a crucial strategy employed by certain positive-sense RNA viruses to efficiently utilize host cell machinery for protein synthesis. IRES elements bypass the typical requirement for a 5' cap on mRNA, enabling tire virus to directly initiate translation at internal sites within its RNA genome. This mechanism is essential for viruses belonging to families like Picornaviridae (e.g., poliovirus, rhinovirus), Flaviviridae (e.g., hepatitis C virus, West Nile virus), Dicistroviridae, and Iflaviridae, each exhibiting distinct IRES structures and functions tailored to their respective translation strategies. However, IRESs are exclusive to positive-sense RNA viruses in the wild; negative-sense RNA viruses, relying on their own RNA-dependent RNA polymerase (RdRp) for transcription and subsequent translation of mRNA, do not utilize IRES elements.
[0093] Kozak sequence or element: A conserved nucleotide motif found in mRNA that aids initiation of translation by facilitating ribosome recognition of tire start codon (ATG in DNA notation or AUG in mRNA notation). The Kozak sequence is located just before tire start codon. The consensus non-viral Kozak sequence is (GCC)GCCRCCAUG, where R represents a purine (adenine or guanine), the AUG within the sequence serves as the start codon, and the nucleotides surrounding it influence tire efficiency of translation initiation. A strong Kozak sequence, particularly with a G at position +4 and an A or G at position -3, enhances ribosomal binding and increases tire likelihood of efficient translation initiation. As such, there can be some variation in the sequence, as long as it still functions to initiate translation. The viral Kozak-like sequences are elements of viral origin and serve a similar role as eukaryotic Kozak sequences. The viral Kozak-like sequences exhibit a looser homology compared to their non-viral counterparts. In general, the consensus viral Kozak-like sequence is (GNN)ARRAUG, where R usually represents an A or C, and N is any ribonucleotide. For example, in Newcastle Disease virus strain UlsterISB-153.01WO Attorney Reference No. 9929-113741-02 the Kozak-like sequence for the first subgenomic promoter is (GCC)AAAAUG, whereas the second subgenomic promoter is (GUA)AAGAUG, and so forth.
[0094] Leader sequence: In many negative-sense RNA viruses, the leader sequence is a short, noncoding sequence at the 3’ end of the genome or antigenome. Called the “leader” because it is the first part of the RNA that the RdRp encounters during transcription.
[0095] Linker: A nucleic acid or amino acid sequence that connects (e.g., covalently links) two nucleic acid or amino acid segments. In some examples, linker sequences may be included to provide rotational freedom to linked polypeptide domains and thereby to promote proper domain folding and inter- and intra-domain bonding. Linkers may be native sequences (for example, those found in naturally occurring proteins) or may be recombinant or artificial sequences. In one non-limiting example, linker sequences include glycine- serine amino acid sequences (or a nucleic acid sequence encoding the amino acid sequence), which include varying numbers of glycine and serine residues (e.g., glycine(4)-serine).
[0096] Naked RNA: RNA that is devoid of, and unassociated with, any viral replication or structural proteins.
[0097] Nanoparticle delivery vehicle: a synthetic nanoscale system engineered to hansport and release therapeutic RNA agents in a controlled manner within the body. Typical range in size is of around 50 to 200 nanometers (nm), depending on the RNA payload. For example, nanoparticles used to deliver RNA molecules of 10-20 kb, such as large mRNA strands or payloads, typically fall within the range of 60 to 150 nm, with most formulations optimized around 80 to 120 nm to balance efficient encapsulation, cellular uptake, and circulation time while minimizing immune clearance. Examples of particular interest include, but are not limited to, lipid-based nanoparticles used for mRNA delivery, as seen in COVID-19 vaccines, solid lipid nanoparticles, polymer-based nanoparticles, inorganic nanoparticles, and hybrid nanoparticles that encapsulate, protect, and deliver nucleic acid material (e.g., RNA or DNA) to cells or tissues. Lipid-based nanoparticlcs (LNPs) are composed of at least one and usually a combination of two or more of the following lipids: (1) ionizable lipids; (2) phospholipids; (3) cholesterol; and (4) polymer-modified lipids such as PEGylated lipids. Ionizable lipids of particular interest are those that become positively charged in acidic environments, aiding in encapsulating and releasing nucleic acids. Phospholipids of interest help form the bilayer structure for stability. Cholesterol molecules of interest improve structural integrity and fluidity. Polymer-modified lipids such as PEGylated lipids aid handling and various other properties, such as reducing immune system recognition and enhancing circulation time. Polymer-based nanoparticles (PBNs) include polylactic-co-glycolic acid (PLGA) nanoparticles, which are biodegradable and used for sustained drug release, polyethylene glycol (PEG)-coated nanoparticles that improve circulation time and reduce immune clearance, and chitosan nanoparticles, which are particularly effective in mucosal drug delivery. Additionally, dendrimers, highly branched polymer structures, allow for precise drug conjugation and controlled release. Inorganic nanoparticles (INNs) include mesoporous silica nanoparticles for high drug-loading capacity and tunable release, goldISB-153.01WO Attorney Reference No. 9929-113741-02 nanoparticles (AuNPs) for targeted therapy, imaging, and photothermal therapy, and iron oxide nanoparticles (IONPS), which serve as contrast agents in MRI and enable magnetic drug targeting. Hybrid nanoparticles (HYNs) combine multiple materials, such as liposome-polymer hybrid nanoparticles. The selection of a specific nanoparticle system depends on factors such as drug solubility, targeting requirements, and desired release kinetics. Solid lipid nanoparticles (SLNs) are composed of solid lipids that remain in a solid state at both room and body temperature, and formulated using biocompatible and biodegradable lipids, such as triglycerides, fatty acids, steroids, and waxes. SLNs are stabilized by surfactants, which prevent aggregation and enhance dispersion in biological environments. They can encapsulate both hydrophobic and hydrophilic drugs, protecting them from degradation while enabling targeted and prolonged drug release. Applications of SLNs span various fields, including oncology, gene therapy, anti-inflammatory treatments, and vaccine delivery. Their advantages over conventional drug carriers, such as emulsions and liposomes, include increased physical stability, lower toxicity, and the ability to be produced on a large scale. However, limitations such as potential drug expulsion during storage and low loading capacity for certain drugs necessitate further optimization for specific medical applications. Of specific interest are lipid-based nanoparticles.
[0098] Newcastle disease virus: A nonsegmented negative-sense parainfluenza RNA virus that infects birds as a primary host and reservoir. The replication cycle of NDV begins when tire virus binds to the host cell surface via its Hemagglutinin-Neuraminidase (H) protein, which interacts with sialic acid receptors, while tire Fusion (F) protein facilitates membrane fusion, allowing the viral ribonucleoprotein (RNP) replication complex to enter tire cytoplasm. Once inside, the nucleoprotein (N)-encapsulated negative-sense single-stranded RNA (3'-Leader-N-P-M-F-H-L-Trailer-5’) is released and serves as a template for transcription by the co-delivered viral RNA-dependent RNA polymerase (L protein, with P protein as a cofactor) or “RdRp”. In this 3’ to 5’ genomic (-RNA) configuration, viral proteins are encoded as the complement nucleotide sequence. The NDV RdRp sequentially synthesizes 5’ capped and 3’ polyadenylated monocistronic subgenomic mRNAs, including transcripts for the N, P, M, F, H, and L genes, following the stop-start mechanism. These mRNAs are translated into viral proteins by host ribosomes, with the N, P, M, F, H, and L proteins undergoing necessary post-translational modifications and trafficking to appropriate cellular locations. When enough newly-translated N protein accumulates, the polymerase shifts from transcription to replication, synthesizing a full-length, positive-sense antigenome (5’- Trailer-N-P-M-F-H-L- Leader-3’), which in turn serves as a template for the production of new negative-sense genomic RNA by viral RdRp action. The newly synthesized viral genomes associate with N, P, and L proteins to form RNP replication complexes, which then interact with the M protein at the plasma membrane, where viral assembly occurs. The F and H proteins are inserted into the host membrane via the Golgi apparatus, and mature virions bud from the membrane, acquiring their envelope and glycoproteins. The H protein cleaves sialic acid residues to prevent self-aggregation, enabling efficient virus release and subsequent infection of new cells, completing the replication cycle.ISB-153.01WO Attorney Reference No. 9929-113741-02 As such, the NDV RdRp is responsible for both genome replication and transcription. During replication, the viral RdRp synthesizes a full-length negative-sense genomic RNA (3’-Leader-N-P-M-F-H-L-Trailer-5’) from the full-length positive-sense antigenome (5’-Trailer-N-P-M-F-H-L-Leader-3’), a process that occurs when sufficient N protein is available for packaging into progeny virions. In addition to replication, the same viral RdRp transcribes the negative-sense viral genome into individual 5’ capped and 3’ polyadenylated subgenomic mRNAs, each encoding one of the viral proteins, following the stopstart mechanism. Since NDV is a negative-sense, single-stranded RNA virus, its genome cannot be directly translated by host ribosomes. Instead, the viral RdRp must first generate discrete mRNAs, which are then translated by the host cell machinery to produce viral proteins. The transition between transcription and replication is primarily regulated by tire availability of the N protein, which encapsulates the nascent genome. As NDV replicates entirely in tire cytoplasm and does not rely on the host RNA polymerase for RNA synthesis, the viral RdRp is solely responsible for both transcription and replication, ensuring the efficient production of viral components necessary for assembly and propagation.
[0099] Nonsegmented negative-sense RNA virus: Type of virus that possesses a single, continuous strand of negative-sense RNA (-RNA) as its genome, rather than a genome divided into multiple RNA molecule segments. All nonsegmented negative-sense RNA viruses classified under the order Mononegavirales contain genes encoding three core proteins essential for their replication cycle: the RNA-dependent RNA polymerase L protein, the nucleoprotein N, and the phosphoprotein P. The L protein functions as the viral polymerase, responsible for both replication and transcription of the viral genome. The N protein encapsidates the viral RNA, forming a nucleocapsid structure that protects the genome and serves as the template for replication. The P protein acts as a cofactor that links the L protein to the nucleocapsid, facilitating proper polymerase activity. Despite differences among virus families within Mononegavirales, these three proteins or functional homologs are conserved across all members. For example, VP35 is a homologue of the P protein that is found in Ebola virus.
[0100] Nucleic acid fragment: A nucleic acid sequence (such as a linear sequence) of any length that, when assembled with (e.g., operably linked to) at least one other nucleic acid fragment, produces a complete nucleic acid molecule. In some embodiments, assembly of at least two nucleic acid fragments produces a nucleic acid that encodes a non-viral therapeutic polypeptide (peptide or protein) of the disclosure.
[0101] Operably linked: A first nucleic acid is operably linked with a second nucleic acid when the first nucleic acid is placed in a functional relationship with the second nucleic acid. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Where necessary to join two protein coding regions, the open reading frames are aligned. Similarly, proteins (including protein subunits, domains, and / or peptides) are operably linked when they are placed in a functional relationship with one another. In some examples, the operablyISB-153.01WO Attorney Reference No. 9929-113741-02 linked segments are in an arrangement that does not occur in nature. Linkers may be included between nucleic acid or protein segments.
[0102] Oncolytic virus: A virus that infects and replicates within cancer cells, leading to their destruction while essentially sparing normal cells. These viruses are capable of infecting tumor cells, replicating within them, and ultimately causing the cells to undergo apoptosis. Direct oncolysis is often accompanied by an immune-stimulating effect, as the destruction of cancer cells releases tumor-associated antigens, triggering the immune system to recognize and attack remaining tumor cells. Some oncolytic viruses occur naturally, such as Reovirus, Newcastle Disease Virus (NDV), Seneca Valley Virus (SVV), Vesicular Stomatitis Virus (VSV), and Coxsackievirus, while others are genetically engineered to enhance tumor selectivity and immune activation, like Talimogene laherparepvec (T-VEC), an engineered herpes simplex virus (HSV-1) for melanoma treatment, and Oncorine, a modified adenovirus used for certain cancers.
[0103] Pseudo-ribonucleotide: A modified ribonucleotide where the canonical nucleobase (adenine, guanine, cytosine, or uracil) is replaced or altered by a different chemical structure, or where the linkage between the base and the ribose sugar is modified, and that is transcriptionally and / or translationally competent. For example, pseudouridine is a natural isomer of uridine where the uracil base is attached to the ribose sugar via a carbon-carbon bond instead of the usual nitrogen-carbon bond. Additional examples include, but are not limited to, Nl-methylpseudouridine (mlT), 5-methoxy uridine, methyluridine, 5-methylcytidine, and 5-hydroxymethylcytidine.
[0104] Pharmaceutical grade: Standard of purity used by manufacturers to help ensure products are of the appropriate chemical purity and quality, in the appropriate solution or compound, to ensure stability, safety, and efficacy for medicinal use or testing in a vertebrate animal. In certain embodiments, pharmaceutical grade means any active or inactive drug, biologic or reagent, for which a chemical purity standard has been established by a recognized national or regional pharmacopeia (e.g., the U. S.
[0105] Pharmacopeia (USP), British Pharmacopeia (BP), National Formulary (NF), European Pharmacopoeia (EP), Japanese Pharmacopeia (JP), etc.).
[0106] Recombinant: A recombinant nucleic acid molecule is one that has a sequence drat is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or by the artificial manipulation of isolated segments of nucleic acid molecules, such as by genetic engineering techniques.
[0107] Ribosome recruitment element: One or more elements in RNA that recruit and promote host ribosome loading for translation. For example, if a trans-acting system, the ribosome recruitment element is a 5’-capping group in combination with a eukaryotic 5’ -untranslated region (5’-UTR), or a 5’ or internal ribosomal entry site (IRES) element. For example, if a cis-acting system, the ribosome recruitment element is a 5’-capping group in combination with 5'-UTR or a subgenomic promoter, andISB-153.01WO Attorney Reference No. 9929-113741-02 preferably, the first subgenomic promoter of the RNA virus genome of interest, or a 5’ or internal IRES element.
[0108] Ribosome skipping element: An element encoded into mRNA that promotes functional cleavage of translated polypeptides into multiple discrete proteins. Examples include, but are not limited to, self-cleaving peptide sequences such as T2A, P2A, E2A, and F2A from Thosea asigna, porcine teschovirus, equine rhinitus, and foot and mouth viruses. Sometimes referred to as ribosome skipping sequence (RSS).
[0109] Self-amplified RNA (saRN ): An engineered virus-derived RNA system designed to amplify a target RNA within cells, often together with self-replication. saRNA refers to a self-amplified construct in which genes encoding a virally derived RNA-dependent RNA polymerase (RdRp), also known as a replicase, and a compatible RdRp promoter are encoded on a single RNA molecule acting in cis for selfamplification.
[0110] Self-propagating: In certain embodiments, the saRNA and taRNA systems are self-propagating in that they include additional virus-derived structural genes needed for self-propagation and cell-to-cell spreading and infection in a manner similar to the natural virus. In other embodiments, the saRNA and taRNA systems are non-propagating in that they exclude virus-derived structural genes needed for selfpropagation.
[0111] Subgenomic promoter: Element on the RNA where the RdRp initiates mRNA synthesis. Necessary for the RdRp to begin the process of transcribing new mRNA molecules.
[0112] Subgenomic trailer: The untranslated sequence immediately preceding the stop codon of the viral subgenomic open-reading-frame, and immediately preceding the polyadenylation signal sequence. Involved in regulation of RdRp transcription and product mRNA stability.
[0113] Subject: A living multi-cellular vertebrate organism, a category that includes both human and veterinary subjects, including human and non-human mammals.
[0114] Trailer sequence: In many negative-sense RNA viruses, the trailer sequence is a short, noncoding sequence at the 5’ end of the genome or antigenome. Called the “trailer” because it is the last part of the RNA that the RdRp encounters during transcription.
[0115] Trans-amplified RNA (taRNA): Refers to a system of two or more RNA molecules in which the RdRp and the compatible RdRp promoter are encoded on separate RNA molecules that act in-trans for amplification of the RNA molecule containing the RdRp promoter. As such, the gene or genes encoding the RdRp when translated produce RdRp protein that can bind and initiate amplification of an RNA containing the compatible RdRp promoter.
[0116] Transduced and transformed: A vector “transduces” a cell when it transfers nucleic acid into the cell. Nucleic acid transduced into the cell can be replicated by the cell, either by incorporation of theISB-153.01WO Attorney Reference No. 9929-113741-02 nucleic acid into the cellular genome, by episomal replication, or by cytoplasmic self-replication or selfamplification. A cell is “transformed” by a nucleic acid transduced into the cell when the nucleic acid becomes stably replicated by the cell. As used herein, the term transformation encompasses all techniques by which a nucleic acid molecule is introduced into a cell, including transformation with plasmid vectors, and introduction of naked DNA or RNA by various mechanisms such as electroporation, lipofection, nanoparticle delivery, and particle gun acceleration.
[0117] Treating or inhibiting a condition: “Treating” a condition refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop. “Inhibiting” refers to inhibiting the full development of the disease or condition. Inhibition of a condition can span the spectrum from partial inhibition to substantially complete inhibition of the condition. In some examples, the term “inhibiting” refers to reducing or delaying the onset or progression of a disease. A subject to be treated can be identified by standard diagnosing techniques for such a disorder, for example, based on signs and symptoms, family history, and / or risk factors to develop tire disease or disorder.
[0118] Vector: A nucleic acid molecule allowing insertion of foreign nucleic acid without disrupting the ability of tire vector to replicate and / or integrate in a host cell. A vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector can also include one or more selectable marker genes and other genetic elements. An expression vector is a vector that contains the necessary regulatory sequences to allow transcription and translation of an inserted gene or genes. In some non-limiting examples, the vector is a mammalian expression vector.
[0119] III. Compositions
[0120] In general, compositions of the disclosure include non-viral nanoparticles encapsulating naked RNA encoding replicase components derived from a nonsegmented negative-sense RNA virus and one or more non-viral therapeutics. The naked RNA includes: (a) positive-sense RNA encoding RdRp L protein and accessory nucleoprotein N and phosphoprotein P derived from nonsegmented negative-sense RNA virus and under control of a ribosome recruitment element; and (b) positive- or negative-sense RNA encoding one or more non-viral therapeutic polypeptides under control of a subgenomic promoter for the RdRp L protein. The virus-derived RdRp L, N and P proteins and tire non-viral therapeutic polypeptide(s) can each individually be encoded on the same or different RNA molecules, with the proviso that when on the same molecule, the RNA is positive-sense and contained in the same non-viral nanoparticle delivery vehicle. The positive-sense RNAs encoding the RdRp L protein normally include accessory nucleoprotein N and phosphoprotein P derived from tire same RNA virus, for example, all derived from NDV. In many embodiments, the encapsulated naked RNA includes one or more pseudoribonucleotides, such as pseudouridine, Nl-methyl-pseudouridine, 5-methoxyuridine, 5-methylcytidine, 5-hydroxymethylcytidine, or methyluridine. RNA encoding virus-derived RdRp L, N and P proteins and non-viral therapeutic polypeptide can each individually incorporate pseudo-ribonucleotide in anyISB-153.01WO Attorney Reference No. 9929-113741-02 combination, and preferably, all RNA encoding RdRp L, N and P proteins are pseudo-ribonucleotidylated, and more preferably, all RNA encoding the RdRp L, N and P proteins and non-viral therapeutic polypeptide are pseudo-ribonucleotidylated. A featured embodiment is where the RNA is pseudo-uridinylated with Nl-methyl-pseudouridine. The compositions of the disclosure are preferably isolated and purified non-viral nanoparticle delivery vehicles encapsulating the naked RNAs. Examples of the delivery vehicle include lipid-based nanoparticles, polymer-based nanoparticles, inorganic nanoparticles, and hybrid lipid-polymer nanoparticles. A preferred embodiment is where the isolated and purified non-viral nanoparticle delivery vehicle is pharmaceutical grade.
[0121] The nonsegmented negative-sense RNA virus is usually a paramyxovirus selected from the Paramyxoviridae family, and the virus-derived elements of the encapsulated RNA are derived essentially from a paramyxovirus genome. In many embodiments, the paramyxovirus genome is selected from Avulavirus, Respirovirus, or Rubulavirus. A particular aspect is where the paramyxovirus genome of (i) Avulavirus is NDV, (ii) Respirovirus is selected from SEV, hPIV1, and hPIV3, and (iii) Rubulavirus is selected from hPIV2, hPIV4, PIV5, and MuV. A featured embodiment is where the paramyxovirus genome is NDV.
[0122] As noted above, a preferred embodiment is where the RNA encoding the RdRp L, N, and P proteins are derived from the same RNA virus. In as many embodiments, the encapsulated RNA further encodes an interferon suppressor, and preferably, a paramyxovirus-derived immune evasion protein V, such as selected from Newcastle disease virus, PIV5, and measles virus. In a specific embodiment, the paramyxovirus genome is NDV and the V protein for non-propagating RNA constructs is derived from measles virus, and for propagating RNA constructs is derived from NDV. The interferon suppressor can also be derived from various sources other than the virus family from which the RdRp L, N, and / or P is / are derived, such as the E3, K3 and / or B18R proteins from vaccinia virus, or NS1 from influenza A virus. In other embodiments, the interferon suppressor is specifically excluded in order to retain or increase the host interferon response.
[0123] In certain embodiments, the system utilizes viral proteins selected from NDV, parainfluenza virus hPIV5, or a combination thereof, such as where the viral proteins are selected from (a) all NDV viral proteins, (b) all hPIV5 viral proteins, or (c) NDV N and P proteins, an NDV L protein, and a hPIV5 virus V protein. For human applications, the wild-type hPIV5 V protein is preferably utilized, whereas for rodent models, a mPIV5 V protein harboring an N100D mutation can be used to better compatibility.
[0124] In some embodiments, the compositions include naked RNA comprising: (a) positive-sense RNA encoding RdRp L protein and accessory nucleoprotein N and phosphoprotein P derived from a nonsegmented negative- sense RNA virus and under control of a ribosome recruitment element; and (b) positive- or negative-sense RNA encoding one or more non-viral polypeptides under control of one or more subgenomic promoters for the RdRp L protein; wherein the naked RNA encoding the RdRp L, N and P proteins and the one or more non-viral polypeptides are each individually encoded on the same orISB-153.01WO Attorney Reference No. 9929-113741-02 different RNA molecule, with the proviso that when encoded on the same molecule the RNA is positivesense; and wherein the RNA comprises one or more pseudo-ribonucleotides, such as pseudouridine, Nl-methyl-pseudouridine, 5-methoxyuridine, 5-methylcytidine, 5-hydroxymethylcytidine, or methyluridine. In many embodiments, the non-viral polypeptide is a therapeutic polypeptide. In certain embodiments, the non-viral polypeptide is a biomarker polypeptide.
[0125] In some embodiments, the compositions include a positive-sense RNA molecule encoding an RdRp protein derived from either a positive-sense or a negative-sense RNA virus, where the RNA molecule encoding the RdRp comprises a 5’ end, a 3’ end, or both a 5’end and a 3’ end modified with one or more exonuclease-resistant hairpins, preferably two to three exonuclease-resistant hairpins, a more preferably one or more exonuclease-resistant hairpins in combination with an IRES for initiating translation.
[0126] In some embodiments, the compositions include one or more positive-sense RNAs encoding RdRp L protein and accessory nucleoprotein N and phosphoprotein P derived from a nonsegmented negative-sense RNA virus, and wherein one or more genes encoding the N, P and RdRp L proteins are operably linked through at least one ribosome skipping element. Examples include, but are not limited to, self-cleaving peptide sequences such as T2A, P2A, E2A, and F2A from Thosea asigna, Porcine teschovirus, Equine rhinitus, and foot and mouth viruses. A specific example is where the ribosome skipping element is T2A. In related embodiments, the positive-sense RNA has 5’ and 3’ ends, the 5’ end containing an IRES element group or capped with an m7G-ribonucleotide or analog, and optionally, the 3’ end modified with an exonuclease resistant group, such as one or more hairpins or a poly- A tail. In certain embodiments, the RNA further includes an immune evasion protein V gene of a nonsegmented negative-sense RNA virus, and the V gene is operably linked to one or more of the N, P and RdRp L genes through a ribosome skipping element. A specific embodiment is where the N, V, P and RdRp L genes are each independently present or absent on a given positive sense RNA molecule, and when present, are operably linked in any position XI through X4 in the 5’ to 3’ direction of the formula 5’-W-X1-Y1-X2-Y2-X3-Y3-X4-Z-3’, wherein: (a) W is a 7mG ribonucleotide or analog capping group or contains an IRES group; (b) XI through X4 are each individually present or absent, with the proviso that at least two of the N, V, P and L genes are present; (c) Y1 through Y3 are each individually a ribosome skipping element that is present or absent, with the proviso that at least one ribosome skipping element is present; and (d) Z is present or absent, and when present, is one or more genes of interest encoding a polypeptide of interest, such as a biomarker or therapeutic polypeptide. In certain embodiments, the RdRp L gene is encoded on a first positive sense RNA molecule, and the N, V and P genes are encoded on a second positive sense RNA molecule and operably linked through at least one ribosome skipping element. In other embodiments, the RdRp L gene is encoded on a first positive sense RNA molecule, and the N and P genes are encoded on a second positive sense RNA molecule and operably linked through the ribosome skipping element. In many embodiments, Z is encoded on a separate negative sense RNA molecule.ISB-153.01WO Attorney Reference No. 9929-113741-02 Another embodiment is where the naked RNA includes a non-viral Kozak sequence or element, or a Kozak-like sequence or element derived from the virus genome. Of particular interest is where the Kozak sequence or element is operably linked 3’ of a promoter and 5’ of a gene of interest for enhancing translation of the gene of interest, such as a viral gene encoding N, P, or RdRp L protein or a non-viral gene encoding a non-viral polypeptide. In certain embodiments, a non-viral Kozak sequence is optionally placed at the start of one or more sub-genomic ORFs in addition to, or in place of, the natural Kozak-like sequence to enhance translation of viral replication proteins. For phasing, care is taken to make sure that the total N protein-recognizable genomic length is maintained as divisible by six, using hexamer phase correction or non-viral Kozak sequences as necessary to meet this requirement. Also, adjusting the design of the Kozak sequence in this manner can be used to enhance first-round translation of viral replication proteins when placed in front of the first subgenomic ORF.
[0127] In certain embodiments, the RdRp L, N and P and the one or more non-viral therapeutic polypeptide are encoded on two or more separate RNA molecules and the ribosome recruitment element is selected from: (i) a 5 ’-capping group in combination with a eukaryotic 5 ’-untranslated region (5’-UTR); or (ii) a 5’ or internal ribosomal entry site (IRES) element. In other embodiments, the RdRp L, N and P proteins and the non-viral therapeutic polypeptide are encoded on the same RNA molecule and the ribosome recruitment element is selected from: (i) a 5’-capping group in combination with a eukaryotic 5’-UTR; (ii) a 5 ’-capping group in combination with a subgenomic promoter, and preferably the first subgenomic promoter, of the nonsegmented negative-sense RNA virus; or (iii) a 5’ or internal IRES element alone or in combination with a 5 ’capping group and / or a subgenomic promoter. In many embodiments, the 5’-capping group is an m7G ribonucleotide or analog selected from m7G-ppp-AG, m7G-ppp-AC, m7G-ppp-AU, or analog thereof, and the IRES is a Class II IRES, such as a Class II IRES derived from encephalomyocarditis virus (ECMV). In as many embodiments, the m7G-ppp-AG or analog thereof is selected from: 7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyladenosine-(5’)phosphate-(5’)-guanosine; 3’-O-methyl-7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyl-adenosine-(5’)phosphate-(5’)-guanosine; and 3’-O-methyl-7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyl-N6-methyladenosine-(5’)phosphate-guanosine. In as many embodiments, the m7G-ppp-AU or analog thereof is selected from: 7-methylguanosine-(5’)triphosphate-(5’)-adenosine-(5’)phosphate-(5’)-uricil; and 7-methylguanosine-(5 ’ )triphosphate-(5 ’ )-2’ -O-methyladenosine-(5 ’ )phosphate-(5 ’ )-uricil. In as many embodiments, the m7G-ppp-AC or analog thereof is selected from 7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyladenosine-(5’)phosphate-(5’)-cytosine (compound 1); 3’-O-methyl-7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyl-adenosine-(5’)phosphate-(5’)-cytosine (compound 2); or 3’-O-methyl-7-methylguanosine-(5’)triphosphate-(5’)-2’-O-methyl-N6-methyladenosine-(5’)phosphate-cytosine (compound 3).ISB-153.01WO Attorney Reference No. 9929-113741-02
[0128]
[0129] compound 1 compound 2 compound 3 When the RdRp L and the non-viral polypeptide are encoded on the same RNA molecule, the encapsulated RNA preferably has a 5’ end that is native or modified, and the native 5’ end is 5’-ACCA, and wherein the modified 5’ end is selected from 5’m7G-ACCA, 5’m7G-A(G / U)CA, 5’m7G-A(G / U)NNNACCA, and 5’m7G-A(G / U)NNNNACCA, wherein N is any ribonucleotide compatible with replication initiated by the RdRp, and wherein m7G is a 7-methylguanosine or analog capping group. These and other modifications can be made to ensure a desired translation initiation and to make sure total genomic length is divisible by six and that taRNA promoters and trailers are in their proper hexamer phasing for nucleoprotein binding, for example, by addition of hexamer phase correction sequence(s), Kozak sequence(s), or gene coding sequence modifications applied to the construct at specific loci. As such, a featured example is where the nonsegmented negative-sense RNA virus is a paramyxovirus, and the encapsulated RNA conforms to the hexamer rule. As noted above, the non-viral polypeptide includes therapeutic and biomarker polypeptides, or combinations thereof, and is preferably a therapeutic polypeptide.
[0130] Turning now to FIG. 3, the figure illustrates an embodiment of the disclosure. As shown in the top left portion of the figure, a nonsegmented negative-sense taRNA encoding one or more therapeutic proteins is co-encapsulated in a non-viral, synthetic nanoparticle alongside a positive-sense mRNA encoding an RdRp L protein and accessory RNA replication proteins (N and P) derived from a nonsegmented negative-sense RNA virus (denoted for brevity as just RdRp in FIG.3, and shown FIGs 4, 5, and 6 in more detail as “positive-sense mRNA transcript encoding RdRp”). The synthetic nanoparticle is endocytosed into the target cell by a pre-designed uptake mechanism (e.g., fusion with low-density lipoprotein receptor or asialoglycoprotein receptor). Following endosomal escape, the positive-sense mRNA is translated by host ribosomal machinery to produce N, P, L, and optionally V protein. In situ translated N, P, and L proteins thereafter associate with the nonsegmented negative-sense taRNA transcript to form an active replication complex. Viral RdRp L performs subgenomicISB-153.01WO Attorney Reference No. 9929-113741-02 transcription to produce positive-sense therapeutic protein mRNA that is both m7G-capped and polyadenylated. This mRNA is translated by host ribosomal machinery to produce a therapeutic protein that is optionally secreted by an export signal sequence through the endoplasmic reticulum pathway. As can be seen in the bottom of the figure, nonsegmented positive-sense saRNA encoding both the viral RdRp L and one or more non-viral therapeutic proteins is encapsulated in a synthetic, non- viral nanoparticle. The synthetic nanoparticle is endocytosed into tire target cell by a pre-designed uptake mechanism (e.g., fusion with low-density lipoprotein receptor or asialoglycoprotein receptor). Following endosomal escape, RdRp L and the accessory viral replication proteins (N, P, and optionally V) are translated by host ribosomal machinery from the m7G-capped saRNA. In situ translated N, P, and L proteins thereafter associate with the positive-sense, nonsegmented taRNA transcript to form an active replication complex. Viral RdRp first performs genomic transcription to produce negative-sense genomic RNA. Subsequently, RdRp L-mediated subgenomic transcription produces positive-sense therapeutic protein mRNA and viral RdRp L mRNA that is both m7G-capped and polyadenylated. This mRNA is translated by host ribosomal machinery to produce a therapeutic protein that is optionally secreted by an export signal sequence through the endoplasmic reticulum pathway. When codon-optimizing the therapeutic protein(s) for inclusion in the trans- or self-amplifying RNA design, care should be taken to avoid codon combinations that produce tire consensus core polyadenylation signal motif ‘AGAAAAA’ or ‘UCUUUUIT found in Paramyxoviridae genomes. Failure to do so could result in premature polyadenylation of subgenomic RdRp-transcribed mRNA. Where possible, the +4 ribonucleotide position of the therapeutic protein should preferentially encode a guanosine to enhance the positive translational effect produced by the Kozak-like sequences that is found in certain Paramyxoviridae subgenomic promoters immediately upstream of the ORF.
[0131] Referring to FIG.4, shown is a nonsegmented negative-sense taRNA system of die disclosure, utilizing a total of two transcripts. RSS indicates a ribosomal skipping sequence such as T2A for compacting cassette size and performance. In this example, the viral proteins are derived from the Paramyxoviridae virus family, indicated by Paramyx N, V, P, and L. The replication-essential nucleoprotein N and phosphoprotein P proteins are preferably from the same virus species as the chosen RdRp L protein. Also depicted in this example is the inclusion of an optional interferon suppression V protein for limiting interferon suppression. The V protein can be derived from a virus of the same or a different species than the N, P, and L proteins, or excluded when an interferon suppression response is desired. The transcripts can incorporate pseudo-ribonucleotides and are preferably N1-methyl-pseudourinated depending on the intended end use. FIG. 4A shows nonsegmented negative-sense taRNA transcript encoding a gene-of-interest (GOI) ORF, comprising a viral negative-sense subgenomic promoter that drives RdRp L-dependent transcription of the GOI, followed by a viral subgenomic trailer and polyadenylation signal. A variable number of subgenomic ORFs from n = 1 to 6 can be incorporated in a given taRNA cassette, each driven by its own subgenomic promoter, terminated on the 3’ end by a genomic promoter and on the 5’ end by a complement antigenomic promoter. Care is taken such that theISB-153.01WO Attorney Reference No. 9929-113741-02 resulting taRNA is divisible by a nucleoprotein-recognizable multiple of six ribonucleotides to conserve hexamer phasing across all viral regulatory elements. FIG. 4B shows two single-transcript configurations of a positive-sense mRNA encoding a nonsegmented negative-sense viral RdRp L protein, either as (i) 5’ m7G or analog capped, polyadenylated mRNA with conventional 5’- and 3’-UTRs, or (ii) hairpin or multi-hairpin terminated, IRES-driven mRNA.
[0132] FIG.5 shows a nonsegmented negative-sense taRNA system of the disclosure utilizing a total of three transcripts. Again, RSS indicates a ribosomal skipping sequence such as T2A, viral proteins N, V, P and L are derived from the Paramyxoviridae virus family, an optional interferon suppression V protein is included, the transcripts are N1-methyl-pseudourinated, and a taRNA transcript cassette encoding one or more GOI ORFs, as described for FIG. 4. Briefly, FIG. 5A and FIG.5B show an expression system using components as described in FIG. 4 configured on a total of three transcripts. The first transcript is a nonsegmented negative-sense taRNA encoding one or more GOI ORFs and shown in FIG.5A. The second and third transcripts are both positive-sense mRNAs encoding the nonsegmented negative-sense viral replication proteins N, V, P and L (FIG. 5B). As can be seen in FIG.5B, the RdRp L protein is encoded on one transcript, and the N, V, and P proteins are encoded on another transcript, and both transcripts are 5’ m7G or analog capped, polyadenylated, and utilize conventional 5’- and 3’-UTRs.
[0133] FIG.6 illustrates several examples of using a nonsegmented negative-sense taRNA system of tire disclosure for encoding one or more non- viral therapeutic proteins. Abbreviations used in prior figures carry tire same meanings. A plurality of different non- viral therapeutic encoding taRNA GOI ORF cassettes are shown in the left side of the figure. Each of these are individually paired with one of the complementary taRNA cassettes encoding the non-structural viral replication proteins N, P, and L, (and optionally V for interferon suppression), as depicted on the right hand side of the figure. As shown, the therapeutic taRNA GOI ORF cassettes encode (i) a single non- viral therapeutic protein in a single subgenomic ORF configuration (e.g., a recombinant IgG-fusion protein such as Etanercept, a short peptide such as Exenatide, or a natural human hormone such as Erythropoietin (Epoetin alpha)), (ii) two non-viral therapeutic proteins in a dual subgenomic ORF configuration (e.g., a monoclonal antibody (mAb) such as Adalimumab, separately encoding its constituent light and heavy chains as discrete subgenomic ORFs), or (iii) three non-viral therapeutic proteins in a triple subgenomic ORF configuration (e.g., a three sub-genomic ORF taRNA construct encoding the light and heavy chains of a mAb, such as Ustekinumab, in combination with an adjuvant therapeutic protein such as hyaluronidase to improve distribution kinetics). Again, a given one of these negative-sense transcript taRNA constructs is combined with a positive-sense mRNA transcript encoding the nonsegmented negative-sense virus RdRp L protein and accessories N and P, and optionally V.
[0134] FIG.7 illustrates another embodiment of the disclosure. Shown are different nonsegmented positive-sense saRNA constructs. Abbreviations used in prior figures carry the same meanings. For example, all transcripts depicted are preferably N1-methyl-pseudourinated and employ a ribosomal skipping sequence RSS such as T2A, and all constructs depict non-structural viral replication proteinsISB-153.01WO Attorney Reference No. 9929-113741-02 RdRp / L, N, and P from a nonsegmented negative-sense virus. Also, in these examples, the interferon-suppressor V protein is included to suppress the initial cellular interferon response. The resulting saRNAs are each individually divisible by a nucleoprotein-recognizable multiple of six ribonucleotides, and conserves hexamer phasing across all viral regulatory elements. FIG.7A and FIG.7B show the N, V, P and L proteins recombinantly placed under control of the first subgenomic ORF promoter of an anti-genomic (positive-sense) segment derived from the virus. One or more therapeutic genes of interest are placed under control of the 2nd to 6th subgenomic promoters of the virus. The 5’ end of the positivesense antigenomic saRNA is modified by capping with an m7G, m7G- AC, or analog (FIG.7A), by single-base C-> G or C-> U substitution for capping with a m7G-AG or m7G- AU or analog, or by addition of a pentamer A(G / U)NNN or hexamer A(G / U)NNNN sequence and m7G or analog cap to die natural 5’ ACCA end of die saRNA (FIG.7B). FIG.7C show the N, V, P and L proteins recombinantly placed under control of the first subgenomic promoter as well, the therapeutic gene or genes of interest placed under the 2nd to 6th subgenomic promoters, and an IRES element placed immediately following the first subgenomic promoter to facilitate ribosomal loading of the transcript and translation of viral replication proteins. Incorporating the IRES element within the first subgenomic ORF permits further subgenomic transcription of mRNA encoding IRES-driven viral replication proteins. A further design includes a di-cistron configuration under the first subgenomic promoter, wherein the first cistron encoding N-P is translated by cap-dependent ribosome recruitment, and a flanking IRES element independently drives L protein translation.
[0135] Referring now to FIGs 8 dirough 11, these figures illustrate additional compositions of the disclosure that can propagate and produce replication-competent virus particles after initial transfection.
[0136] FIG.8 shows a trans-amplified propagating system and cycle. As can be seen, engineered trans-amplified propagating, nonsegmented negative-sense viral RNA encoding one or more therapeutic proteins and all non-structural and structure viral proteins are encapsulated in the same, or as depicted, separate non-viral synthetic nanoparticles. In particular, nanoparticles such as LNPs (Lipid Nanoparticles) are manufactured by combining lipids and the naked RNA constructs in a controlled environment, followed by purification and sterile filtration to create a stable, encapsulated LNP nanoparticle delivery system. In this example, the naked RNAs contained in the nanoparticles include a positive-sense mRNA molecule encoding RdRp L, N and P (and optionally V) proteins (denoted for brevity as just RdRp in FIG. 8 and 9, and shown FIGs 10A and 11C in more detail as “positive-sense mRNA hanscript encoding RdRp”), and a negative-sense RNA molecule encoding all replication proteins (N, P, L, and optionally V) as well as viral structural proteins (M, H, F) and a therapeutic protein(s) of interest, where the viral components are each derived from the nonsegmented negativesense RNA virus (denoted for brevity as just “propagating, nonsegmented negative-sense RNA” in FIG.
[0137] 8 and shown in more detail as “propagating, nonsegmented negative-sense trans-amplified viral RNA” in FIG. 10A and FIGs 11A through 11C). As a first step, the manufactured non-viral nanoparticles are administered to, and then endocytosed by, a target cell (e.g., fusion with low-density lipoprotein receptorISB-153.01WO Attorney Reference No. 9929-113741-02 or asialoglycoprotein receptor). Following endosomal escape, the positive-sense mRNA is translated by host ribosomal machinery to produce N, P, L, and optionally V protein. In situ translated N, P, and L proteins thereafter associate with the nonsegmented negative-sense viral RNA transcript to form an active replication complex. Viral RdRp L performs subgenomic transcription to produce positive-sense therapeutic and viral protein mRNA that is both m7G-capped and polyadenylated. This mRNA is translated by host ribosomal machinery to produce a therapeutic protein (such as a di-scFv bi-specific T-cell engager depicted in the illustration), that is optionally secreted by an export signal sequence through the endoplasmic reticulum pathway. Simultaneously, viral structural (M, H, F) and non-structural (N, P, L, V) protein encoding mRNAs are translated by host machinery. N, P, L proteins perform antigenomic transcription and subsequent genomic transcription to produce pre-formed replication complex, which associates with matrix protein and localizes to the inner cell membrane with cell-surface exported F and H proteins. Viral budding thereafter occurs, generating a fully-mature, replication-competent engineered virus particle capable of propagating in vivo, without the need for the initial positive-sense mRNA encoding the RdRp replicase system that was co-administered to prime the process to begin with.
[0138] FIG. 9 shows a self-amplified propagating system and cycle. As shown, the naked, engineered RNA is encapsulated in a manufactured, synthetic non- viral nanoparticle, such as an LNP. The naked RNA is an m7G-capped, self-amplified propagating, nonsegmented positive-sense viral RNA encoding RdRp L protein and other essential RNA replication proteins (N, P), one or more therapeutic proteins, and viral structural proteins (M, F, H) derived from a nonsegmented negative-sense RNA virus genome. Upon administration, the synthetic nanoparticles are endocytosed into the target cell and processed as described above for FIG.8, with the exception being replication proteins being translated directly from the saRNA without a need for a separate positive- sense taRNA RdRp replicase construct to initiate the propagation cycle. Viral budding thereafter occurs, generating a fully-mature, replication- competent engineered virus particle.
[0139] FIG. 10 shows the architectures of two different propagating nonsegmented negative-sense RNA virus genome constructs in detail. One is presented as a trans-amplified configuration that requires initial priming with a positive-sense RNA encoding the RdRp L, N and P replicase complex (FIG. 10A) and the other is a cis, self-amplified construct containing all elements needed for translation initiation and propagation (FIG. 10B). Preferably, all transcripts depicted are N1-methyl-pseudourinated. Also, the RNAs are designed to be divisible by a nucleoprotein-recognizable multiple of six ribonucleotides, and conserves hexamer phasing across all viral regulatory elements. As shown in FIG. 10A, the propagating, nonsegmented negative-sense trans-amplified viral RNA system encodes one or more therapeutics using subgenomic promoters from related viral strains. Briefly, assuming a NDV system, a natural virus strain such as Newcastle Disease Strain LaSota, is modified to insert 1 to 3 additional subgenomic replicons from a related strain, such as Newcastle Disease Strain Bl or Ulster. Under these 1 to 3 additional subgenomic promoters is inserted one or more therapeutic proteins, optionally utilizing ribosomal skipping sequences (RSS) to encode multiple therapeutics under a single subgenomic promoter.ISB-153.01WO Attorney Reference No. 9929-113741-02 Delivered in parallel with the recombinantly engineered negative-sense viral genome is a positive-sense mRNA transcript encoding RdRp and other required viral replication proteins P and N, and optionally an interferon suppressor V protein. FIG. 10B shows a propagating, nonsegmented positive-sense selfamplified viral RNA system in a cis configuration of the disclosure. Briefly, essential non-structural viral replication proteins from a nonsegmented negative-sense virus, including RdRp L, nucleoprotein N, and phosphoprotein P, are recombinantly placed in the first subgenomic promoter of an anti-genomic (positive-sense) configured viral saRNA. One or more therapeutic genes of interest are placed under the 2nd to 4th sub-genomic promoters, utilizing the natural P subgenomic promoter to drive the first therapeutic protein, and utilizing ribosomal skipping sequences (RSS) or inserting recombinant subgenomic promoters from other related strains to drive subsequent therapeutic proteins. The 5’ end of the positive-sense antigenomic RNA is modified by co-transcriptional or post-transcriptional capping with a m7G or an m7G analog such as m7G-AC analog, by single-base C-> G or C-> T substitution for capping with a m7G-AG or m7G-AU or analog, or by addition of a pentamer A(G / U)NNN or hexamer A(G / U)NNNN sequence and m7G or analogue cap to the natural 5’ ACCA end of the RNA. Interferon-suppressor V protein is optionally included and placed upstream of any GOIs or viral structural genes so as to suppress the initial interferon response against RNA transfection into cells.
[0140] Turning now to FIG. 11. This figure depicts a series of examples of the propagating, nonsegmented negative-sense trans-amplified viral RNA genomes, targeted at different cancers. All constructs are delivered in trans with a positive-sense mRNA molecule encoding RdRp L and viral replication proteins N and P, and optionally V. RSS indicates a ribosomal skipping sequence such as T2A, as above. FIG. 11A depicts a pancreatic-cancer targeted NDV LaSota strain, incorporating a transmembrane-anchored anti-CA19-9 single-chain variable fragment (scFv) under a recombinant subgenomic promoter from NDV Ulster strain. Virus particles presenting transmembrane-anchored anti-CA19 scFv are targeted specifically towards CA19+ pancreatic cancer cells, utilizing the natural hemagglutinin-mediated fusion mechanism for cell entry. FIG. 11B shows an example of a colorectal-cancer targeted NDV LaSota strain, incorporating a transmembrane-anchored anti-CEACAM5 singlechain variable fragment (scFv) under a recombinant subgenomic promoter from NDV Ulster strain. Linked by a ribosomal skipping sequence (RSS) to the TM-anchored scFv is an anti-PDLl x anti-CD3 di-scFv bi-specific T-cell engager (BiTE). Virus particles presenting transmembrane-anchored anti-CEACAM5 scFv are targeted specifically towards CEACAM5+ colorectal cancer cells, utilizing the natural hemagglutinin-mediated fusion mechanism for cell entry. Target cells infected with virus will locally produce and export the PDLl-targeted BiTE in the intra-tumoral space. FIG. 11C depicts an acute lymphoblastic leukemia (ALL) targeted NDV LaSota strain, incorporating a transmembrane-anchored anti-CD19 single-chain variable fragment (scFv) under a subgenomic promoter from NDV Ulster strain. Under a second recombinant subgenomic promoter from strain Ulster is an anti-PDLl x anti-CD3 di-scFv bi-specific T-cell engager (BiTE). Virus particles presenting transmembrane-anchored anti-CD19 scFv are targeted specifically towards CD19+ ALL cancer cells, utilizing the naturalISB-153.01WO Attorney Reference No. 9929-113741-02 hemagglutinin-mediated fusion mechanism for cell entry. Target cells infected with virus will locally produce and export the PDLl-targeted BiTE.
[0141] As such, the non-viral therapeutic polypeptide can generally include single chain, multi-subunit, secreted, non-secreted, and membrane anchored polypeptides. Examples of the non-viral therapeutic polypeptide include, but are not limited to antibodies, fusion proteins, enzymes, hormones, growth factors, blood products, neoantigens, coagulation factors, cell surface and tissue biomarkers, toxins, venoms, and derivatives thereof. Of particular interest is where the non-viral therapeutic polypeptide is selected from Fc-fusion proteins and antibodies. A featured aspect is where the antibody includes light and heavy chain subunits, and where the RNA encoding the light chain subunit is positioned upstream of the RNA encoding the heavy chain subunit. In many embodiments, the encapsulated RNA encodes two or more non-viral therapeutic polypeptides each independently regulated by its own subgenomic promoter.
[0142] Neoantigen vaccines are of specific interest, for example, a neoantigen vaccine for colorectal cancer (CRC) immunotherapy. A potential vaccine design preferably incorporates recurrent CRC-associated mutations, such as KRAS G12D and G12V, TP53 R175H and R248Q, PIK3CA E545K and H1047R, BRAF V600E, and RNF43 G659fs. A panel including these neoantigens has the potential to elicit immune responses across diverse HLA alleles, enhancing population coverage. For instance, peptides derived from KRAS G12D have been shown to be presented by HLA-All:01 and HLA-C08:02, supporting their relevance for targeted T-cell immunotherapies (Ng et al., 2024; Hartley, 2016).
[0143] Similarly, KRAS G12V has demonstrated binding to HLA-All:01 and HLA-A03:01, further expanding the applicable patient population (Ng et al., 2024; Sim et al., 2024). The TP53 R175H mutation generates immunogenic peptides that are presented by HLA-A*02:01, and several clinical trials are investigating T cell-based therapies targeting this epitope (NCI Clinical Trials, 2024). While the HLA restriction of TP53 R248Q is less well-characterized, its high prevalence and recurrence in CRC make it a compelling target for further study. Though definitive HLA-binding data are limited for PIK3CA E545K, H1047R, and BRAF V600E mutations, their frequent occurrence in CRC and roles in tumorigenesis make them attractive for inclusion in shared neoantigen vaccines. Notably, the RNF43 G659fs frameshift mutation is enriched in microsatellite instability-high (MSI-H) CRC and is likely to produce novel peptide sequences capable of generating strong neoantigenic responses, although its HLA presentation profile remains to be elucidated. To enhance immunogenicity and HLA coverage, a focused neoantigen panel could prioritize mutations frequently presented in CRC and known to bind HLA-A* 11:01, such as KRAS G12D, PIK3CA E545K, TP53 R248Q, BRAF V600E, and FBXW7 R479Q (see, e.g., SEQ ID NO. 32).
[0144] Polypeptide examples of specific interest are provided in Tables 1 (non-viral polypeptide) and Table 3 (corresponding RNA) below. The viral polypeptides and the viral RNA of specific interest are provided in Table 2 (viral polypeptide) and Table 4 (corresponding RNA) below. In addition, Tables 5 to 20 below depict the amino acid and RNA sequences for such exemplary constructs of the disclosure. As can be seen, some of the constructs include secretion signals or other accessary elements. TheseISB-153.01WO Attorney Reference No. 9929-113741-02 examples are provided for illustrative purposes only and are not intended to be limiting; other accessory sequences may be included or excluded based on the specific requirements of the intended end use. Table 1. Non- viral polypeptides
[0145]
[0146] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0147]
[0148] Table 2. Viral polypeptides
[0149]
[0150] ISB-153.01WO Attorney Reference No. 9929-113741-02 Table 3. RNAs encoding non-viral polypeptides
[0151]
[0152] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0153]
[0154] Table 4. RNAs encoding viral RdRp and viral accessory proteins
[0155]
[0156] The following Tables 5-13 depict amino acid and RNA sequences for constructs of the disclosure. In particular, Table 5 depicts non-viral polypeptide amino acids (standard one letter amino acid code) SEQ ID NOs 1-32. Table 6 depicts viral polypeptide amino acid sequences (standard one letter amino acid code) SEQ ID NOs 33-47. Table 7 depicts nonsegmented negative-sense trans-ISB-153.01WO Attorney Reference No. 9929-113741-02 amplified RNA (3'->5') nucleotide sequences (standard one letter ribonucleotide code) SEQ ID NOs 48-64. Table 8 depicts positive-sense RdRp and viral accessory mRNA (5'->3') nucleotide sequences (standard one letter ribonucleotide code) SEQ ID NOs 65-69. Table 9 depicts nonsegmented positivesense self-amplified RNA (5'->3') nucleotide sequences (standard one letter ribonucleotide code) SEQ ID NOs 70-75. Table 10 depicts propagating, nonsegmented negative-sense trans-amplified viral RNA (3->5') nucleotide sequences (standard one letter ribonucleotide code) SEQ ID NOs 76-81. Table 11 depicts propagating, nonsegmented positive-sense self-amplified viral RNA (5'->3') nucleotide sequences (standard one letter ribonucleotide code) SEQ ID NOs 82-87. Table 12 depicts nonsegmented negativesense trans-amplified RNA (3'->5') nucleotide sequences (standard one letter ribonucleotide code) SEQ ID NOs 88-89. Table 13 depicts positive-sense RdRp and viral accessory mRNA (5'->3') nucleotide sequences (standard one letter ribonucleotide code) SEQ ID NOs 90-93.
[0157] Table 5. Non-viral polypeptides
[0158]
[0159] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0160]
[0161] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0162]
[0163] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0164]
[0165] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0166]
[0167] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0168]
[0169] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0170]
[0171] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0172]
[0173] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0174]
[0175] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0176]
[0177] Table 6: Viral polypeptides
[0178]
[0179] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0180]
[0181] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0182]
[0183] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0184]
[0185] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0186]
[0187] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0188]
[0189] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0190]
[0191] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0192]
[0193] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0194]
[0195] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0196]
[0197] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0198]
[0199] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0200]
[0201] Table 7. Nonsegmented Negative-Sense Trans- Amplified RNA (3'->5')
[0202]
[0203] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0204]
[0205] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0206]
[0207] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0208]
[0209] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0210]
[0211] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0212]
[0213] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0214]
[0215] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0216]
[0217] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0218]
[0219] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0220]
[0221] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0222]
[0223] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0224]
[0225] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0226]
[0227] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0228]
[0229] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0230]
[0231] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0232]
[0233] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0234]
[0235] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0236]
[0237] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0238]
[0239] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0240]
[0241] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0242]
[0243] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0244]
[0245] Table 8. Positive-Sense RdRp and Viral Accessory mRNA (5’- >3’)
[0246]
[0247] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0248]
[0249] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0250]
[0251] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0252]
[0253] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0254]
[0255] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0256]
[0257] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0258]
[0259] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0260]
[0261] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0262]
[0263] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0264]
[0265] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0266]
[0267] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0268]
[0269] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0270]
[0271] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0272]
[0273] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0274]
[0275] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0276]
[0277] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0278]
[0279] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0280]
[0281] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0282]
[0283] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0284]
[0285] ISB-153.01WO Attorney Reference No. 9929-113741-02 Table 9: Nonsegmented Positive-Sense Self-Amplified RNA (5'->3')
[0286]
[0287] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0288]
[0289] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0290]
[0291] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0292]
[0293] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0294]
[0295] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0296]
[0297] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0298]
[0299] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0300]
[0301] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0302]
[0303] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0304]
[0305] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0306]
[0307] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0308]
[0309] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0310]
[0311] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0312]
[0313] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0314]
[0315] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0316]
[0317] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0318]
[0319] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0320]
[0321] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0322]
[0323] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0324]
[0325] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0326]
[0327] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0328]
[0329] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0330]
[0331] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0332]
[0333] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0334]
[0335] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0336]
[0337] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0338]
[0339] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0340]
[0341] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0342]
[0343] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0344]
[0345] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0346]
[0347] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0348]
[0349] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0350]
[0351] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0352]
[0353] Table 10: Propagating, Nonsegmented Negative-Sense Trans-Amplified Viral RNA (3'->5')
[0354]
[0355] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0356]
[0357] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0358]
[0359] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0360]
[0361] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0362]
[0363] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0364]
[0365] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0366]
[0367] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0368]
[0369] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0370]
[0371] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0372]
[0373] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0374]
[0375] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0376]
[0377] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0378]
[0379] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0380]
[0381] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0382]
[0383] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0384]
[0385] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0386]
[0387] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0388]
[0389] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0390]
[0391] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0392]
[0393] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0394]
[0395] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0396]
[0397] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0398]
[0399] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0400]
[0401] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0402]
[0403] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0404]
[0405] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0406]
[0407] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0408]
[0409] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0410]
[0411] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0412]
[0413] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0414]
[0415] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0416]
[0417] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0418]
[0419] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0420]
[0421] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0422]
[0423] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0424]
[0425] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0426]
[0427] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0428]
[0429] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0430]
[0431] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0432]
[0433] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0434]
[0435] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0436]
[0437] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0438]
[0439] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0440]
[0441] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0442]
[0443] Table 11. Propagating, Nonsegmented Positive-Sense Self-Amplified Viral RNA (5'->3')
[0444]
[0445] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0446]
[0447] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0448]
[0449] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0450]
[0451] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0452]
[0453] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0454]
[0455] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0456]
[0457] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0458]
[0459] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0460]
[0461] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0462]
[0463] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0464]
[0465] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0466]
[0467] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0468]
[0469] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0470]
[0471] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0472]
[0473] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0474]
[0475] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0476]
[0477] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0478]
[0479] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0480]
[0481] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0482]
[0483] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0484]
[0485] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0486]
[0487] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0488]
[0489] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0490]
[0491] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0492]
[0493] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0494]
[0495] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0496]
[0497] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0498]
[0499] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0500]
[0501] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0502]
[0503] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0504]
[0505] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0506]
[0507] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0508]
[0509] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0510]
[0511] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0512]
[0513] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0514]
[0515] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0516]
[0517] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0518]
[0519] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0520]
[0521] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0522]
[0523] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0524]
[0525] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0526]
[0527] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0528]
[0529] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0530]
[0531] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0532]
[0533] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0534]
[0535] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0536]
[0537] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0538]
[0539] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0540]
[0541] Table 12. Nonsegmented Negative-Sense Trans- mplified RNA (3'->5')
[0542]
[0543] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0544]
[0545] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0546]
[0547] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0548]
[0549] ISB-153.01WO Attorney Reference No. 9929-113741-02 Table 13. Positive-Sense RdRp and Viral Accessory mRNA (5'->3')
[0550]
[0551] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0552]
[0553] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0554]
[0555] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0556]
[0557] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0558]
[0559] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0560]
[0561] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0562]
[0563] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0564]
[0565] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0566]
[0567] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0568]
[0569] Tables 14 - 20 depict nucleotide keys for the RNA sequences SEQ ID NOs 48-93. In particular, Table 14 depicts nucleotide key for RNA sequences encoding nonsegmented negative-sense transamplified RNA (3'->5') SEQ ID NOs 48-64. Table 15 depicts nucleotide key for RNA sequences encoding positive-sense RdRp and viral accessory mRNA (5'->3') SEQ ID NOs 65-69. Table 16 depicts nucleotide key for RNA sequences encoding nonsegmented positive-sense self-amplified RNA (5'->3’> SEQ ID NOs 70-75. Table 17 depicts nucleotide key for RNA sequences encoding propagating, nonsegmented negative- sense trans-amplified viral RNA (3'->5') SEQ ID NOs 76-81. Table 18 depicts nucleotide key for RNA sequences encoding propagating, nonsegmented positive-sense self-amplified viral RNA (5'->3') SEQ ID NOs 82-87. Table 19 depicts nucleotide key for RNA sequences encoding nonsegmented negative- sense trans-amplified RNA (3'->5') SEQ ID NOs 88-89. Table 20 depicts
[0570]
[0571]
[0572]
[0573]
[0574]
[0575]
[0576]
[0577]
[0578]
[0579]
[0580]
[0581]
[0582]
[0583]
[0584]
[0585]
[0586]
[0587]
[0588]
[0589]
[0590]
[0591]
[0592]
[0593]
[0594]
[0595]
[0596]
[0597]
[0598]
[0599]
[0600] ISB-153.01WO Attorney Reference No. 9929-113741-02 Table 20. Nucleotide Key for RNA Sequences Encoding Positive-Sense RdRp and Viral Accessory mRNA (5'->3'); [C] = Complement; nt = nucleotide; n.a. = not applicable
[0601]
[0602] As such, polypeptides and RNAs of particular interest include a full, partial, or otherwise homologous sequence of a SEQ ID NO selected from the above Tables.
[0603] Featured non- viral therapeutic polypeptides include, or are selected from, etanercept (SEQ ID NO. 4), cemiplimab (SEQ ID NOs. 5 and 6), adalimumab (SEQ ID NOs. 7 and 8, and 94 and 95), erythropoietin (SEQ ID NO. 9), granulocyte colony stimulating factor (SEQ ID NO. 10), ustekinumab (SEQ ID NOs. 11 and 12, or 100 and 101), hyaluronidase (SEQ ID NO. 13), dulaglutide (SEQ ID NO.
[0604] 14), exenatide (SEQ ID NO. 15), fuzeon (SEQ ID NO. 16), denosumab (SEQ ID NOs. 17 and 18), hCEACAM5-hCD3 di-scFv BiTE (SEQ ID NO. 19), COVID19 A:02:01 TCR-(a-CD3 + B) BiTE (SEQISB-153.01WO Attorney Reference No. 9929-113741-02 ID NOs. 20 and 21), gamma-delta (82-CD3 + y9) BiTE (SEQ ID NOs. 22 and 23), pembrolizumab (SEQ ID NOs. 24 and 25), CEACAM5-TM-scFv (SEQ ID NO. 27), CA19-TM-scFv (SEQ ID NO. 28), CD19-TM-scFv (SEQ ID NO. 29), CEACAM5-TM-scFv-(T2A)-PDLl-CD3 di-scFv BiTE (SEQ ID NO. 30), PDL1-CD3 BiTE (SEQ ID NO. 31), colorectal cancer neoantigen vaccine (HLA-A*ll:01) (SEQ ID NO.
[0605] 32), FGF21 (L98R, P171G, A180E) (SEQ ID NO: 96), GLP1 (7-37) (A8G) (SEQ ID NO: 97), GLP1 (7-37) (A8G) (SEQ ID NO: 98), GLP2 (SEQ ID NO:99), and derivatives thereof. In some embodiments, a biomarker is utilized in place of the therapeutic polypeptide, such as one or more selected from mEGFP (SEQ ID NO. 1), tagBFP2 (SEQ ID NO. 2), mCherry (SEQ ID NO. 3), firefly luciferase (SEQ ID NO.
[0606] 26), AkaLuciferase (SEQ ID NQ:102), mScarlet3 (SEQ ID NQ:103); and Rat Albumin-3xFlag (SEQ ID NO: 104), and derivatives thereof. For example, in as many embodiments, the polypeptides can include or exclude accessory sequences such as a homologous or heterologous secretion signal (or a de novo secretion signal for normally non-secreted polypeptides) (e.g., interleukin-2 secretion signal, human growth hormone secretion signal, VH secretion signal, etc.), purification tags (e.g., His-tag, streptavidin, etc.), and the like, depending on the intended end use. As such, tire non-viral therapeutic polypeptides and biomarkers disclosed herein may include one or more substitutions, deletions, or insertions, depending on the intended end use.
[0607] Likewise, featured RNAs encoding the non-viral therapeutic polypeptides include, or are selected from, etanercept (SEQ ID NO. 49), cemiplimab (SEQ ID NOs. 50), adalimumab (SEQ ID NOs. 51, 70-75, and 88-89), erythropoietin (SEQ ID NO. 52), granulocyte colony stimulating factor (SEQ ID NO. 53), ustekinumab and hyaluronidase (SEQ ID NO. 54), dulaglutide (SEQ ID NO. 55), exenatide (SEQ ID NO. 56), fuzeon (SEQ ID NO. 57), denosumab (SEQ ID NOs. 58), hCEACAM5-hCD3 di-scFv BiTE (SEQ ID NO. 59), COVID19 A:02:01 TCR-(a-CD3 + B) BiTE (SEQ ID NO. 60), gamma-delta (32-CD3 + y9) BiTE (SEQ ID NO. 61), pembrolizumab (SEQ ID NO. 62), CEACAM5-TM-scFv (SEQ ID NO.
[0608] 77), CA19-TM-scFv (SEQ ID NO. 78), CD19-TM-scFv (SEQ ID NO. 79), CEACAM5-TM-scFv-(T2A)-PDL1-CD3 di-scFv BiTE (SEQ ID NOs. 80, and 82-87), PDL1-CD3 BiTE (SEQ ID NO. 63), CEACAM5-TM-scFv + PDL1-CD3 di-scFv BiTE (SEQ ID NOs. 81), colorectal cancer neoantigen vaccine (HLA-A*ll:01) (SEQ ID NO. 32), and derivatives thereof. In some embodiments, a biomarker is utilized in place of the therapeutic polypeptide, such as one or more selected from mEGFP+tagBFP2+mCherry (SEQ ID NO. 48) and firefly luciferase (SEQ ID NO. 76), and derivatives thereof. Again, the RNAs can include or exclude accessory sequences such as those encoding a secretion signal, purification tags, and the like, and therefore one or more substitutions, deletions, or insertions, depending on the intended end use.
[0609] In other embodiments, one or more of the therapeutic polypeptides can be engineered to include a short peptide linker sequence Gly-Phe-Lys that is susceptible to cleavage by the endopeptidase neprilysin (NEP). Incorporation of an NEP-cleavable linker enables site-specific enzymatic cleavage in the kidney, facilitating the release and subsequent urinary excretion of cleaved fragments generally less than about 60-70 kilodaltons (kDa). The modification reduces renal retention of such fragments withoutISB-153.01WO Attorney Reference No. 9929-113741-02 compromising functionality of larger constructs. In a related embodiment, NEP-mediated cleavage can be used to release a payload or functional domain into the renal tubule system along with the rest of the glomerular filtrate. As such, in some embodiments, one or more of the polypeptides, and in particular the BiTE or Fc-BiTE molecules, optionally include a NEP cleavage site Gly-Phe-Lys for cleaving the polypeptide in the renal brush border membrane region where NEP is found in abundance.
[0610] Featured viral proteins of the disclosure include, or are selected from, but not limited to, Nucleoprotein (N) NDV Strain Ulster (SEQ ID NO:33), Phosphoprotein (P) NDV Strain Ulster (SEQ ID NO: 34), RNA-dependent RNA Polymerase (L) NDV Strain Bl (SEQ ID NO: 35), Interferon-Suppressor (V) Measles Strain Ichinose-B95A (SEQ ID NO:36), Nucleoprotein (N) SeV Strain Ohita (SEQ ID NO: 37), Phosphoprotein (P) SeV Strain Ohita (SEQ ID NO:38), RNA-dependent RNA Polymerase (L) SeV Strain Ohita (SEQ ID NO:39), Nucleoprotein (N) PIV5 Strain W3A (SEQ ID NO:40), Phosphoprotein (P) PIV5 Strain W3A (SEQ ID NO:41), Interferon-Suppressor (V) PIV5 Strain W3A (SEQ ID NO:42), RNA-dependent RNA Polymerase (L) PIV5 Strain W3A (SEQ ID NO:43), Nucleoprotein (N) NDV Strain LaSota (SEQ ID NO:44), Phosphoprotein (P) NDV Strain LaSota (SEQ ID NO:45), RNA-dependent RNA Polymerase (L) NDV Strain LaSota (SEQ ID NO:46), Interferon-Suppressor (V) NDV Strain LaSota (SEQ ID NO: 104), Interferon-Suppressor (V) PIV5 Strain W3A (N100D) (SEQ ID NO: 105), RNA-dependent RNA Polymerase (L) NDV Strain Ulster (SEQ ID NO: 105), or derivatives thereof.
[0611] Featured RNA molecules of the disclosure, include, but are not limited to:
[0612] Nonsegmented Negative-Sense Trans- Amplified RNA (3 ’->5"), comprising, or selected from: mEGFP + tagBFP2 + mCherry (SEQ ID NO:48), Etanercept (SEQ ID NO:49), Cemiplimab LC + HC (SEQ ID NQ:50), Adalimumab LC + HC (SEQ ID NO:51), Erythropoietin (SEQ ID NO:52), GCSF (SEQ ID NO:53), Ustekinumab LC + HC + Hyaluronidase (SEQ ID NO:54), Dulaglutide (SEQ ID NO:55), Exenatide (SEQ ID NO:56), Fuzeon (SEQ ID NO:57), Denosumab LC + HC (SEQ ID NO:58), hCEACAM5-hCD3 di-scFv BiTE (SEQ ID NO:59), COVID19 A*02:01 TCRBiTE (a-CD3 + B) (SEQ ID NO:60), Gamma Delta BiTE (82-CD3 + y9) (SEQ ID NO:61), Pembrolizumab LC + HC (SEQ ID NO:62), PDL1-CD3 di-scFv BiTE (SEQ ID NO:63), Colorectal Cancer Neoantigen Vaccine (HLA-A*11:01 Targeted); Neoantigens: KRAS G12D, PIK3CA E545K, TP53 R248Q, BRAF V600E, FBXW7 R479Q (SEQ ID NO:64), Adalimumab LC + HC (Alternate Signal Sequence) (SEQ ID NO: 107), Ustekinumab LC + HC (Alternate Signal Sequence) (SEQ ID NO: 108), FGF21 (L98R, P171G, A180E) + GLP1 L7-37J (A8G) - Direct Signal Sequence Cleavage (SEQ ID NO:109), FGF21 (L98R, P171G, A180E) + GLP1 [7-37] (A8G) - Signal Sequence + Spacer + Furin Cleavage (SEQ ID NO:110), GLP2 (A8G) - Direct Signal Sequence Cleavage (SEQ ID NO:111), F-Luc (SEQ ID NO:112), F-Luc (Capped) (SEQ ID NO: 113), AkaLuciferase (Capped) (SEQ ID NO: 114), mScarlet3 (Capped) (SEQ ID NO: 115), Flag-tagged Albumin (Capped) (SEQ ID NO:116), mEGFP (SEQ ID NO: 117), mEGFP (Capped) (SEQ ID NO: 118), and mEGFP (Ribozyme) (SEQ ID NO: 119);ISB-153.01WO Attorney Reference No. 9929-113741-02 Positive-Sense RdRp & Viral Accessory mRNA (5’->3’) comprising, or selected from: 5’UTR-N(NDV)-T2A-V(Measles)-T2A-P(NDV)-3'UTR-polyA (SEQ ID NO:65), 5’UTR-L(NDV)-3’UTR-polyA (SEQ ID NO:66), 5’UTR-N(NDV)-T2A-V(Measles)-T2A-P(NDV)-T2A-L(NDV)-3’UTR-polyA (SEQ ID NO:67), 5'Hairpin-IRES-N(NDV)-T2A-V(Measles)-T2A-P(NDV)-3’Hairpin (SEQ ID NO:68), 5'Hairpin-IRES-N(NDV)-T2A-V(Measles)-T2A-P (NDV)-T2A-L (NDV)-3’Hairpin (SEQ ID NO:69), 5'UTR-N(NDV)-T2A-V(PIV5)-T2A-P(NDV)-3'UTR-polyA (SEQ ID NO: 120), 5’UTR-N(NDV)-T2A-V(PIV5[N100D])-T2A-P(NDV)-3'UTR-polyA (SEQ ID NO: 121), and 5’UTR-L(NDV Ulster)-3’UTR-polyA (SEQ ID NO: 122);
[0613] Nonsegmented Positive-Sense Self-Amplified RNA (5'->3') comprising, or selected from: Adalimumab LC + HC (AC) (SEQ ID NQ:70), Adalimumab LC + HC (AG) (SEQ ID NO:71), Adalimumab LC + HC (AU) (SEQ ID NO:72), Adalimumab LC + HC (AG Pentamer) (SEQ ID NO:73), Adalimumab LC + HC (AG Hexamer) (SEQ ID NO:74), and Adalimumab LC + HC (IRES-driven) (SEQ ID NO:75);
[0614] Propagating, Nonsegmented Negative-Sense Trans-Amplified Viral RNA (3'->5') comprising, or selected from: Firefly Luciferase (SEQ ID NO:76), CEACAM5 scFv (Transmembrane Anchored) (SEQ ID NO:77), CA-19 scFv (Transmembrane Anchored) (SEQ ID NO:78), CD19 scFv (Transmembrane Anchored) (SEQ ID NO:79), CEACAM5 TM-scFv - T2A - PDL1-CD3 di-scFv BiTE (SEQ ID NQ:80), and CA-19 TM-scFv + PDL1-CD3 di-scFv BiTE (SEQ ID NO:81);
[0615] Propagating, Nonsegmented Positive-Sense Self-Amplified Viral RNA (5'->3') comprising, or selected from: CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (AC) (SEQ ID NO: 82), CEACAM5 TM-scFv -T2A - PDL1-CD3 di-scFv BiTE (AG) (SEQ ID NO:83), CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (AU) (SEQ ID NO:84), CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (AG Pentamer) (SEQ ID NO:85), CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (AG Hexamer) (SEQ ID NO: 86), and CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (IRES-driven) (SEQ ID NO: 87);
[0616] taRNA Designs Based on Additional Paramyxoviridae Genera of Nonsegmented Negative-Sense Trans-Amplified RNA (3'->5') comprising, or selected from: Murine Respirovirus (Sendai Virus) [SeV] -Adalimumab LC + HC (SEQ ID NO:88), Human Parainfluenza Virus 5 [PIV5] - Adalimumab LC + HC (SEQ ID NO:89), Human Parainfluenza Virus 5 [PIV5] - mEGFP (SEQ ID NO: 123), and Murine Respirovirus (Sendai Vims) [SeV] - mEGFP (SEQ ID NO: 124); and
[0617] taRNA Designs Based on Additional Paramyxoviridae Genera of Positive-Sense RdRp & Viral Accessory mRNA (5'->3') comprising, or selected from: 5'UTR-N(SeV)-T2A-V(Measles)-T2A-P(SeV)-3'UTR-polyA (SEQ ID NO:90), 5'UTR-L(SeV)-3'UTR-polyA (SEQ ID NO:91), 5'UTR-N(PIV5)-T2A-V(PIV5)-T2A-P(PIV5)-3'UTR-polyA (SEQ ID NO:92), and 5'UTR-L(PIV5)-3'UTR-polyA (SEQ ID NO:93).ISB-153.01WO Attorney Reference No. 9929-113741-02
[0618] IV. Methods of RNA Production and Manufacturing
[0619] In certain embodiments, the disclosure provides methods for producing RNA molecules having precisely defined 5’ and / or 3’ termini. Such RNA molecules may be suitable for use in the compositions and systems described herein, including taRNA systems and RNA molecules encoding one or more therapeutic polypeptides.
[0620] Plasmid-Based RNA Production
[0621] In certain embodiments, RNA encoding a gene of interest (e.g., a gene of interest encoded on a taRNA) is generated from a DNA template, such as a plasmid, configured to produce transcripts with controlled or defined termini. In certain embodiments, the DNA template comprises, in operable linkage: (a) a promoter suitable for transcription, including in vitro transcription (IVT); (b) a ribozyme autocleavage sequence; and (c) a nucleotide sequence encoding the RNA of interest. In certain embodiments, the promoter comprises a bacteriophage RNA polymerase promoter, such as a T7 RNA polymerase promoter, including Class II or Class III promoter variants.
[0622] Generation of Defined 3 ’ Termini
[0623] In some embodiments, a defined 3’ end of the RNA is generated by one or more of the following approaches: (i) positioning an autocleaving ribozyme sequence 3’ of the RNA-encoding sequence; (ii) linearizing the DNA template at a restriction enzyme recognition site located downstream of the RNA-encoding sequence, followed by runoff transcription; (iii) linearizing the DNA template using PCR primers to define the 3’ end of the RNA-encoding sequence followed by transcription of the linear template; or (iv) a combination of (i), (ii) and (iii). In certain embodiments, the ribozyme comprises a hepatitis delta virus (HDV) ribozyme, including genomic, antigenomic, or minimal variants. In other embodiments, alternative self-cleaving ribozymes may be used. In embodiments employing restriction-mediated linearization, the DNA template is digested prior to transcription to linearize the template to allow the ribozyme to function when present, or so that RNA polymerase terminates at a defined position, thereby producing an RNA transcript with a defined 3’ end. Primers can also be used with PCR to linearize the DNA template following standard approaches in the art.
[0624] Ribozyme-Mediated Processing
[0625] In certain embodiments, transcription of the DNA template generates an RNA precursor comprising a ribozyme sequence that undergoes autocatalytic cleavage to produce a defined 3’ terminus. In certain embodiments, cleavage occurs under conditions that support ribozyme folding and catalytic activity, including in the presence of divalent cations such as Mg++. In certain embodiments, the ribozyme generates a 3’ terminus comprising a 2 ’,3 ’-cyclic phosphate.ISB-153.01WO Attorney Reference No. 9929-113741-02 Combined Linearization and Ribozyme Processing
[0626] In certain embodiments, the DNA template is linearized downstream of a ribozyme sequence prior to transcription, thereby enabling efficient runoff transcription while the ribozyme provides post-transcriptional cleavage to generate a homogeneous 3’ end. This combined approach may improve control over transcript end homogeneity and reduce variability in RNA populations.
[0627] Modified Nucleotide Incorporation
[0628] In certain embodiments, the RNA is synthesized in the presence of one or more modified nucleotides. In certain embodiments, the modified nucleotides comprise N1 -methylpseudouridine (in IT). In certain embodiments, the RNA comprises about 50%, about 75%, about 85%, or about 100% substitution of uridine with m'. In some embodiments, additional or alternative modified nucleotides may include pseudouridine, 5-methoxyuridine, 5-methylcytidine, 5-hydroxymethylcytidine, or methyluridine. In certain embodiments, such modifications result in RNA molecules having improved stability and / or reduced activation of innate immune sensors.
[0629] Production Without PCR Amplification
[0630] In certain embodiments, the RNA is produced from a plasmid template without the need for PCR amplification. Such embodiments may provide advantages in manufacturing scalability, reproducibility, and control of RNA sequence integrity.
[0631] RNA Molecules with Defined Termini
[0632] In certain embodiments, the methods described herein produce RNA molecules having defined 5’ and 3’ ends. In certain embodiments, the RNA molecule comprises: (a) a 3’ end comprising a 2’, 3’-cyclic phosphate; and (b) one or more modified ribonucleotides. In certain embodiments, the 2’,3’-cyclic phosphate is derived from cleavage of a precursor RNA comprising an autocleaving ribozyme sequence. In some embodiments, the 5’ end of the RNA is a 5’ppp, 5’ hydroxyl, 5’ m7G (CapO), or 5’ m7G (Capl). In certain embodiments when PCR template linearization is used, the 3’ end of the RNA is a hydroxyl group.
[0633] Integration with RNA Delivery Systems
[0634] In certain embodiments, an RNA molecule produced by the methods described herein is incorporated into a delivery system. In certain embodiments, the delivery system comprises a non-viral nanoparticle, including a lipid nanoparticle. In certain embodiments, the nanoparticle encapsulates: (a) one or more RNA molecules encoding viral replication proteins derived from a nonsegmented negativesense RNA virus, including RNA-dependent RNA polymerase (RdRp L), nucleoprotein (N), and phosphoprotein IP); and (b) one or more RNA molecules encoding one or more non-viral polypeptides. In certain embodiments, the RNA encoding the one or more non-viral polypeptides comprises a 3’ end generated by ribozyme cleavage.ISB-153.01WO Attorney Reference No. 9929-113741-02 In certain embodiments, the RNA molecules are distributed across multiple RNA species, including: (a) a first RNA molecule encoding N, V, and P proteins; (b) a second RNA molecule encoding RdRp L; and (c) a third RNA molecule encoding one or more non-viral therapeutic polypeptides. In certain embodiments, the RNA molecules are present in a defined mass ratio, including about 2:1:1 for the first, second, and third RNA molecules, respectively.
[0635] V. Methods of Use
[0636] Also disclosed herein are methods of using the disclosed nanoparticle delivery vehicles and RNA constructs. The methods include, but are not limited to, use of the disclosed nanoparticle delivery vehicles and RNA constructs in medical treatments, industrial applications, as well as educational and research applications, depending on the intended end use. Of particular interest is a method of treatment that involves administering to a subject in need thereof a composition of the disclosure, and preferably, administration of a non-viral nanoparticle composition encapsulating naked RNA derived from a nonsegmented negative sense RNA virus encoding RdRp L protein and one or more non-viral therapeutic polypeptides.
[0637] In certain embodiments, the compositions of the disclosure are used in treating a cancer by including a neoantigen panel as the therapeutic on the RNA alone or in combination with a pd-1 axis binding antagonist, and applied in a cancer vaccine treatment, such as a colorectal cancer, or pancreatic cancer treatment as described in WO2024137589A2.
[0638] For example, the disclosed compositions can be used for the delivery of RNA encoding therapeutic, prophylactic, diagnostic, or functional polypeptides to a target cell, tissue, or subject. Such applications include, without limitation, protein replacement therapies, immunotherapies, gene modulation, vaccination, and regenerative medicine. In certain embodiments, the RNA is configured as a self-amplifying RNA (saRNA) or trans-amplified RNA (taRNA) system derived from a nonsegmented negative-sense RNA virus, enabling sustained intracellular expression of one or more encoded polypeptides.
[0639] The compositions of the disclosure may be administered via a variety of routes, including but not limited to intramuscular (IM), intravenous (IV), subcutaneous (SC), intradermal (ID), mucosal, inhalational, or oral administration. Selection of the route of administration may be based on the desired biodistribution, target tissue, or therapeutic outcome. In certain embodiments, intramuscular administration is used to achieve localized expression with systemic immune activation, for example in vaccine applications. In other embodiments, intravenous administration is used to achieve systemic delivery, including targeting of organs such as the liver and spleen. In further embodiments, oral administration is employed to enable delivery to the gastrointestinal tract and, in some cases, systemic exposure following uptake.ISB-153.01WO Attorney Reference No. 9929-113741-02 In some embodiments, the RNA constructs are formulated in lipid nanoparticles (LNPs), including ionizable lipid-based formulations such as SM-102 LNPs, or in other non-viral nanoparticle delivery systems suitable for RNA delivery. The formulations may optionally include stabilizing excipients, buffering agents, or cryoprotectants, and may be provided in liquid or lyophilized form.
[0640] In illustrative embodiments, IM administration of LNP-formulated RNA constructs of the disclosure (e.g., encoding a therapeutic protein, a reporter protein, or a combination thereof) results in detectable in vivo expression in mammalian subjects for extended durations. In other embodiments, IV administration results in systemic distribution with preferential accumulation and / or expression in organs such as the liver and spleen.
[0641] In further embodiments, the compositions are configured for oral delivery. For example, oral administration of LNP-formulated RNA constructs, including lyophilized or liquid formulations comprising suitable buffers and stabilizers, results in expression of encoded proteins within gastrointestinal tissues. In certain embodiments, the RNA encodes a secreted protein, and oral delivery results in detectable levels of the expressed protein in systemic circulation, indicating transport from the gastrointestinal compartment. In some embodiments, the disclosed RNA constructs support expression across multiple cell types, including, but not limited to, cells representative of kidney, liver, muscle, and gastrointestinal tissues.
[0642] VI. Utility and Advantages
[0643] The compositions of the present disclosure represent an important new class of RNA-based therapeutics with broad potential for treating individuals in need thereof. Unlike conventional nonreplicating mRNA, the self-amplifying compositions encoding a wide range of different therapeutics in various formats facilitates intracellular RNA amplification, leading to significantly higher and more sustained protein expression at much lower doses. The self-propagating constructs offer tissue-specific targeting as well as durable therapeutic protein expression. The trans-amplifying RNA systems further modularizes this system by separating the RdRp L replicase and therapeutic-encoding components into two or more RNA molecules, which can improve flexibility, reduce vector size constraints, and enhance safety through titratable control of replication and other aspects described in more detail below. The ability to produce multiple therapeutic polypeptides and multi-subunit proteins, including antibodies, provides an important additional feature for rapid and scalable responses to emerging therapeutic challenges.
[0644] From an economic standpoint, the self- and trans-amplifying RNA construct systems of the disclosure offer several advantages over traditional biologies. First, they can be manufactured synthetically and rapidly, allowing for faster production timelines and easier adaptation to new targets. This contrasts with protein biologies, which often require complex cell culture systems and lengthy purification processes. Furthermore, the lower effective dose of self- and trans-amplifying RNAs of the disclosure reduce the need for large-scale raw material inputs, cutting down on production costs. StorageISB-153.01WO Attorney Reference No. 9929-113741-02 and distribution can also be more flexible with emerging formulation and delivery improvements, including lipid nanoparticles. Overall, saRNA and taRNA therapeutics combine the potency and programmability of nucleic acid therapies with the cost-effectiveness and speed of modern mRNA manufacturing platforms, making them an attractive option for both high-income and resource-limited settings.
[0645] In addition, encapsulating naked virally derived RNA elements into non-viral nanoparticles provides a number of significant advantages over using live virus particles for delivery. One important benefit is safety. Unlike live-attenuated or replication-competent viral vectors, non-viral nanoparticles formulated with naked RNA is non-infectious and reduces the risk of reversion to virulence or unwanted integration into the host genome. This feature makes constructs of the present disclosure more suitable for repeated dosing in chronic as well as acute indications, including for use in immunocompromised patients.
[0646] From a manufacturing perspective, non-viral nanoparticles offer scalability and reproducibility using well-defined, cell-free processes that avoid the complexities of viral culture and purification. This reduces the risk of contamination with host cell proteins or adventitious agents and enables more rapid and cost-effective production. Additionally, the nanoparticles themselves can be readily modified to alter biodistribution or improve cellular uptake, allowing for tailored delivery to specific tissues or cell types.
[0647] Non-viral nanoparticles also allow for more consistent and controllable dosing compared to live virus particles, whose replication and transgene expression can vary based on the host immune status and preexisting immunity, hi contrast, non-viral nanoparticle delivery of saRNA or taRNA offers controlled, durable expression of an encoded antigen or therapeutic protein. This is particularly important for many therapies where safety and dose consistency are critical for safety and efficacy.
[0648] The present disclosure also offers several additional advantages. One is the range of immunogenicity and toxicity of nonsegmented negative-sense RNA viruses, which can be exploited depending on the intended end use. For example, low immunogenicity and low cellular toxicity is observed in humans for certain genera, such as NDV and the respirovirus and rubellavirus genera of the Paramyxoviridae family, to produce a replication-competent, synthetic nanoparticle-encapsulated naked RNA system that is capable of sustained protein expression.
[0649] Another advantage is manufacturing. Contemporary therapeutic strategies for producing engineered nonsegmented, negative-sense RNA viruses or viral replicon particles rely on co-transfection of five to seven DNA plasmids (N, P, L, F, H, M and dual ribozyme-terminated viral genome template; or N, P, L, G, and dual ribozyme-terminated viral genome template also encoding M) into a constitutively T7 RNA-polymerase expressing cell culture system to produce live virus particles incorporating pre-formed ribonucleotide replication complex (Zimmer et al., 2010; and US 7,442,379 B2). This is followed by purification and infusion of the live-virus into patients, typically intended as a vaccine vector or oncolytic virus. Research use of minimal nonsegmented, negative-sense mini genomesISB-153.01WO Attorney Reference No. 9929-113741-02 has likewise relied on co-transfection of at least four DNA plasmids (N, P, L, and dual ribozyme-terminated viral genome template) into a constitutive T7-expressing cell culture to express recombinant protein (Marcus et al., 2005). While reverse genetic strategies such as these are sufficient for producing virus or recombinant protein within in vitro cell culture, the use of multiple plasmid DNA molecules and the requirement for T7 polymerase expression renders these approaches incompatible with direct in vivo delivery into humans in the absence of a live viral vector.
[0650] In contrast, the present disclosure employs naked RNA encapsulated in a non- viral nanoparticle to produce in vivo compatible, trans- and self-amplifying nonsegmented negative-sense therapeutic protein expression systems. The naked RNA approach facilitates virus-free, viral envelope and viral protein-free, and plasmid DNA-free delivery of replicating, engineered nonsegmented negative-sense constructs or minigenomes encoding one or more therapeutic proteins, permitting week-long sustained protein expression. This significantly improves tire safety and dramatically lowers the in vivo immunogenicity associated with viral or plasmid DNA-based delivery systems.
[0651] Another advantage is stability. An unexpected finding of the present disclosure was tire finding that nonsegmented negative-sense taRNA and saRNA is compatible with complete Nl-methylpseudouridine substitution (in I ). This discovery supports significantly reduced in vivo immunogenicity and improved exonuclease-resistance against endogenous mammalian viral defense pathways (Kariko et al., 2008). This was an unexpected finding given that saRNA derived from positivesense alphavirus is incompatible with m IT (Azizi et al., 2024).
[0652] Yet a further advantage is that nonsegmented RNA replication can be performed in cis without accessory positive-sense mRNA. The 5’ terminus of the antigenome (positive-sense) can be modified with a m7G or analog cap, while maintaining correct hexamer phasing, and moving essential viral replication proteins N, P, and L into the first subgenomic ORF position as a single ribosome skipping sequence linked cistron. This permits first cycle ribosomal translation of all viral proteins necessary for replication complex formation and further genomic and subgenomic amplification.
[0653] Another advantage is the robust expression of multiple recombinant protein transcripts from tire utilization of two or more independent subgenomic open-reading frames. This was accomplished by maintaining correct hexamer-phasing at each viral RNA regulatory element, including each promoter and trailer. This permits linker-free expression of heterodimeric therapeutics, such as monoclonal antibody light and heavy chains or multi-chain bi- specific T-cell engagers. It also permits delivery of combinatorial or adjuvant therapeutics, such as the combination of a monoclonal antibody, Fc-fusion, or recombinant human protein with hyaluronidase for improved in vivo distribution kinetics.
[0654] The non-viral nanoparticle-encapsulated naked inRNA approach can also be utilized to produce a self-propagating, recombinant full-length, nonsegmented negative-sense RNA vims using either a cis- or trans-component strategy. An advantage of this system is that it can be applied to a wide range of naturally occurring cell types using a built-in replication priming element that does not require additionISB-153.01WO Attorney Reference No. 9929-113741-02 of or preformed ribonucleoprotein complexed RNAs. For example, the trans system employs (i) nonsegmented negative-sense viral naked RNA encoding all viral proteins and one or more therapeutic proteins, and (ii) a positive-sense naked mRNA encoding for N, P, and L proteins that is co-delivered for priming a first-cycle of replication. After formation of the initial replication complex, the negative-sense viral genome becomes self-propagating and generates live engineered virus. The cis system employs a self-amplification strategy in which the full-length viral antigenome (positive-sense) is modified with a m7G capping group or analog while maintaining correct hexamer phasing, and moving essential viral replication proteins N, P, and L into the first subgenomic promoter position as a single RSS-linked cistron. This permits first-cycle ribosomal translation of all viral proteins necessary for replication complex formation and subsequent replication and propagation of engineered live virus. Again, naked RNA is employed and the target cells does not require prior co-transfection with live virus or helper plasmids.
[0655] Additionally, capping the 5’ end of tire taRNA with 5’m7G or analog cap, strain matching or mismatching of the Paramyxoviridae replication machinery, or a combination thereof can be advantageously used to modulate viral replication kinetics, which may be exploited to control tire timing and duration of therapeutic expression.
[0656] Further advantages relate to RNA production and manufacturing. In certain embodiments, inclusion of a ribozyme enables production of taRNA from a plasmid or other DNA template without PCR amplification, while generating taRNA molecules having defined 5' and 3' termini following ribozyme cleavage. In some embodiments, taRNA produced using a Class II T7 promoter and incorporating Nl-methylpseudouridine (ml'P) exhibits enhanced expression and / or extended expression duration in a host cell relative to taRNA synthesized using a Class III T7 promoter. Accordingly, the use of a ribozyme, selection of a T7 RNA polymerase promoter, and incorporation of modified nucleotides (e.g., m I ), individually or in combination, can be used to modulate expression kinetics, enhance replication efficiency, and / or reduce host sensing, for example relative to taRNA lacking defined termini.
[0657] As such, the present invention provides cost-effective, sustained-expression delivery of therapeutic proteins encoded as naked, nonsegmented taRNA or saRNA of nonsegmented negative-sense RNA virus architecture, as well as in vivo production of engineered, therapeutics delivered as naked, propagating taRNA or saRNAs.
[0658] EXAMPLES
[0659] The following examples are provided to illustrate certain particular features and / or embodiments. These examples should not be construed to limit the disclosure to the particular features or embodiments described.ISB-153.01WO Attorney Reference No. 9929-113741-02 Example 1: General materials and methods
[0660] For 96-well cell transfection experiments, a total RNA mass of 100 ng was transfected. For 12-well cell transfection experiments, a total RNA mass of 500 ng was transfected. For 30 ml Expi293F cultures, a total RNA mass of 30ug was transfected.
[0661] Transfected adherent HEK293 cells were placed in an Incucyte S3 live-cell imager (Sartorius), performing imaging every 4 hours for the course of approximately 7 days. Cells were imaged in phase contrast, mEGFP channel, and mCherry channels. Fluorescent quantification analysis was performed by automated machine vision provided by Incucyte software.
[0662] A separate plate of transfected adherent HEK293 cells was analyzed by flow cytometry at day 5 in tagBFP2, mEGFP, and mCherry channels on an Attune NxT cytometer (Thermo Scientific). During flow cytometry, dead cells were excluded from analysis using the amine-reactive dye, Live-or-Dye 750 / 777 (Biotium Sciences). Flow cytometry data was analyzed and visualized using FlowJo (BD Biosciences).
[0663] A separate plate of electroporated adherent HEK293 cells was imaged at day 4 in brightfield, tagBFP2, mEGFP, and mCherry channels on an ImageExpress Micro Confocal microscope (Molecular Devices). Comparative fluorescent images were analyzed in Fiji (ImageJ), utilizing identical exposure processing parameters.
[0664] An aliquot of transfected suspension Expi293F cells was placed and imaged at 44h in an Incucyte S3 live-cell imager (Sartorius), using phase contrast and mEGFP channels. Fluorescent quantification analysis was performed by automated machine vision provided by Incucyte software.
[0665] An aliquot of transfected suspension Expi293F cells was analyzed by flow cytometry at 44h in mEGFP and Live-or-Dye 750 / 777 (Biotium Sciences) channels on an Attune NxT cytometer. Flow cytometry data was analyzed and visualized using FlowJo (BD Biosciences).
[0666] Example 2: Synthesis, Cloning, and Transcription of RNA In Vitro Transcription (IVT) Templates NP-V-P & L IVT Templates: Nucleoprotein (N) and Phosphoprotein (P) amino acid sequences from Newcastle Disease Virus (NDV) strain Ulster (SEQ ID NO. 33-34) and RNA-dependent RNA Polymerase (L) from NDV strain Bl (SEQ ID NO. 35) were mammalian-codon optimized and recombinantly synthesized as DNA. Interferon suppressor (V) protein from Measles virus strain Ichinose-B95A (SEQ ID NO. 36) was also mammalian-codon optimized and recombinantly synthesized as DNA. Recombinant N, V, and P nucleic acid sequences were cloned into a single cistron, linking each protein with a ribosomal skipping sequence (RSS) such as a T2A self-cleavable peptide sequence from Thosea asigna virus. The resulting cistron was cloned into an in vitro transcription (IVT) plasmid vector encoding a mutant T7 RNA polymerase promoter containing a mutant ‘AG’ transcriptional start site (TSS), a mammalian 5’ untranslated region (UTR) sequence, a non-viral Kozak sequence, a mammalianISB-153.01WO Attorney Reference No. 9929-113741-02 3’ UTR sequence, and a defined poly A tract. (SEQ ID NO. 65). Recombinant L nucleic acid sequence was separately cloned into an identical IVT vector. (SEQ ID NO. 66). The IVT plasmids were linearized using a single BspQI restriction cut site at the terminus of the polyA tract. Following linearization, the IVT templates were transcribed using recombinant T7 RNA polymerase in the presence of CleanCap AG (NEB HiScribe T7 mRNA with CleanCap AG Kit) and with complete substitution of Nl-methylpseudouridine in place of uridine. Following DNAse-I digestion to remove IVT template, RNA was purified using NEB Monarch Spin RNA Cleanup Kit. RNA was quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently frozen at -80°C.
[0667] NP-V-P Hairpin-Terminated IRES IVT Template: N, V, and P sequences were also cloned into a recombinant IVT template comprising a T7 RNA polymerase promoter, a terminal 5’ hairpin of 24 paired nucleotides with a GC content of approximately 70%, a short spacer sequence, and a class II internal ribosome entry site (IRES) from encephalomyocarditis virus (Solodushko et al., 2023) with the IRES-encoded start site encoding the start of the viral N protein. N, V, and P sequences were linked into a single cistron by T2A peptide sequences. Proceeding the stop codon of tire cistron, a short nucleotide spacer was placed, followed by two 3’ terminal hairpins, each comprised of 20 and 22 paired nucleotides with a GC content of approximately 60% and 50%. (SEQ ID NO. 68). A BspQI restriction cut site was placed at tire terminus of the second 3' terminal hairpin to produce a T7 RNA polymerase readthrough-capable 5’ overhang. Following linearization of tire IVT plasmid template with BspQI, transcription was performed using recombinant T7 RNA polymerase (HiScribe T7 mRNA Kit) with complete substitution of N1 -methylpseudouridine in place of uridine. Following DNAse-I digestion to remove IVT template, RNA was purified using NEB Monarch Spin RNA Cleanup Kit. RNA was quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently frozen at -80°C.
[0668] N-V-P-L IVT Template: Nucleoprotein (N) and Phosphoprotein (P) amino acid sequences from Newcastle Disease Virus (NDV) strain Ulster and RNA-dependent RNA Polymerase (L) from NDV strain Bl are mammalian-codon optimized and recombinantly synthesized as DNA. Interferon suppressor (V) protein from Measles virus strain Ichinose-B95A is mammalian-codon optimized and recombinantly synthesized as DNA. Recombinant N, P, L, and V nucleic acid sequences are cloned into a single cistron, linking each protein with a T2A self-cleavable peptide sequence from Thosea asigna virus. The resulting cistron is cloned into an in vitro transcription (IVT) vector encoding a mutant T7 RNA polymerase promoter containing a mutant ‘AG’ TSS, a mammalian 5’ UTR sequence, a non-viral Kozak sequence, a mammalian 3’ UTR sequence, and a defined polyA tract. (SEQ ID NO. 67). The IVT plasmid is linearized using a single BspQI restriction cut site at the terminus of the polyA tract. Following linearization, the IVT template is transcribed using recombinant T7 RNA polymerase in the presence of CleanCap AG (NEB HiScribe T7 mRNA with CleanCap AG Kit) and with complete substitution of N1-methylpseudouridine in place of uridine. Following DNAse-I digestion to remove IVT template, RNA is purified using NEB Monarch Spin RNA Cleanup Kit. RNA is quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently is frozen at -80°C.ISB-153.01WO Attorney Reference No. 9929-113741-02 N-V-P-L Hairpin-Terminated IRES IVT Template: N, V, P, and L sequences are also cloned into a recombinant IVT template comprising a T7 RNA polymerase promoter, a terminal 5’ hairpin of 24 paired nucleotides with a GC content of approximately 70%, a short spacer sequence, and a class II IRES from encephalomyocarditis virus with the IRES-encoded start site encoding the start of the viral N protein. N, V, and P sequences were linked into a single cistron by T2A peptide sequences. Proceeding the stop codon of the cistron, a short nucleotide spacer was placed, followed by two 3’ terminal hairpins, each comprised of 20 and 22 paired nucleotides with a GC content of approximately 60% and 50%. (SEQ ID NO. 69). A BspQI restriction cut site was placed at the terminus of the second 3’ terminal hairpin to produce a T7 RNA polymerase readthrough-capable 5’ overhang. Following linearization of the IVT plasmid template with BspQI, transcription was performed using recombinant T7 RNA polymerase (HiScribe T7 mRNA Kit) with complete substitution of N1 -methylpseudouridine in place of uridine. Following DNAse-I digestion to remove IVT template, RNA was purified using NEB Monarch Spin RNA Cleanup Kit. RNA was quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently frozen at -80°C.
[0669] Nonsegmented Negative-Sense Trans- Amplifying (taRNA) IVT Template: Monomeric enhanced green fluorescent protein (mEGFP), blue fluorescent protein (tagBFP2), and monomeric red fluorescent protein (mCherry) amino acid sequences (SEQ ID NOs. 1-3) were mammalian-codon optimized and recombinantly synthesized as DNA in negative-sense configuration. Recombinant sequences were cloned into a partial, recombinant negative-sense genomic template of NDV strain Ulster, replacing viral gene N with mEGFP, viral gene P with tagBFP2, and viral gene M with mCherry. The downstream region encompassing the subgenomic trailer of viral protein M to the stop codon of viral gene L was deleted, and the stop codon of mCherry was fused with subgenomic trailer of viral gene L. Fluorophore sequences were modified with additional terminal glycine codons to ensure the total genomic length was divisible by six (SEQ ID NO. 48). The resulting recombinant, negative-sense DNA template was cloned into an IVT expression vector, comprising a mutant T7 RNA polymerase promoter with a mutant ‘AC’ TSS at the 5’ end of the viral genome and a single BspQI restriction cut site located at the 3’ terminus of the viral genome, engineered to produce a T7 RNA polymerase read-through-capable 5’ overhang. Additional biologic-expressing taRNA sequences were designed (e.g., SEQ ID NO.
[0670] 4-25, 31-32, 49-64) and can be cloned in the same manner. A non-viral Kozak sequence was also designed and placed at the end of the first sub-genomic promoter in addition to the natural Kozak-like sequence for Fuzeon peptide RNA (SEQ ID NO. 57). Again, the total N protein-recognizable genomic length was maintained as divisible by six, using hexamer phase correction to meet this requirement.
[0671] The resulting plasmid was linearized by BspQI digest or by PCR reaction utilizing a forward primer upstream of the T7 promoter and a reverse primer at the precise 3’ terminus of the viral genome. Alternatively, manufacturing of the gene of interest (GOI) or trans-amplified RNA (taRNA) was performed using a plasmid template without the need for PCR by utilizing a ribozyme sequence (see Examples below). Linearized IVT template was transcribed by recombinant T7 RNA polymeraseISB-153.01WO Attorney Reference No. 9929-113741-02 (HiScribe T7 mRNA Kit) with complete substitution of N1 -methylpseudouridine in place of uridine. Following DNAse-I digestion to remove IVT template, RNA was purified using NEB Monarch Spin RNA Cleanup Kit. RNA was quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently frozen at -80°C.
[0672] Nonsegmented Positive- Sense Self-Amplifying RNA (saRNA) IVT Template: Light chain and heavy chain amino acid sequences from Adalimumab (SEQ ID NO. 7 and SEQ ID NO. 8) are mammalian-codon optimized and recombinantly synthesized as DNA in positive- sense configuration. Recombinant sequences are cloned as open-reading frames (ORFs) into the 2nd and 3rd sub-genomic promoters of partial, recombinant positive-sense anti-genomic template of NDV strain Ulster. In the 1st sub-genomic promoter position, viral gene N is replaced with a multi-cistronic ORF encoding codon-optimized N and P amino acid sequences from NDV strain Ulster, L protein from NDV strain Bl, and V protein from Measles virus strain Ichinose-B95A. N, P, L, and V are functionally separate by a ribosomeskipping sequence (RSS). An alternate configuration includes only viral proteins N, P, and L in the first sub-genomic promoter position, optionally migrating the V or interferon-suppressor protein into a downstream sub-genomic ORF. An additional design is where an IRES element is placed immediately downstream of tire first subgenomic promoter, to enable cap-independent translation of viral replication proteins (SEQ ID NO. 75). In all designs, at the terminus of tire most 3’ recombinant sub-genomic ORF is placed the viral sub-genomic trailer sequence and polyadenylation signal from the NDV L protein, followed by the 3’ terminal antigenomic promoter sequence.
[0673] The 5’ terminus of the recombinant construct is either tire natural positive-sense sequence (ACCA) (SEQ ID NO. 70 and SEQ ID NO. 75), modified by single-base C-> G or C-> U substitution (AGCA or AUCA) (SEQ ID NOs. 71-72), or appended by a pentamer or hexamer nucleotide sequence beginning with AG or AU (AGNNN or AGNNNN) (SEQ ID NOs. 73-74). The total N protein-recognizable genomic length is always maintained as divisible by six, using hexamer phase correction or non-viral Kozak sequences as necessary to meet this requirement.
[0674] The resulting recombinant, positive-sense DNA template is cloned into an IVT expression vector, comprising a mutant T7 RNA polymerase promoter with a mutant ‘AC’, ‘AG’, or ‘AU’ TSS at the 5’ terminus of the viral antigenome and a single BspQI restriction cut site located at the 3’ terminus of the viral antigenome, engineered to produce a T7 RNA polymerase readthrough-capable 5’ overhang. The resulting plasmid is linearized by BspQI digest or by PCR reaction utilizing a forward primer upstream of the T7 promoter and a reverse primer at the precise 3’ terminus of the viral antigenome.
[0675] Linearized IVT template is transcribed by recombinant T7 RNA polymerase (HiScribe T7 mRNA Kit) with complete substitution of N1 -methylpseudouridine in place of uridine. Co-transcriptional capping is performed with CleanCap AG, CleanCap AG-3’OMe, or CleanCap M6 in the presence of an AG TSS, CleanCap AU in tire presence of an AU TSS, or a m7G-AC cap or analog in the presence of an AC TSS. Alternatively, post-transcriptional enzymatic capping with vaccinia or faustovirus cappingISB-153.01WO Attorney Reference No. 9929-113741-02 enzyme may be performed to add a m7G to the 5’ end of the saRNA. For the IRES-con taming construct (SEQ ID NO. 75), no 5’ capping is performed.
[0676] Following DNAse-I digestion to remove IVT template, RNA is purified using NEB Monarch Spin RNA Cleanup Kit. RNA is quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently frozen at -80°C.
[0677] Propagating, Nonsegmented Negative-Sense Trans-Amplified Viral RNA IVT Template:
[0678] Negative-sense viral genome sequence from Newcastle Disease Virus (NDV) strain LaSota is recombinantly engineered to insert 1-3 additional subgenomic promoters from NDV strain Ulster proceeding the polyadenylation signal of viral matrix (M) gene and before the subgenomic-promoter of viral fusion (F) gene. A transmembrane (TM) domain-fused single-chain variable fragment (scFv) targeting protein against the primary tumor marker of interest, such as CEACAM5, CA-19, CD19, or DLL3 is inserted after the first additional subgenomic promoter. (SEQ ID NOs. 27-29, and SEQ ID NOs.
[0679] 77-79). Optionally, a bi-specific T-cell engager protein recruiting T-cells (CD3) or NK cells (CD16) to a secondary tumor marker of interest, such as PDL1, is encoded in the same cistron using an RSS sequence, or inserted after tire second additional subgenomic promoter. (SEQ ID NOs. 30-31 and 80-81). Optionally, a third non-viral therapeutic protein, such as a recombinant human tumor protein 53 (TP53) fused to a viral tetramerization domain is encoded in the same cistron using an RSS or inserted after tire third additional subgenomic promoter. One or more fluorescent (e.g., mEGFP or mKate2) or luminescent reporters (firefly luciferase) may be encoded in place of or additional to the therapeutic proteins for viral propagation tracking. (SEQ ID NO. 26 and SEQ ID NO. 76). The total N protein-recognizable genomic length is always maintained as divisible by six, using hexamer phase correction or non-viral Kozak sequences as necessary to meet this requirement.
[0680] These negative-sense configured, self-propagating negative-sense virus genomes are recombinantly-synthesized and cloned into an IVT plasmid vector comprising a mutant T7 RNA polymerase promoter containing an ‘AC’ TSS at die 5’ end of the viral genome and a single BspQI restriction enzyme cut site at die 3’ terminus of the viral genome, engineered to produce a T7 RNA polymerase readdirough-capable 5’ overhang. Following IVT plasmid template linearization by BspQI digestion or by PCR reaction utilizing a forward primer upstream of the T7 promoter and a reverse primer at the precise 3’ terminus of the viral genome, the IVT template is transcribed using recombinant T7 RNA polymerase (NEB HiScribe T7 mRNA) with complete substitution of Nl-metiiylpseudouridine in place of uridine. Following DNAse-I digestion to remove IVT template, RNA is purified using NEB Monarch Spin RNA Cleanup Kit. RNA is quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently is frozen at -80°C.
[0681] Propagating, Nonsegmented Positive- Sense Self-Amplifying Viral RNA IVT Template: The positive-sense antigenomic sequence from Newcastle Disease Virus (NDV) strain LaSota is recombinantly engineered to place codon-optimized N, P, V, L protein from NDV strain LaSota (SEQ IDISB-153.01WO Attorney Reference No. 9929-113741-02 NOs. 44-47) in a multi-cistron, RSS-linked ORF under the native N subgenomic promoter. Under the native P subgenomic promoter is cloned a recombinant (TM) domain-fused single-chain variable fragment (scFv) targeting protein sequence against the primary tumor marker of interest, such as CEACAM5, CA-19, CD19, or DLL3 is inserted after the first additional subgenomic promoter.
[0682] Optionally, a bi-specific T-cell engager protein recruiting T-cells (CD3) or NK cells (CD16) to a secondary tumor marker of interest, such as PDL1, is encoded in the same cistron using an RSS sequence, or inserted using an additional recombinant subgenomic promoter. Optionally, a third non-viral therapeutic protein, such as a recombinant human tumor protein 53 (TP53) fused to a viral tetramerization domain is encoded in the same cistron using an RSS or inserted after a third additional recombinant subgenomic promoter. One or more fluorescent (e.g. mEGFP or mKate2) or luminescent reporters (luciferase) may be encoded in place of or additional to the therapeutic proteins for viral propagation tracking. Following tire therapeutic protein ORFs are placed tire native subgenomic promoters and ORFs of viral matrix (M) gene, viral fusion peptide (F) gene, and viral haemagglutininneuraminidase (H). The subgenomic trailer of tire native L ORF is fused to the end of the H gene, followed by the natural end of tire antigenome including the antigenomic promoter.
[0683] The 5’ terminus of the recombinant construct is either tire natural positive-sense sequence (ACCA) (SEQ ID NO. 82 and SEQ ID NO. 87), modified by single-base C-> G or C-> U substitution (AGCA or AUCA) (SEQ ID NOs. 83-84), or appended by a pentamer or hexamer nucleotide sequence beginning with AG or AU (AGNNN or AGNNNN) (SEQ ID NOs. 85-86). The total N protein-recognizable genomic length is always maintained as divisible by six, using hexamer phase correction or non-viral Kozak sequences as necessary to meet this requirement.
[0684] The resulting recombinant, positive-sense DNA template is cloned in an IVT expression vector, comprising a mutant T7 RNA polymerase promoter with a mutant ‘AC’, ‘AG’, or ‘AU’ TSS at the 5’ end of the viral antigenome and a single BspQI restriction cut site located at the 3’ terminus of tire viral antigenome, engineered to produce a T7 RNA polymerase readthrough-capable 5' overhang. The resulting plasmid is linearized by BspQI digest or by PCR reaction utilizing a forward primer upstream of the T7 promoter and a reverse primer at the precise 3’ terminus of the viral genome.
[0685] Linearized IVT template is transcribed by recombinant T7 RNA polymerase (HiScribe T7 mRNA Kit) with complete substitution of N1 -methylpseudouridine in place of uridine. Co-transcriptional capping is performed with Cleancap AG, Cleancap AG-3’OMe, or Cleancap M6 in the presence of an AG TSS, Cleancap AU in the presence of an AU TSS, or a m7G-AC cap or analog in the presence of an AC TSS. Alternatively, post-transcriptional enzymatic capping with vaccinia or faustovirus capping enzyme may be performed to add a m7G to the 5’ end of the saRNA. For the IRES-containing construct (SEQ ID NO. 87), no 5’ capping is performed.ISB-153.01WO Attorney Reference No. 9929-113741-02 Following DNAse-I digestion to remove IVT template, RNA is purified using NEB Monarch Spin RNA Cleanup Kit. RNA is quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently frozen at -80°C.
[0686] Nonsegmented Negative-Sense taRNA Designs Based on Additional Paramyxoviridae Genera: Nonsegmented negative-sense taRNA construct enumerations based on additional Paramyxoviridae genera are designed using the same principles as Newcastle Disease Virus (avulavirus).
[0687] Recombinant Adalimumab light chain and heavy chain sequences are cloned into a partial, recombinant negative-sense genomic template of parainfluenza virus 5 (PIV5) (rubellavirus) and mouse parainfluenza virus (Sendai Virus - SeV) (respirovirus). For PIV5, viral gene N ORF is replaced with Adalimumab light chain and viral gene P ORF is replaced with Adalimumab heavy chain. The downstream region encompassing the subgenomic trailer of viral protein P to the stop codon of viral gene L is deleted, and the stop codon of Adalimumab heavy chain is fused to the subgenomic trailer sequence of viral gene L. (SEQ ID NO. 89). For SeV, the subgenomic promoter of viral gene P / C ORF is skipped due to multiple staggered translational start sites of the natural encoded proteins. For SeV, viral gene N ORF is replaced with Adalimumab light chain, the stop codon of which is fused to the subgenomic trailer sequence of P, followed by the subgenomic ORF of viral protein M that is replaced with Adalimumab heavy chain. The stop codon of Adalimumab heavy chain is fused with the trailer sequence of viral gene L. (SEQ ID NO. 88).
[0688] The resulting recombinant, negative-sense DNA template is cloned in an IVT expression vector, comprising a mutant T7 RNA polymerase promoter with a mutant ‘AC’ TSS at the 5’ end of the viral genome and a single BspQI restriction cut site located at the 3’ terminus of tire viral genome, engineered to produce a T7 RNA polymerase readthrough-capable 5’ overhang.
[0689] For PIV5, the resulting plasmid is linearized by BspQI digest or by PCR reaction utilizing a forward primer upstream of the T7 promoter and a reverse primer at the precise 3’ terminus of the viral genome. For SeV, the resulting plasmid is linearized by PCR reaction utilizing a forward primer upstream of the T7 promoter and a reverse primer at the precise 3’ terminus of the viral genome.
[0690] Linearized IVT template is transcribed by recombinant T7 RNA polymerase (HiScribe T7 mRNA Kit) with complete substitution of N1 -methylpseudouridine in place of uridine or 5-methylcytosine in place of cytosine. Following DNAse-I digestion to remove IVT template, RNA is purified using NEB Monarch Spin RNA Cleanup Kit. RNA is quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently frozen at -80°C.
[0691] To ensure the total genomic length is divisible by six and that taRNA promoters and bailers are in their proper hexamer phasing for nucleoprotein binding, addition of hexamer phase correction sequence(s) or non-viral Kozak sequence(s) are applied to the construct at specific loci.ISB-153.01WO Attorney Reference No. 9929-113741-02 To generate positive-sense mRNA encoding RdRp and other essential viral replication proteins, Nucleoprotein (N), Phosphoprotein (P), RdRP (L), and interferon-suppressor (V) amino acid sequences from PIV5 strain W3A Virus (SEQ ID NOs. 40-43) are mammalian-codon optimized and recombinantly synthesized as DNA. Recombinant PIV5 N, V, and P nucleic acid sequences are cloned into a single cistron, linking each protein with a ribosomal skipping sequence such as a T2A peptide sequence from Thosea asigna virus. (SEQ ID NO. 92). Recombinant PIV5 L nucleic acid sequence is separately cloned as a single-cistron. (SEQ ID NO. 93). Alternatively, L nucleic acid sequence may be operably linked by a ribosomal skipping sequence to the N, V, P cistron.
[0692] For SeV, Nucleoprotein (N), Phosphoprotein (P), and RdRP (L) amino acid sequences from SeV strain Ohita, and interferon suppressor (V) protein from Measles virus strain Ichinose-B95A (SEQ ID NOs. 36-39) are mammalian-codon optimized and recombinantly synthesized as DNA. Recombinant SeV N, P and Measles V nucleic acid sequences are cloned into a single cistron, linking each protein with a ribosomal skipping sequence such as a T2A peptide sequence from Thosea asigna virus. (SEQ ID NO.
[0693] 90). Recombinant SeV L nucleic acid sequence is separately cloned as a single-cistron. (SEQ ID NO. 91). Alternatively, L nucleic acid sequence may be operably linked by a ribosomal skipping sequence to the N, V, P cistron.
[0694] The resulting cistrons are separately cloned into an in vitro transcription (IVT) plasmid vector encoding a mutant T7 RNA polymerase promoter containing an ‘AG’ TSS, a mammalian 5’ untranslated region (UTR) sequence, a Kozak sequence, a mammalian 3’ UTR sequence, and a defined poly A tract. Recombinant L nucleic acid sequence is separately cloned into an identical IVT vector. The IVT plasmids are linearized using a single BspQI restriction cut site at tire terminus of the poly A tract.
[0695] Following linearization, tire IVT templates are transcribed using recombinant T7 RNA polymerase in tire presence of CleanCap AG (NEB HiScribe T7 mRNA with CleanCap AG Kit) and with complete substitution of N1 -methylpseudouridine in place of uridine. Following DNAse-I digestion to remove IVT template, RNA is purified using NEB Monarch Spin RNA Cleanup Kit. RNA is quantified by calibrated UV absorbance on a NanoDrop 2000 (Thermo Scientific), and subsequently frozen at -80°C.
[0696] In vitro Transfection of Human Cells with RNA Constructs: Constructs were co-transfected into human HEK293 or Expi293F cells, utilizing cationic polymer-based TransIT-mRNA (Mirus Biosciences), cationic lipid-based Lipofectamine MessengerMax (Thermo Scientific), electroporation (Lonza 4D Nucleofector SF Kit), or poly(2-hydroxypropyleneimine) cationic polymer-based Expifectamine (Thermo Scientific). A 1:1:1 mass ratio between SEQ ID NO. 48 negative-sense taRNA (encoding mEGFP + tagBFP2 + mCherry), SEQ ID NO. 66 positive-sense L mRNA, and SEQ ID NO.
[0697] 65 or SEQ ID NO. 68 positive-sense N-V-P mRNA was utilized for respective transfections. Likewise, a 1:1:1 mass ratio between negative-sense taRNA encoding mEGFP (SEQ ID NO. 1) or Epogen (erythropoietin alpha) (SEQ ID NO. 9), SEQ ID NO. 66 positive-sense L mRNA, and SEQ ID NO. 65 positive-sense N-V-P mRNA was utilized for respective transfections. Similarly, a 1: 1 mass or molar ratio between SEQ ID NO. 48 negative-sense taRNA and SEQ ID NO. 67 or SEQ ID NO. 69 N-V-P-LISB-153.01WO Attorney Reference No. 9929-113741-02 positive-sense mRNA is utilized for respective transfections. A 1:1 mass or molar mass ratio is utilized for propagating, nonsegmented negative-sense trans-amplified viral RNA SEQ ID NOs. 76-81 and SEQ ID NO. 67 or SEQ ID NO. 69 N-V-P-L positive-sense mRNA. Alternatively, a 1:1:1 mass or molar mass ratio can also be utilized for propagating, nonsegmented negative-sense trans-amplified viral RNA SEQ ID NOs. 76-81, SEQ ID NO. 66 positive-sense L mRNA, and SEQ ID NO. 65 positive-sense N-V-P mRNA.
[0698] As shown in FIG. 16, a 3-10% transfection efficiency was achieved with Expifectamine, in serum-free, suspension Expi293F cell shake-cultures as measured by GFP+ expression, both by Sartorius Incucyte automated microscopy analysis (5-10%) and by flow cytometry (3-4%). Significantly, taRNA-mediated cell death at 44 hours appeared minimal (about 4-5% as measured by Live-or-Dye-750 / 777 apoptotic dye (Biotium Sciences) in flow cytometry). For reference, alphaviral saRNA typically induces 35-50% cell death at 48h, depending on cell type.
[0699] As can be seen in FIG. 17, negative-sense taRNA encoding Epogen (erythropoietin) (SEQ ID NO. 9) modified with a 6x His-tag and 5’ capped positive-sense RdRp and accessory mRNA transcripts (SEQ ID NO. 65 and SEQ ID NO. 66) was readily expressed in serum-free, suspension Expi293F cell shake-cultures. Briefly, the cell culture supernatants were harvested at 72h and subsequently His-tag purified using Cobalt HisPure resin (Thermo Scientific). Accounting for negative-control background, a total of about 40ug of secreted Epogen was recovered by his tag purification. Assuming a 6% taRNA transfection efficiency and a 50% Epogen purification loss, it was estimated that the Epogen taRNA constructs produced and secreted about 44 ug of Epogen per ug of RNA in tire serum-free, suspension Expi293F cell shake-cultures.
[0700] The data demonstrate the efficacy of tire disclosed RNA constructs in producing therapeutically relevant recombinant proteins. For example, therapeutic doses of Epogen typically range between 50-150 lU / kg per dose, administered 3 times per week for anemia. That amounts to about 15-50 pg of Epogen per dose for a 70 kg patient. Assuming a transfection efficiency of 36% for LNPs loaded with the taRNA system used to generate the data in FIG. 17, and continuous expression of Epogen over 7 days based on in vitro data in FIG. 13, about 1 ug of the administered taRNA Epogen system would produce approximately 15 pg of Epogen and sustained expression over multiple days would amplify this effect. This is within the therapeutic window for Epogen. In addition, the amount of mRNA currently approved and dosed for the mRNA SPIKEVAX (Moderna) COVID-19 vaccine is 50 pg or less, indicating that LNP formulations containing an Epogen taRNA construct disclosed herein could adopt similar delivery formats. Administration of taRNAs of the disclosure encoding longer acting erythropoietins such as Darbepoeitin alfa would reduce the amounts needed even further.
[0701] For nonsegmented positive-sense saRNA (SEQ ID NO. 70-75) or propagating, nonsegmented positive-sense self-amplified viral RNA (SEQ ID NO. 82-87), only one RNA species is present in the transfection. For SeV and PIV5 taRNA designs, a 1:1:1 mass or molar mass ratio between SEQ ID NO.ISB-153.01WO Attorney Reference No. 9929-113741-02 88 or SEQ ID NO. 89 negative-sense taRNA, SEQ ID NO. 91 or SEQ ID NO. 93 positive-sense L mRNA, and SEQ ID NO. 90 or SEQ ID NO. 92 positive-sense N-V-P mRNA is utilized for respective transfections.
[0702] Example 3: Lipid nanoparticle RNA formulations
[0703] Lipid nanoparticle RNA (RNA-LNP) formulations are outsourced or prepared de novo following standard processes known in the art. Examples of commercial contract manufacturing organizations (CMOs) specializing in research to pharmaceutical grade production of RNA-LNP formulations include, but are not limited to, Precision NanoSystems (now NanoAssemblr by Cytiva), Acuitas Therapeutics, Millipore Sigma, and CDMOs like Lonza, WuXi Biologies, and Samsung Biologies.
[0704] For de novo synthesis, lipid components may include an ionizable lipid (e.g., DLin-MC3-DMA, commercially available from Cayman Chemical, www.caymanchem.com), structural lipid (e.g., 1,2-distearoyl-sn-glycero-3-phosphocholine (e.g., DSPC, NOF Corporation, www.nofamerica.com), cholesterol (e.g., Croda, www.croda.com), and a PEG-lipid conjugate (e.g., DMG-PEG2000, Avanti Polar Lipids, avantilipids.com). RNA synthesis and purification can be performed using various methods, such as in vitro transcription using T7 RNA polymerase followed by purification with silica membrane columns, size-exclusion chromatography, or high-performance liquid chromatography (HPLC) to ensure removal of impurities including double-stranded RNA, unincorporated nucleotides, and enzymes (Pardi et al., 2018; Sahin et al., 2014; and Kariko et al., 2011). For long mRNA transcripts such as 10 to 20 kb constructs, integrity should be closely monitored throughout synthesis and formulation using appropriate methods such as capillary electrophoresis, as these transcripts are more prone to fragmentation or degradation. Additionally, protective measures such as the inclusion of RNase inhibitors during RNA handling steps may be beneficial.
[0705] Citrate buffer (pH 4.0 to 5.0) serves as the encapsulation medium, ethanol (e.g., USP grade, Sigma- Aldrich, www.sigmaaldrich.com) dissolves the lipid components, and phosphate-buffered saline (e.g., PBS, Thermo Fisher Scientific, www.thermofisher.com) is used for buffer exchange. For LNP formulations containing different RNA molecules, lipid components are dissolved in ethanol at a molar ratio of 50:10:38.5:1.5 (ionizable lipid: DSPC:cholesterol: PEG-lipid) and sterile filtered (0.22 pm, using filters from suppliers like MilliporeSigma, www.milliporesigma.com). Each mRNA construct is diluted separately in citrate buffer (pH 4.5) to a target concentration (e.g., 1 mg / mL), sterile filtered (0.22 pm), and stored at 2 to 8°C. For long mRNAs, such as those exceeding 10 kb in length, it may be necessary to reduce the working concentration (e.g., to 0.5 mg / mL) to avoid issues with viscosity or aggregation, which can negatively impact encapsulation efficiency and reproducibility.
[0706] The ethanol-lipid solution and the two mRNA solutions are pumped into a microfluidic mixing system (e.g., NanoAssemblr® GMP system from Precision NanoSystems / Cytiva, www.cytiva.com / en / solutions / cell-and-gene-therapy / nanoassemblr-systems) at a defined flow rate ratio (e.g., 3:1 ethanoktotal aqueous), with tire two mRNA solutions combined immediately prior to mixingISB-153.01WO Attorney Reference No. 9929-113741-02 with the lipid solution. When working with 15 kb transcripts, care should be taken to reduce shear stress during mixing, which may otherwise lead to RNA fragmentation. This can be addressed by optimizing the flow rate or employing a lower-shear microfluidic mixer configuration. Controlled mixing facilitates LNP self-assembly, encapsulating both mRNAs through rapid electrostatic interactions and hydrophobic phase transitions that occur as the ionizable lipid interacts with the negatively charged RNA in an aqueous environment, typically at low pH (Kulkami et al., 2018; Pattani et al., 2022; and Maier et al., 2013). The resulting LNP suspension is then subjected to UF / DF using tangential flow filtration (TFF) (e.g., systems and membranes from suppliers Sartorius, www.sartorius.com) to remove ethanol and exchange tire buffer to PBS. The final LNP-RNA concentration is adjusted to meet product specifications (e.g., 1 mg / mL total RNA), but this may be lowered in the case of large constructs if solubility or stability becomes limiting.
[0707] The process for a single RNA per LNP particle follows the same steps except only the single RNA solution is used in tire microfluidic mixing step. Following purification, LNP suspensions are sterile filtered (0.22 qm PVDF filter) and transferred to an aseptic filling line within an ISO 5 environment. The bulk drug product is filled into sterile vials, stoppered, capped, and visually inspected. A series of quality control tests is performed for each construct, including encapsulation efficiency (e.g., RiboGreen™ assay, target > 90% (insert relevant RiboGreen assay reference)), particle size and PDI (dynamic light scattering (DLS), target: 80 to 120 nm and a PDI below 0.2 (e.g., Malvern Panalytical, www.malvernpanalytical.com)), residual ethanol content (gas chromatography (GC)), mRNA integrity (capillary electrophoresis), endotoxin testing, and sterility testing. In the case of longer mRNAs, integrity testing is particularly critical both before and after encapsulation, as these transcripts are inherently more sensitive to shear, hydrolysis, and heat. For LNPs containing different RNA constructs, mRNA ratios can be determined by, for example, quantitative PCR or other suitable method. Filled vials are stored at -20°C or -80°C, and stability studies (long-term and accelerated) are conducted per ICH guidelines (www.ich.or ). For large mRNAs, it may be advisable to include additional stabilizers (e.g., sugars or antioxidants) in the final buffer to preserve long-term integrity.
[0708] Example 4: mEGFP Time-Course Expression Across Cell Lines
[0709] Translational versatility was evaluated by transfecting multiple human cell lineages and tracking expression of mEGFP by time-course fluorescence captured on Incucyte S3. Following template linearization by PCR (taRNA), mEGFP NDV taRNA (SEQ ID NO: 117) was synthesized by T7 polymerase with 100% Nl-methylpseudouridine (mlpsi) substitution.
[0710] NDV mEGFP taRNA plasmid template was linearized by PCR for IVT with the following DNA primers using Platinum SuperFi II Polymerase Master Mix (Thermo Scientific) with lOng of plasmid template per 50ul reaction. Cycle parameters were as follows: step 1, 98°C (30 seconds); step 2 - 98°C (10 seconds); step 3, 60°C (10 seconds); step 4, 72°C (30 seconds); repeat steps 2-4 a total of 30x; step 5, 72°C (5 minutes); and step 6, 4°C (indefinite). The forward primer (5’->3’) upstream of the T7 promoterISB-153.01WO Attorney Reference No. 9929-113741-02 was: CTGCTTACTGGCTTATCGAAATTAATAC. The reverse primer (5 ’->3’) terminating precisely on taRNA 3’ genomic end was as follows: ACCAAACAGAGAATCGGTGAGTTACG. The same template linearization technique was used for all PCR-based approaches in the subsequent Examples unless otherwise specified.
[0711] Following template linearization by BspQI, m7G NP(NDV)-V(Measles)-P(NDV) mRNA (SEQ ID NO:65) and m7G NDV Strain Bl L mRNA (SEQ ID NO:66) were synthesized with T7 polymerase and CleanCap-AG with 100% mlpsi substitution. Following DNAse treatment and purification, RNA transcripts were co-encapsulated at a 1:2:1 (taRNA: NVP: L) raw mass ratio in SM102 LNPs by vendor (Genscript). LNPs were applied to 293T (human kidney), Caco2 (human intestinal epithelium), HepG2 (human liver), and C2C12 (mouse myoblast) cell lines growing in antibiotic-free Fluorobrite DMEM Media (w / 10% FBS, GlutaMax, MNEAA). Media was changed on cell cultures 6 hours after addition of LNPs, with tire exception of one 293T replicate where LNP- media was left on cells indefinitely. Cells were thereafter placed in Incucyte and imaged every 3h in tire green channel using the 10x lens.
[0712] Automated Incucyte image analysis was used to calculate background-subtracted green object intensity (RFU) per field of view tile (FOV) over the course of 168h post-transfection. Resulting data was plotted as kinetic expression curves for each cell line (FIG. 18).
[0713] As can be seen in FIG. 18, robust and sustained mEGFP expression across multiple human-derived cell lines was observed, representing distinct anatomical compartments and differentiation states (kidney, intestinal epithelium, hepatic parenchyma, and myoblast lineage). As can also be seen, sustained expression in human cell lines relative to reduced expression in murine cell lines was observed. Without being bound by theory, these observations are consistent with embodiments in which selection of host species-matched or host species-mismatched viral proteins, including V proteins, is used to modulate expression activity and / or duration in a host-dependent manner.
[0714] Example 5: NDV mEGFP taRNA 5’ Modification Variants
[0715] Following template linearization by PCR, NDV mEGFP taRNA (SEQ ID NO: 117) was T7 polymerase synthesized with 100% Nl-methylpseudouridine (mlpsi), 85% mlpsi + 15% uridine, or 100% uridine. Following DNase treatment and purification, 100% mlpsi NDV mEGFP taRNA was aliquoted and subjected to different 5’ end group modifications. Unaltered taRNA harbors a 5’ppp (triphosphate) group. To generate 5’ m7G CapO taRNA, taRNA was first heat denatured at 65C for 5 min and then snap cooled on ice. Faustovirus capping enzyme with SAM and GTP was incubated with taRNA at 37C for lh. To generate 5’ m7G-Capl taRNA (SEQ ID NO:118), taRNA was first heat denatured at 65C for 5 min and then snap cooled on ice. Faustovirus capping enzyme and mRNA Cap 2'-O-Methyltransferase with SAM and GTP was incubated with taRNA at 37C for lh. To generate 5’OH taRNA, taRNA was first heat denatured at 65C for 5 min and then snap cooled on ice. taRNA was first incubated with RNA 5' Pyrophosphohydrolase to convert 5’ppp to 5’p, followed by a secondary incubation with QuickCIP (NEB) to convert 5’p to 5’OH. Generated taRNA variants were mixed at aISB-153.01WO Attorney Reference No. 9929-113741-02 1:2:1 (taRNA: NVP: L) raw mass ratio with T7 polymerase + CleanCap-AG synthesized m7G NP(NDV)-V(Measles)-P(NDV) mRNA (SEQ ID NO:65) and m7G NDV Strain Ulster L mRNA (SEQ ID NO: 122) with 100% mlpsi substitution and complexed with Expifectamine transfection reagent. RNA complexes were applied to 293Ts plated in antibiotic-free Fluorobrite DMEM Media (with 10% FBS, GlutaMax, MNEAA). After 5 hours incubation, media was replaced and cells were placed in Incucyte S3, imaging in the green channel using the 10x lens. Automated Incucyte image analysis was used to calculate background-subtracted green object intensity (RFU) per field of view tile (FOV) over the course of 168h post-transfection. Resulting data was plotted as kinetic expression curves for each taRNA variant and shown in FIG. 19A.
[0716] As depicted in FIG. 19A, manipulation of the taRNA 5’ end-group chemistry yielded a tiered effect on recombinant protein expression kinetics and magnitude. Enzymatic conversion of the 5’ terminus to a 7-methylguanosine cap (both CapO and Capl variants) was tolerated, which was unexpected since 5’ m7G capping is not known to occur on the genomic RNA of nonsegmented negative sense viruses. The 5 ’OH modification, which eliminates both the triphosphate and cap structures, resulted in an attenuated expression profile. These data support embodiments in which tuning the 5’ structure of taRNA can be exploited to control expression kinetics and protein yield across target cell types.
[0717] Example 6: 5’ Non-Capped and Capped taRNA Encoding Firefly Luciferase (FLuc)
[0718] Production and testing of 5’ non-capped and capped taRNA encoding FLuc within SM102 lipid nanoparticles was carried out as follows. Following template linearization by PCR, NDV Flue taRNA (SEQ ID NO: 112) was synthesized using CleanScribe RNA polymerase (TriLink Biotechnologies) and 100% mlpsi substitution. Following DNase treatment and purification, an aliquot of the taRNA was further subjected to 5' m7G (Capl) enzymatic capping using Faustovirus capping enzyme and mRNA Cap 2'-O-Methyltransferase to produce 5’ m7G (Capl) FLuc taRNA (SEQ ID NO: 113). taRNA were mixed at a 1:2:1 (taRNA: NVP: L) with vendor-synthesized (Genscript) m7G NP(NDV)-V(PIV5[N100D])-P(NDV) mRNA (vendor codon-optimized variant of Seq #121) and m7G NDV Strain Ulster L mRNA (vendor codon-optimized variant of SEQ ID NO: 122) with 100% mlpsi substitution, and co-encapsulated in SM102 LNPs by vendor (Genscript). LNPs were applied to 293T cells (human kidney) and C2C12 cells (mouse myoblast) plated in a 12-well plate. 15h after addition of LNPs, media was removed and transfected cells were lysed in 250ul Cell Lysis Buffer (Pierce Firefly Luciferase Flash Assay Kit) alongside non-transfected cell control wells. 20ul of each cell lysate was mixed with D-luciferin reconstituted in Firefly Flash Assay Buffer according to Pierce Firefly Luciferase Flash Assay Kit protocol. Luminescence was read on a Synergy HT plate reader, and signal-to-noise ratio was calculated by first subtracting non-transfected lysate emission from the transfected lysate emission, and then dividing the net transfected lysate emission by the blank emission (cell lysis buffer + D-luciferinISB-153.01WO Attorney Reference No. 9929-113741-02 assay buffer). Results were plotted as signal- to-noise ratios as shown in FIG. 19B for both capped and non-capped taRNA variants in both cell lines.
[0719] As can be seen in FIG. 19B, encapsulation of FLuc taRNA-mRNA-mRNA complexes within SM102 lipid nanoparticles preserved the translational competence of the 5’ non-capped and capped taRNAs. The magnitude of luminescence signal in human 293T cells was found to substantially exceed that in murine C2C12 cells across both taRNA end-group variants, further supporting embodiments in which the paramyxoviridae-derived replication machinery exhibits species-dependent activity for human host.
[0720] Example 7: mEGFP 3’ Ribozyme Variant Expression
[0721] To facilitate rapid, PCR-free production of the taRNA with defined termini and ml T substitution suitable for replication and reduced host sensing, a plasmid-based ribozyme expression system was examined. Several 5 ’-autocleaving ribozyme species were cloned onto the 3’ end of NDV mEGFP taRNA plasmid template, followed by BspQI cut-site at the 3’ terminus of each ribozyme. Species included 3’ antigenomic HDV ribozyme (SEQ ID NO:119), 3’ genomic HDV ribozyme, 3’ minimal HDV67 ribozyme, and 3’ Twister ribozyme. taRNA plasmids templates were linearized by BspQI digestion, followed by T7-polymerase mediated taRNA synthesis using either 100% mlpsi or 85% mlpsi+15% uridine. DNasel-XT (NEB) and DNasel-XT Buffer (containing 10mM MgCl2 at IX concentration) was added to the reaction and incubated for 30 minutes at 37C, enabling DNA digestion and Mg2+ catalyzed ribozyme cleavage. taRNA was purified and mixed at a 1:2:1 (taRNA: NVP: L) ratio with T7 polymerase + CleanCap-AG synthesized m7G NP(NDV)-V(PIV5[N100D])-P(NDV) mRNA (SEQ ID NO: 121) and m7G NDV Strain Ulster L mRNA (SEQ ID NO: 122) with Expifectamine transfection reagent. RNA complexes were applied to 293T cells in antibiotic-free Fluorobrite DMEM Media (w / 10% FBS, GlutaMax, MNEAA). Cell media was changed 5 hours thereafter, and cells were placed in Incucyte and imaged every 3h in the green channel using the 10x lens. Automated Incucyte image analysis was used to calculate background-subtracted green object intensity (RFU) per field of view tile (FOV) over the course of 168h post-transfection. Resulting data was plotted as kinetic expression curves for each taRNA 3’ ribozyme variant (FIG. 20).
[0722] The 3’ antigenomic HDV ribozyme with 85% to 100% in I substitution or a 3’ minimal HDV ribozyme with 100% in I substitution generated better expression (FIG. 20). The antigenomic and genomic HDV ribozymes, which generate a 2’,3’-cyclic phosphate at tire 3’ end of the upstream RNA upon cleavage, support embodiments in which ribozyme selection, nucleotide composition (e.g., m 11| / versus mixed incorporation), and taRNA-to-mRNA stoichiometry are utilized to optimize construct performance for a given end use, including modulation of expression kinetics and yield.ISB-153.01WO Attorney Reference No. 9929-113741-02 Example 8: PIV5 mEGFP taRNA Expression Kinetics
[0723] Following template linearization by PCR (taRNA), PIV5 mEGFP taRNA (SEQ ID NO: 123) was T7 RNA polymerase synthesized, followed by DNAse digestion and purification. Note, the forward primer (5’->3’) upstream of the T7 promoter for PCR linearization was the same as above (i.e., CTGCTTACTGGCTTATCGAAATTAATAC), whereas the reverse primer (5’->3’) terminating precisely on taRNA 3’ genomic end for PIV5 construct was as follows:
[0724] ACCAAGGGGAAAATGAAGTGGTGACT. Following template linearization by BspQI digest, m7G NP(PIV5)-V(PIV5)-P(PIV5) mRNA (SEQ ID NO:92) and m7G PIV5 L mRNA (SEQ ID NO:93) were synthesized with T7 polymerase + CleanCap-AG. RNA was complexed at a 1:2:1 raw mass ratio of taRNA: NP-V-P: L with Expifectamine transfection reagent, and complexes were applied to 293Ts in antibiotic-free Fluorobrite DMEM Media (w / 10% FBS, GlutaMax, MNEAA). Cell media was changed 5 hours thereafter, after which cells were placed in a Incucyte S3 and imaged every 3h in the green channel using the 10x lens. Automated Incucyte image analysis was used to calculate background-subtracted green object intensity (RFU) per field of view tile (FOV) over tire course of 240h post-transfection. Kinetic expression curves are shown in FIG.21.
[0725] The PIV5-based platform variant presented in FIG.21 supports embodiments in which the taRNA-mRNA co-expression system is transferable across distinct paramyxovirus species, with preserved functional output. Although the expression kinetics of the PIV5 system exhibit a more delayed biphasic onset. Without being bound by theory, tire observed temporal shift may reflect differences in viral component compatibility and host-cell interactions, and RdRp-mediated taRNA replication and transcription speed. The sustained plateau of mEGFP expression over tire 240-hour observation window indicates that PIV5-derived systems enable extended mRNA-based protein production.
[0726] Example 9: Adalimumab Protein Production and Purification
[0727] Following template linearization by PCR (taRNA) Adalimumab NDV taRNA (SEQ ID NO: 107) was synthesized by CleanScribe RNA polymerase (TriLink Biotechnologies) with 100% mlpsi substitution. Following template linearization by BspQI digest (mRNA), m7G NP(NDV)-V(Measles)-P(NDV) mRNA (SEQ ID NO:65), and m7G NDV Strain Ulster mRNA (Seq #122) were synthesized with T7 RNA polymerase + CleanCap-AG with 100% mlpsi substitution. A total of 40ug of RNA was complexed at a 1:2:1 raw mass ratio of taRNA: NP-V-P: L with Expifectamine transfection reagent. RNA complexes were added to a 30ml culture of Expi293 suspension cells. Four days after addition of RNA, supernatant was collected from the culture, sterile-filtered, Amicon-concentrated, and purified by Protein G resin spin-column. Following washing, four successive elutions were made from the resin spin column. Eluates were resuspended in Laemelli buffer. Lanes 1-4 indicate the four elutions without reducing agent, while tire lanes 5-8 indicate the lanes with reducing agent (Beta-mercaptoethanol) and heat denaturation at 65°C for 3 minutes. Lysates were ran on a 4-20% BioRad Stain-Free Gel, after which they were imaged in a BioRad ChemiDoc. Approximate molecular weights of detected protein bands are indicatedISB-153.01WO Attorney Reference No. 9929-113741-02 on the gel in FIG.22. Heavy chain (HC), light chain (LC), and full-length antibody (IgG) bands are annotated.
[0728] Table 21 shows approximate purified therapeutic protein yields produced by 40ug of NDV taRNA in 30ml Expi293 cultures over 4 days. Erythropoietin (SEQ ID NO:52) and FGF21 + GLP1 (SEQ ID NO:110) were modified to encode a 6xHis tag, enabling cobalt-IMAC resin purification. Approximate protein yields were determined by Nanodrop A280 absorbance normalized against individual protein extinction coefficient, and blanked against respective elution buffer.
[0729] Table 21. taRNA-Encoded Therapeutic Protein Approximate Purified
[0730] Yields (30ml Expi293 Culture over 4 Days)
[0731]
[0732] As can be seen, milligram-scale yields were obtained from 40 pg taRNA input in 30 mL culture. Production was achieved across structurally and functionally distinct therapeutic modalities, including full-length antibodies (e.g., adalimumab), blood proteins (e.g., erythropoietin), and combinatorial constructs (e.g., FGF21 and GLP1). These results support use of tire RNA biologies platform of the disclosure for synthesis and secretion of therapeutically relevant amounts of multiple polypeptide therapeutics, and in certain embodiments, for targeted delivery, local expression, or ex vivo production applications.
[0733] Example 10: Effect of In Vitro Transcription (IVT) Promoter on NDV and PIV5 Expression To assess tire impact of RNA polymerase (e.g., T7) promoter architecture on taRNA synthesis yields and downstream expression kinetics, two T7 promoter variants were incorporated into template plasmids and tested for RNA production. The first, a modified phi2.5 (Class II) T7 promoter, incorporated an ‘at’ adenine-thymidine dinucleotide substitution immediately 5’ to tire native sequence (full modified sequence: attaatacgactcactatt (SEQ ID NO: 125)). The second, a phi6.5 (Class III) promoter, represents a distinct structural class with different transcription initiation properties from tire Class II T7 promoter.
[0734] Following template linearization by PCR, NDV mEGFP taRNA (SEQ ID NO: 117) was T7 polymerase synthesized using a template-encoded modified phi2.5 (Class II) T7 promoter or a phi6.5 (Class III) T7 promoter with 100% mlpsi substitution. The modified phi2.5 promoter incorporated an ‘at’ substitution immediately 5’ to the native phi2.5 sequence (full modified sequence: attaatacgactcactatt (SEQ ID NO: 125)). Following template linearization by BspQI digest (mRNA), m7G NP(NDV)-V(Measles)-P(NDV) mRNA (SEQ ID NO:65), and m7G NDV Strain Ulster mRNA (Seq #122) were synthesized with T7 RNA polymerase + CleanCap-AG with 100% mlpsi substitution. RNA was complexed at a 1:2:1 raw mass ratio of taRNA: NP-V-P: L with Expifectamine transfection reagent. Complexes were added to 293T cells in antibiotic-free Fluorobrite DMEM Media (w / 10% FBS,ISB-153.01WO Attorney Reference No. 9929-113741-02 GlutaMax, MNEAA). Cell media was changed 5 hours thereafter, and cells were placed in Incucyte S3 for imaging in the green channel with the 10x lens. Automated Incucyte image analysis was used to calculate background-subtracted green object intensity (RFU) per field of view tile (FOV) over the course of 168h post-transfection. The results are shown in FIG.23A.
[0735] The effect of IVT promoter on PIV5 mEGFP taRNA expression is depicted in FIG.23B.
[0736] Following template linearization by PCR, PIV5 mEGFP taRNA (SEQ ID NO: 123) was T7 polymerase synthesized using a template-encoded modified phi2.5 (Class II) T7 promoter or a phi6.5 (Class III) T7 promoter. The modified phi2.5 promoter incorporated an ‘at’ substitution immediately 5’ to the native phi2.5 sequence (full modified sequence: attaatacgactcactatt (SEQ ID NO: 125)). Following template linearization by BspQI digest (mRNA), m7G NP(PIV5)-V(PIV5)-P(PIV5) mRNA (SEQ ID NO:92), and m7G PIV5 L mRNA (Seq #93) were synthesized with T7 RNA polymerase + CleanCap-AG with 100% mlpsi substitution. RNA was complexed at a 1:2:1 raw mass ratio of taRNA: NP-V-P: L with Expifectamine transfection reagent. Complexes were added to 293T cells in antibiotic-free Fluorobrite DMEM Media (w / 10% FBS, GlutaMax, MNEAA). Cell media was changed 5 hours thereafter, and cells were placed in Incucyte S3 for imaging in the green channel with die 10x lens. Automated Incucyte image analysis was used to calculate background- subtracted green object intensity (RFU) per field of view tile (FOV) over the course of 240h post-transfection (FIG.23B).
[0737] The promoter-engineering data presented in FIGS. 23A-23B indicate that the choice of T7 promoter architecture exerts measurable effects on bofli die transcription efficiency and die downstream translational competence of tire syntiiesized taRNA. The modified phi2.5 Class II T7 promoter, which incorporates additional 5 ’-flanking sequence complexity, consistently yields higher peak mEGFP expression and extended duration of expression plateau across botii NDV and PIV5 platforms compared to the phi6.5 variant. The reproducibility of this effect across two distinct paramyxovirus systems (NDV and PIV5) suggests a platform-independent benefit of the modified phi2.5 architecture. The modular optimization of the promoter element, when combined with the 5’ end-group and 3’ ribozyme optimizations described in prior figures, supports embodiments in which iterative optimization of promoter, 5’ end-group and 3’ end-group elements facilitate tuning of expression kinetics and yield. Example 11: FLuc taRNA LNP Encapsulation Integrity
[0738] Following template linearization by PCR, NDV Flue taRNA (SEQ ID NO: 112) was synthesized using CleanScribe RNA polymerase (TriLink Biotechnologies) with 100% mlpsi substitution. Following DNase treatment and purification, manufacturing was outsourced for contracted production of SM102 LNPs as follows. taRNA was mixed at a 1:2:1 ratio with m7G NP(NDV)-V(PIV5[N100D])-P(NDV) mRNA (codon-optimized variant of SEQ ID NO:121, manufactured by GenScript) and m7G NDV Strain Ulster L mRNA (codon-optimized variant of SEQ ID NO: 122, manufactured by GenScript) with 100% mlpsi substitution, and co-encapsulated in SM102 LNPs (GenScript). Following dialysis into Tris-HCl pH 7.5 + 10% sucrose buffer, a sample of the LNPs was lysed with Tween-20 and NEB Buffer BX, andISB-153.01WO Attorney Reference No. 9929-113741-02 the encapsulated RNA was purified using Monarch Spin RNA Cleanup columns. Purified RNA was run on a ladder-calibrated Agilent Tapestation using the RNA Tape Assay. Three transcripts were observed correlated with the expected sizes of taRNA (1968bp), NP-V-P mRNA (3754bp), and L mRNA (6923bp), and the corresponding expected raw mass ratio of 1:2:1 (FIG.24).
[0739] For quality control, LNP nanoparticle physical characteristics were assessed by Dynamic Light Scattering (Z-average particle size and polydispersity index), Laser-Doppler Electrophoresis (Zeta potential), RiboGreen assay (RNA encapsulation efficiency), osmolality, and endotoxin (see Table 22).
[0740] Table 22. Quality control analytics for FLuc SM102 LNPs
[0741]
[0742] These measurements support embodiments in which the LNP formulations exhibit physicochemical properties suitable for in vivo delivery and reproducible encapsulation of multicomponent RNA systems.
[0743] Example 12: Intravenous and Intramuscular Delivery and Expression in Mice
[0744] To evaluate systemic and localized delivery, in vivo studies were conducted in murine models. RNA payloads encoding either standard firefly luciferase or AKA-luciferase were encapsulated in lipid nanoparticles comprising SM102 (SM102 LNPs) (GenScript). The resulting RNA-LNP formulations were prepared in a buffer containing 20 rnM TRIS (pH 7.5) and 10% sucrose. These formulated LNPs were administered to the mice via direct intravenous (IV) and intramuscular (IM) injection to assess biodistribution and localized protein expression and durability kinetics as follows.
[0745] Following template linearization by PCR, NDV Flue taRNA (SEQ ID NO: 112) was synthesized using CleanScribe RNA polymerase (TriLink Biotechnologies) with 100% mlpsi substitution. Following DNase treatment and purification, an aliquot of taRNA was set aside for 5’ppp taRNA (non-capped) sample, and another aliquot heat denatured at 65°C for 5 min and then snap cooled on ice. Faustovirus capping enzyme and mRNA Cap 2 -O- Methyl transferase with SAM and GTP was incubated with the snap cooled taRNA aliquot at 37°C for Ih to generate 5’ m7G (Capl) taRNA. Capped and uncapped taRNAs were shipped to a contract manufacturer for production of SM102 LNPs as follows. 5’ppp taRNA (non-capped) and m7G (Capl) taRNA were separately mixed at a 1:2:1 ratio with vendor-synthesized (Genscript) m7G NP(NDV)-V(PIV5[N100D])-P(NDV) mRNA (vendor codon-optimized variant of SEQ ID NO:121) and m7G NDV Strain Ulster L mRNA (vendor codon-optimized variant of SEQ ID NO: 122) with 100% mlpsi substitution, and co-encapsulated in SM102 LNPs. FollowingISB-153.01WO Attorney Reference No. 9929-113741-02 dialysis into Tris-HCl pH 7.5 + 10% sucrose buffer, samples were frozen and stored at -80°C until subsequent use.
[0746] For in vivo mouse experiments, samples were thawed and immediately prepared for injection. lOug of non-capped and m7G Capl FLuc taRNA-LNPs were each separately injected either IV (retro-orbital), or via IM into the right hindlimb muscle of 4 NU / J mice (Jackson Labs) with a 29G insulin syringe. At 24h, mice were interperitoneally (IP) injected with 150mg / kg dose of D-Luciferin. Following anesthesia induction by isofluorane, mice were imaged at repeated intervals between 8-20 minutes postIP injection on an IVIS Spectrum bioluminescent imager. Imager was set to auto-expose capture with medium binning and F-stop of 1 with a ‘D’ field-of-view setting. A consistently-sized region-of-interest was defined to capture the peak photon flux (photons / second) of each mouse within the 8-20 minute postIP injection window. Mice were subjected to this same IP injection and imaging process at day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, and day 14. A subset of animals did not complete tire imaging protocol due to complications associated with anesthesia and imaging equipment during the procedure.
[0747] FIGS.25A025B shows representative images of the mice from m7G (Capl) and 5’ppp Flue taRNA-LNP IM groups from each day of bioluminescent imaging. FIG.25C shows the mean photon flux (ph / s) of the defined ROI in mice in the m7G (Capl) and 5’ppp Flue taRNA-LNP IM groups. Bars indicate range of individual mouse ROI flux values. Also indicated is the average background luminescence of 4 control NU / J IP-injected with 150mg / kg D-Luciferin, imaged on day 1. As can be seen, both formulations produced detectable bioluminescent signal at the injection site over multiple days, with tire m7G (Capl) Flue taRNA-LNP IM group exhibiting increased magnitude and duration of expression relative to tire 5’ppp group, and signals remaining above background levels throughout the observation period of 2 weeks allowed by tire IACUC approved protocol. These observations support embodiments in which IM administration results in sustained expression for at least about 14 days following a single dose. In contrast, IV administration resulted in a majority of the luciferase expression localizing to the spleen by 24 hours, with signal diminishing by 48 hours (data not shown). These observations support embodiments in which IV administration results in preferential organ distribution, including spleen localization.
[0748] Example 13: LNP Preparation for Oral Delivery and Expression in Rats
[0749] To demonstrate the viability including embodiments directed to oral administration and gastrointestinal expression, in vivo delivery was performed in rat models. RNA payloads were engineered to encode Aka-luciferase encapsulated in SM102 LNPs formulated as either (a) 20 mM TRIS (pH 7.5) with 10% sucrose and encapsulated as a liquid in size 9h enteric capsules designed to dissolve at pH 5.5 and above (Evonik), or (b) 20 mM histidine (pH 6.5) with 10% sucrose and encapsulated as a freeze-dried powder in tire size 9h enteric capsules (Evonik). For dosing, three of the size 9h enteric capsules (Evonik) were administered to each rat via an oral gavage tube adapted for 9h capsule mounting attachedISB-153.01WO Attorney Reference No. 9929-113741-02 a syringe loaded with 0.25 mL of acetate buffer with 50 mM N-acetylcysteine (pH 4.5) to discharge the capsules from the gavage tube. The capsules contained approximately 8 pg of RNA per capsule for the lyophilized LNP formulations, or approximately 2 pg of RNA per capsule for the liquid LNP formulations.
[0750] More specifically, following template linearization by PCR, NDV AkaLuc taRNA (SEQ ID NO: 114) was synthesized using CleanScribe RNA polymerase (TriLink Biotechnologies) with 100% mlpsi substitution. Following DNase treatment and purification, taRNA was prepared as capped taRNA as described above in Example 12 and transferred to contract manufacturer GenScript for outsourced SM102 LNP encapsulation and production as follows. The 5’ m7G (Capl) taRNA was mixed at a 1:2:1 ratio with vendor-synthesized (Genscript) m7G NP(NDV)-V(PIV5[N100D])-P(NDV) mRNA (vendor codon-optimized variant of SEQ ID NO: 121) and m7G NDV Strain Ulster L mRNA (vendor codon-optimized variant of SEQ ID NO: 122) with 100% mlpsi substitution, and co-encapsulated in SM102 LNPs. LNPs were subsequently aliquoted and dialyzed into either 25mM Tris-HCl pH 7.5 + 10% sucrose buffer or 20mM Histidine pH 6.5 + 10% sucrose buffer, and frozen in aliquots at -80°C LNPs until later use. The LNPs dialyzed into histidine buffer were distributed in approximately 200ul aliquots in 2ml flatbottom glass serum vials, and subsequently lyophilized in a tray-style vacuum freeze-dryer.
[0751] Lyophilization cycle parameters were as follows:
[0752] 1. Annealing step -41°C (shelf) for 35 minutes, condenser and vacuum off
[0753] 2. Primary Drying Step #1: Ramp to -25°C (shelf) at 0.2°C / min, condenser: -72°C, vacuum: 100mTorr
[0754] 3. Primary Drying Step #2: Hold at -25°C (shelf) for 14 hours, condenser: -72°C, vacuum: 100mTorr
[0755] 4. Secondary Drying Step #1: Ramp to 20°C (shelf) at 0.18C / min, condenser: -72°C, vacuum: 100mTorr
[0756] 5. Secondary Drying Step #2: Hold at 20°C (shelf) for 8 hours, condenser: -72°C, vacuum: 100mTorr
[0757] The lyophilized LNPs in the 2ml flat-bottom glass serum vials were immediately crimp top sealed and stored at 4°C until later use.
[0758] Example 14: Capsule Loading, Oral Delivery and Expression in Rats
[0759] Evonik Eudracap® pre-clinical enteric size 9h capsules were used for oral delivery release of the RNA payload in the intestinal environment following gastric transit of the LNPs prepared in Example 13. These capsules are pre-coated gelatin dosage forms comprising an Eudragit® polymer designed to dissolve at pH greater than 5.5, thereby enabling release in the post-stomach gastrointestinal environment. For lyophilized taRNA-LNP formulations, the capsules were filled with approximately 8ISB-153.01WO Attorney Reference No. 9929-113741-02 gg of RNA payload per capsule unit and stored at 4°C prior to use. For liquid taRNA-LNP formulations, the internal capsule surface was swabbed with a thin layer of petroleum jelly to improve neutral aqueous payload resistance, followed by loading immediately prior to oral gavage with approximately 2 ug of RNA payload in liquid form. Lastly, to ensure consistent administration of both liquid and freeze dried formulations, each capsule was lightly coated with a thin layer of petroleum jelly to facilitate secure and reproducible seating within Instech FTPU-C9-85 capsule dosing tubes immediately prior to oral gavage.
[0760] For dosing, each rat received three of the size 9h capsules prepared as described above, containing either the freeze dried or liquid taRNA-LNPs. The capsules were administered following standard protocols and ejected from the dosing tube with a 250ul bolus of acetate buffer pH 4.5 with 50mM sodium N-acetyl-cysteine to prevent premature capsule polymer coating dissolution and assist intestinal mucus layer penetration. 2 rats received freeze dried AkaLuc taRNA-LNPs and 2 rats received liquid AkaLuc taRNA-LNPs. Control rats received no AkaLuc taRNA-LNP payload.
[0761] For imaging, each rat was interperitoneally injected with AkaLumine-HCl (TokeOni) at 25mg / kg at 24h after oral gavage. Rats were individually imaged for bioluminescence at repetitive intervals between 5-30 minutes post-IP injection in an IVIS Spectrum imager. Imager was set to auto-expose capture with medium binning and F-stop of 1 with a ‘D’ field-of-view setting. Rats were adjusted during imaging to capture different emission angles (e.g., see FIG.26, subpanels i and j). This imaging procedure was repeated on day 2, day 3, and day 4 post-oral gavage. For day 1 imaging, the control rat was on alfalfa-free chow (Teklad Global 2914). For day 2-4 imaging, the control rat was switched to a diet-matched animal (regular chow) to control for any potential food-related bioluminescence differential. The results for rats receiving freeze dried LNPs (rat #1 and rat #2) are depicted in FIG.26 (color scaled matched between images) and Table 23 (flux readings and ratios for regions of interest (ROIs) compared to skin background). Luciferase expression in rats receiving the liquid LNP capsules (rat # 3 and rat #4) showed no detectable signal above control background (data not shown).
[0762] As can be seen, FIG.26 shows bioluminescence indicative of luciferase expression in the perianal region of rat #2 on day 1, the cecum area of tire gut in rat #2 on day 2, and the cecum area of the gut in rat #1 and rat #2 by day 3. These observations are consistent with embodiments in which orally administered taRNA-LNP compositions achieve intracellular expression within gastrointestinal tissues. These results are also consistent with the ROI flux trends reported in Table 23. As shown in Table 23, the luciferase expression signal diminished by day 4 in rat #2, but was still detectable in rat #1 at the end of the approved duration of the protocol.
[0763] Table 23: Region of Interest (ROI) Flux Analysis
[0764]
[0765] ISB-153.01WO Attorney Reference No. 9929-113741-02
[0766]
[0767] Note for comparison to Table 23 that luciferase expression in the perianal region of rat #2 on day 1 exhibited a flux of 5.72E+04, the background a flux of 1.90E+04, and a perianal to background flux ratio of 3.01 that dissipated by day 2, possibly representing signal from goblet-cell-adjacent surface cells and mucus-trapped material.
[0768] Results from IM and oral administration of SM102 LNPs loaded with FLuc or AkaLuc taRNA, respectively, were shown to functionally express luciferase in muscle or GI compartment tissues until the end of the approved protocol (2 weeks for IM and 4 days for oral), indicating that expression persists for at least the duration of the protocol and may extend beyond.
[0769] It will be understood that while specific examples of suppliers and materials are provided, that equivalent suppliers and materials from other qualified sources may be employed without departing from the scope of the disclosure. Similarly, while the example illustrate a general process flow for research to pharmaceutical grade RNA nanoparticles, those skilled in the art will recognize that specific parameters, equipment configurations, and process steps may require optimization and adaptation depending on factors such as the chosen materials, desired product characteristics, scale of production, and specific requirements of the manufacturing process. Such modifications and adaptations are considered to be within the scope of the disclosure.
[0770] REFERENCES: each of the following references are hereby incorporated by reference in its entirety for all purposes.
[0771] Azizi, H., et al. (2024) Self-amplifying RNAs generated with the modified nucleotides 5-methylcytidine and 5 -methyluridine mediate strong expression and immunogenicity in vivo. NAR Molecular Medicine 1(2), ugae004, https: / / doi.org / 10.1093 / narmme / ugae004
[0772] Beissert, T., et al. (2017) Improvement of in vivo expression of genes delivered by self-amplifying RNA using vaccinia virus immune evasion proteins. Human Gene Therapy 28(12):1138-1146.ISB-153.01WO Attorney Reference No. 9929-113741-02 Blakney, A. K., et al. (2021) An Update on Self- Amplifying mRNA Vaccine Development. Vaccines 9(2):97. doi.org / 10.3390 / vaccines9020097
[0773] Bloom, K., et al. (2021). Self-amplifying RNA vaccines for infectious diseases. Gene Therapy 28(3- 4): 117-129. doi.org / 10.1038 / s41434-020-00204-y
[0774] Bukreyev, A., et al. (2006) Nonsegmented negative-strand viruses as vaccine vectors. Journal of Virology 80(21): 10293-10306.
[0775] Cassel WA, and Garrett RE. (1965) Newcastle disease virus as an antineoplastic agent. Cancer 18:863- 868. doi: 10.1002 / 1097-0142(196507)18:7<863::aid-cncr2820180714>3.0.co;2-v.
[0776] Cassel, W. A., et al. (1983) A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52:856-860.
[0777] Chen, Y., et al. (2024) Anticancer effect of the oncolytic Newcastle disease virus harboring the PTEN gene on glioblastoma. Oncology Letters 28(5):405. www.spandidos- publications.com / 10.3892 / ol.2024.14752
[0778] Chinsomboon, J., & Sriratana, T. (2014) Oncolytic Newcastle Disease Virus for cancer therapy: old challenges and new directions. OncoTargets and Therapy 7:2235-2248. PMC4241685
[0779] Cong, J., et al. (2023) Structure of the Newcastle Disease Virus L protein in complex with tetrameric phosphoprotein. Nature Communications 14(1): 1324.
[0780] Freeman, A. I., et al. (2006) Phase I / II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13:221-228.
[0781] Garcia-Sastre, A., and Palese, P. (1998) Recombinant Newcastle disease virus RNA expression systems and vaccines. US Patent 7,442,379 B2.
[0782] Garcia-Sastre, A., et al. (1998) Recombinant Newcastle disease virus as a vaccine vector. Journal of Virology 72(10):7888-7891.
[0783] Garcia-Sastre, A., and Palese, P. (2011) Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy. Journal of Clinical Oncology 29(15_suppl):2530-2530.
[0784] Harper, J., et al., (2020) A recombinant Newcastle disease virus expressing IL-12 has potent pre-clinical immunomodulatory and anti-tumor properties (abstract). In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020,80(16 Suppl): Abstract nr 6535.
[0785] Henderson, J. M., et al. (2021) Cap analogs improve mRNA stability and translation efficiency in mammalian systems. Molecular Therapy - Nucleic Acids 26:125-134.
[0786] https: / / doi. Org / 10.1016 / j.omtn.2021.07.016ISB-153.01WO Attorney Reference No. 9929-113741-02 Hoffmann, D., et al. (2024) Mammalian cell-derived Newcastle disease virus overcomes complement- mediated neutralization and shows promise in pancreatic cancer therapy. Molecular Therapy- Oncolytics. doi.org / 10.1016 / j.omto.2024.100789
[0787] Huberts, M., et al. (2025) Cell-derived Newcastle disease virus variant with two amino acid substitutions near cleavage site of F shows favorable traits as oncolytic virus. Molecular Therapy-Oncolytics 33(l):200915. oi.org / 10.1016 / j.omton.2024.200915
[0788] Karika, K., et al. (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy 16(11): 1833- 1840.
[0789] Kariko, K., et al. (2011) Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Research, 39(21), el42. https: / / doi.org / 10.1093 / nar / gkr695
[0790] Kulkami, J. A., et al. (2018) The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 13, 709-723. https: / / doi.org / 10.1038 / s41565-018-0195-y
[0791] Kunitomi, A., et al. (2022) Improved Sendai viral system for reprogramming to naive pluripotency. Cell Reports Methods 2(11).
[0792] Lauber, C., & Gorbalenya, A. E. (2012) Toward genetics-based virus taxonomy: Comparative analysis of a genetics-based classification and the ICTV classification of RNA viruses. Journal of Virology 86(7):3905-3915. doi.org / 10.1128 / JVI.07149-l 1
[0793] Li, Y., et al. (2025) Advances in preclinical and clinical studies of oncolytic virus combination therapy.
[0794] Frontiers in Oncology 15:1545542.
[0795] Liu, X., et al. (2022) Expression of Fc-Fusion Proteins by Newcastle Disease Virus: A Novel Approach for Immunotherapy. Springer. Retrieved from link.springer.com
[0796] Lundstrom, K. (2025) Self-amplifying RNA virus vectors for drug delivery. Expert Opinion on Drug Delivery 22(2): 181-195. doi.org / 10.1080 / 17425247.2024.2445675
[0797] Maier, M. A., et al. (2013). Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Molecular Therapy, 21(8), 1570-1578. https: / / doi.org / 10.1038 / mt.2013.124
[0798] Marcos, F., et al. (2005) Mapping of the RNA promoter of Newcastle disease virus. Virology 331(2):396-406.
[0799] Najmuddin, S., et al. (2023) A mini-review on oncolytic Newcastle Disease Virus (NDV): From highly contagious virus to a biological tool for cancer therapy. The Open Biotechnology Journal.
[0800]
[0801] ISB-153.01WO Attorney Reference No. 9929-113741-02 Nakaya, T., et al. (2001) Recombinant Newcastle disease virus as a vaccine vector. Journal of Virology 75(23):11868-11873.
[0802] Ogino, T., & Green, T. J. (2019) RNA synthesis and capping by nonsegmented negative strand RNA viral polymerases: lessons from a prototypic virus. Frontiers in microbiology 10:1490.
[0803] Ouizougun-Oubari, M., & Fearns, R. (2023) Structures and mechanisms of nonsegmented, negativestrand RNA virus polymerases. Annual Review of Virology 10(1): 199-215.
[0804] Park, M. S., et al. (2003) Newcastle disease virus V protein is a determinant of host range restriction.
[0805] Journal of Virology 77(17):9522-9532.
[0806] Pardi, N., et al. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17, 261-279. https: / / doi.org / 10.1038 / nrd.2017.243
[0807] Pattani, A., et al. (2022) Mechanistic understanding of lipid nanoparticle delivery of mRNA vaccines.
[0808] Nature Reviews Bioengineering, 1, 51-65. https: / / doi.org / 10.1038 / s44222-022-00006-l Pecora, A. L„ et al. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20:2251-2266.
[0809] Pekos, A., et al. (1999) Reverse genetics of negative-strand RNA viruses: Closing the circle. Proceedings of the National Academy of Sciences 96:8804-8806.
[0810] Romer-Oberdorfer, A., et al. (1999) Generation of recombinant lentogenic Newcastle disease virus from cDNA. Journal of General Virology 80:2987-2995.
[0811] Sahin, U., et al. (2014) mRNA-based therapeutics — developing a new class of drugs. Nature Reviews Drug Discovery, 13, 759-780. https: / / doi.org / 10.1038 / nrd4278
[0812] Schirrmacher, V. (2016) Fifty years of clinical application of Newcastle disease virus: Time to celebrate! Molecular Therapy 24(6): 1053-1055. doi.org / 10.1038 / mt.2016.108
[0813] Schnell, M. J. (2001) Viral vectors as potential HIV-1 vaccines. FEMS Microbiology Letters 200(2): 123- 129.
[0814] Singh, M., & Billeter, M. A. (1999) A recombinant measles virus expressing biologically active human interleukin- 12. Journal of General Virology 80:101-106.
[0815] Solodushko, V., et al. (2023) Terminal hairpins improve protein expression in IRES-initiated mRNA in the absence of a cap and polyadenylated tail. Gene Ther 30, 620-627 (2023). https: / / doi.org / 10.1038 / s41434-023-00391-4
[0816] Sun, W., et al. (2020) Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine 62.ISB-153.01WO Attorney Reference No. 9929-113741-02 Sun, W., et al. (2020) Newcastle disease virus vectors as novel vaccines. Vaccines 8(4):673.
[0817] doi.org / 10.3390 / vaccines8040673
[0818] Thess, A., et al. (2015) Sequence-engineered mRNA without modified nucleosides improves stability and translational efficiency in vivo. Molecular Therapy 23(9): 1456-1464. https: / / doi.org / 10.1038 / mt.2015.103
[0819] Vanluchene, H., et al. (2023) Alphavirus replicase-induced translational shutdown. Molecular Therapy- Nucleic Acids 32:481-493. doi.org / 10.1016 / j.omtn.2023.01.007
[0820] Vanluchene, H., et al. (2024) Less is more: Self-amplifying mRNA becomes self-killing upon dose escalation in immune-competent retinal cells. European Journal of Pharmaceutics and Biopharmaceutics 196:114204.
[0821] Vigil, A., et al. (2008) Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy.
[0822] Molecular Therapy 16(ll):1883-1890. doi.org / 10.1038 / mt.2008.181
[0823] Vigil, A., et al., (2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67(17):8285-8292. doi: 10.1158 / 0008-5472. CAN-07-1025.
[0824] Whalen, R. G. (1998) DNA vaccines for infectious diseases, allergies and cancer. In: Eibl, M. M., Huber, C., Peter, H. H., Wahn, U. (Eds.), Symposium in Immunology VII (pp. 172-184). Springer, Berlin, Heidelberg, doi.org / 10.1007 / 978-3-642-80466-3_14
[0825] Yildiz, A., et al. (2024) Trans-amplifying RNA: a journey from alphavirus research to future vaccines.
[0826] Viruses 16(4):503. doi.org / 10.3390 / vl6040503
[0827] Zamarin D., et al. (2009) Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 16(6):796-804. doi: 10.1038 / gt.2009.14.
[0828] Zamarin, D., & Palese, P. (2012) Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future microbiology, 7(3), 347-367.
[0829] Zamarin, D., et al. (2019) Newcastle Disease Virus-Based Immunotherapy: Targeting Tumor Immunosuppression and Enhancing Anti-Tumor Responses. Journal of Virology. Retrieved from journals.asm.org
[0830] Zamarin, D., Palese, P., & Wolchok, J. D. (2012) Intratumoral oncolytic Newcastle disease virus administration induces local and systemic antitumor effects. Molecular Therapy 20(6): 1071-1080. doi.org / 10.1038 / mt.2012.22
[0831] Zhang, Y., et al. (2024) Recombinant Newcastle disease virus expressing al,3GT elicits effective antitumor immunity in patients with advanced cancers. Cell. doi.org / 10.1016 / j.cell.2024.03.005ISB-153.01WO Attorney Reference No. 9929-113741-02 Zhao H, et al. (2008) Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Virus Res. 136(1 -2):75-80. doi:
[0832] 10.1016 / j.virusres.2008.04.020.
[0833] Zhao, H., et al. (2003) Recombinant Newcastle disease virus as a viral vector: Effect of genomic location of foreign gene on gene expression and virus replication. Journal of General Virology 84:781-788. doi.org / 10.1099 / vir.0.18884-0
[0834] Zhao, J., et al. (2022) Newcastle Disease Virus Expressing VEGF-Trap Inhibits Tumor Growth by Suppressing Angiogenesis. PLOS ONE. Retrieved fromjournals.plos.org
[0835] Zhong, L., et al. (2024) Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell 188(4): 1119-1136.e23. doi.org / 10.1016 / j.cell.2024.12.010 Zimmer, G. (2010) RNA replicons-a new approach for influenza virus immunoprophylaxis. Viruses 2(2):413-434.
[0836] In view of the many possible embodiments to which tire principles of tire disclosure may be applied, it should be recognized that the illustrated embodiments are only examples and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
Claims
ISB-153.01WO Attorney Reference No. 9929-113741-02CLAIMSWe claim:
1. A composition, comprising:non-viral nanoparticle delivery vehicle encapsulating naked RNA, the naked RNA comprising: (a) positive-sense RNA encoding RNA-dependent RNA polymerase L (RdRp L) protein and nucleoprotein N and virus phosphoprotein P derived from nonsegmented negative-sense RNA virus and under control of a ribosome recruitment element; and(b) positive- or negative-sense RNA encoding one or more non-viral therapeutic polypeptides under control of a subgenomic promoter for tire RdRp L;wherein the RdRp L, N, and P proteins and the one or more non-viral therapeutic polypeptides are each individually encoded on tire same or different RNA molecules, with the proviso drat when on the same molecule, the RNA is positive-sense and contained in the same non-viral nanoparticle delivery vehicle.
2. The composition of claim 1, wherein one or more of the RdRp L, N, and P proteins and the one or more non-viral therapeutic polypeptides are encoded on separate RNA molecules.
3. The composition of claim 1, wherein tire RdRp L, N, and P proteins and the one or more non-viral therapeutic polypeptides are encoded on the same RNA molecule.
4. The composition of claim 1, wherein the subgenomic promoter for the RdRp L is derived from the same nonsegmented negative-sense RNA virus as the RdRp L.
5. The composition of claim 1, wherein when the RdRp L, N, and P protein and the one or more non-viral therapeutic polypeptides are encoded on:separate RNA molecules, the ribosome recruitment element is selected from: (i) a 5 ’-capping group in combination with a eukaryotic 5 ’-untranslated region (5’-UTR); or (ii) a 5’ or internal ribosomal entry site (IRES) element; orthe same RNA molecule, the ribosome recruitment element is selected from: (i) a 5 ’-capping group in combination with a eukaryotic 5’-UTR; (ii) a 5’-capping group in combination with a subgenomic promoter, and preferably the first subgenomic promoter, of the nonsegmented negative-ISB-153.01WO Attorney Reference No. 9929-113741-02 sense RNA virus; or (iii) a 5’ or internal IRES element alone or in combination with a 5’capping group and / or a subgenomic promoter.
6. The composition of claim 5, wherein the 5 ’-capping group is an m7G ribonucleotide selected from m7G-ppp-AG, m7G-ppp-AC, m7G-ppp-AU, or an analog thereof.
7. The composition of claim 5, wherein the IRES is a Class II IRES, such as a Class II IRES derived from encephalomyocarditis virus (ECMV).
8. The composition of claim 5, wherein the RdRp L and the non-viral therapeutic polypeptide are encoded on the same RNA molecule, tire encapsulated RNA has a 5’ end that is native or modified, and tire native 5’ end is 5’-ACCA, and wherein the modified 5’ end is selected from 5’m7G-ACCA, 5’m7G-A(G / U)CA, 5’m7G-A(G / U)NNNACCA, and 5’m7G-A(G / U)NNNNACCA, wherein N is any ribonucleotide compatible with replication initiated by the RdRp, and wherein m7G is a 7-methylguanosine or analog capping group.
9. The composition of claim 5, wherein the nonsegmented negative-sense RNA virus is a paramyxovirus, and wherein the encapsulated RNA conforms to the hexamer rule.
10. The composition of claim 1, wherein tire encapsulated RNA of (a), (b), or a combination of (a) and (b), contains pseudo-ribonucleotide incorporated into tire naked RNA.
11. The composition of claim 10, wherein the pseudo-ribonucleotide is Nl-methyl-pseudouridine.
12. The composition of claim 1, wherein the encapsulated RNA encoding the RdRp L comprises a 5’-terminus, a 3’-termnus, or both a 5’- and 3’-terminus modified with an exonuclease-resistant group capable of suppressing exonuclease degradation of the RNA, the exonuclease-resistant group selected from a 5’-terminal ribonucleotide capping group or analog thereof, a 5’-terminal hairpin, a 3’-terminal hairpin, a 3’-poly-A tail, or a combination thereof.ISB-153.01WO Attorney Reference No. 9929-113741-02 13. The composition of claim 12, wherein the 5’- and 3’-terminus are each independently modified with an exonuclease-resistant group, and wherein the 5’-terminus is modified with an m7G-5’-capping group or analog thereof, and wherein the 3 ’-terminus is modified with one or more exonuclease-resistant 3 ’-terminal hairpins or a poly- A tail.
14. The composition of claim 12, wherein the exonuclease-resistant group comprises (i) one or more exonuclease-resistant hairpins on the 5’-terminus, the 3’-terminus, or both the 5’-terminus and the 3’-terminus, and (ii) an internal ribosomal entry site (IRES) located 3’ of the 5’-terminus.
15. The composition of claim 1, wherein the encapsulated RNA comprises a non-viral Kozak sequence operably linked 3’ of a promoter and 5’ of a gene of interest for enhancing translation of the gene of interest, such as a viral N, P, or RdRp L protein or the non-viral therapeutic protein.
16. The composition of claim 1, wherein the nonsegmented negative-sense RNA virus is a paramyxovirus selected from Paramyxoviridae.
17. The composition of claim 16, wherein virus-derived elements of the encapsulated RNA are derived essentially from a paramyxovirus genome.
18. The composition of claim 17, wherein the paramyxovirus genome is selected from Avulavirus, Respirovirus, or Rubulavirus.
19. The composition of claim 18, wherein the paramyxovirus genome of (i) Avulavirus is New Castle Disease virus (NDV), (ii) Respirovirus is selected from Sendai virus (SEV, or Murine Respiro virus), parainfluenza virus hPIVl and hPIV3, and (iii) Rubulavirus is selected from parainfluenza virus hPIV2, hPIV4, and PIV5, and mumps virus MuV.
20. The composition of claim 19, wherein the paramyxovirus genome is selected from NDV, PIV5, or a combination thereof.ISB-153.01WO Attorney Reference No. 9929-113741-02 21. The composition of claim 1, wherein the RdRp L, the nucleoprotein N, and the phosphoprotein P, are encoded by the same RNA virus species, such as Newcastle Disease virus (NDV), and optionally strain matched.
22. The composition of claim 1, wherein the encapsulated RNA further encodes an interferon suppressor.
23. The composition of claim 22, wherein the interferon suppressor is a paramyxovirus-derived immune evasion protein V.
24. The composition of claim 23, where the V protein is selected from Newcastle disease virus (NDV), parainfluenza virus PIV5, and measles virus.
25. The composition of claim 1, wherein tire encapsulated RNA encodes two or more viral non-structural proteins separated by a ribosome skipping peptide sequence.
26. The composition of claim 25, wherein the ribosome skipping peptide sequence is T2A.
27. The composition of claim 1, wherein the non-viral nanoparticle delivery vehicle is selected from lipid-based nanoparticles, polymer-based nanoparticles, inorganic nanoparticles, and hybrid lipidpolymer nanoparticles.
28. The composition of claim 1, wherein the non-viral nanoparticle delivery vehicle is isolated and purified, and pharmaceutical grade.
29. The composition of claim 1, wherein the non-viral therapeutic polypeptide is selected from single chain, multi-subunit, secreted, non-secreted, and membrane anchored polypeptides.ISB-153.01WO Attorney Reference No. 9929-113741-02 30. The composition of claim 29, wherein the non- viral therapeutic polypeptide is selected from antibodies, fusion proteins, enzymes, hormones, growth factors, blood products, coagulation factors, cell surface and tissue biomarkers, toxins, venoms, and derivatives thereof.
31. The composition of claim 30, wherein the non- viral therapeutic polypeptide is selected from Fc-fusion proteins and antibodies.
32. The composition of claim 31, wherein the antibody comprises light and heavy chain subunits, and wherein the RNA encoding the light chain subunit is positioned upstream of the RNA encoding the heavy chain subunit.
33. The composition of claim 29, wherein the encapsulated RNA encodes two or more non- viral therapeutic polypeptides each independently regulated by its own subgenomic promoter.
34. The composition of claim 29, wherein the non-viral therapeutic polypeptide comprises, or is selected from etanercept (SEQ ID NO. 4), cemiplimab (SEQ ID NOs. 5 and 6), adalimumab (SEQ ID NOs. 7 and 8, or SEQ ID NO:94 and 95), erythropoietin (SEQ ID NO. 9), granulocyte colony stimulating factor (SEQ ID NO. 10), ustekinumab (SEQ ID NOs. 11 and 12, or SEQ ID NO: 100 and 101), hyaluronidase (SEQ ID NO. 13), dulaglutide (SEQ ID NO. 14), exenatide (SEQ ID NO. 15), fuzeon (SEQ ID NO. 16), denosumab (SEQ ID NOs. 17 and 18), hCEACAM5-hCD3 di-scFv BiTE (SEQ ID NO. 19), COVID19 A:02:01 TCR-(a-CD3 + B) BiTE (SEQ ID NOs. 20 and 21), gamma-delta (52-CD3 + y9) BiTE (SEQ ID NOs. 22 and 23), pembrolizumab (SEQ ID NOs. 24 and 25), CEACAM5-TM-scFv (SEQ ID NO. 27), CA19-TM-scFv (SEQ ID NO. 28), CD19-TM-scFv (SEQ ID NO. 29), CEACAM5-TM-scFv-(T2A)-PDLl-CD3 di-scFv BiTE (SEQ ID NO. 30), PDL1-CD3 BiTE (SEQ ID NO. 31), colorectal cancer neoantigen vaccine (HLA-A*ll:01) (SEQ ID NO. 32), FGF21 (L98R, P171G, A180E) (SEQ ID NO: 96), GLP1 (7-37) (A8G) (SEQ ID NO: 97), GLP1 (7-37) (A8G) (SEQ ID NO: 98), GLP2 (SEQ ID NO:99), or derivatives thereof.
35. The composition of claim 29, where the non-viral therapeutic polypeptide comprises a neprilysin cleavage site for activating or deactivating the polypeptide.ISB-153.01WO Attorney Reference No. 9929-113741-02 36. A composition, comprising:naked RNA having, and comprising:(a) positive-sense RNA encoding RNA-dependent RNA polymerase L (RdRp L) protein and accessory nucleoprotein N and phosphoprotein P derived from nonsegmented negative-sense RNA virus and under control of a ribosome recruitment element; and(b) positive- or negative-sense RNA encoding one or more non- viral polypeptides under control of a subgenomic promoter for the RdRp L;wherein the RdRp L, N, and P proteins and the one or more non- viral polypeptides are each individually encoded on the same or different RNA molecules, with the proviso that when on the same molecule, the RNA is positive-sense; andwherein the RNA comprises 5' and 3’ ends, and one or more additional modifications comprising, or selected from:(i) one or more pseudo-ribonucleotides, such as pseudouridine, Nl-methyl- pseudouridine, 5-methoxyuridine, 5-methylcytidine, 5-hydroxymethylcytidine, or methyluridine, incorporated in the RNA encoding (a), (b), or a combination of (a) and (b);(ii) one or more ribosome skipping elements operably linking one or more genes encoding the N, P, and RdRp L proteins, and optionally, non-viral therapeutic polypeptides;(iii) an internal ribosomal entry site (IRES) element, or a m7G-ribonucleotide or analog capping group, at the 5' end of the positive-sense RNA, and optionally, an exonuclease resistant group, such as one or more hair-pins or a poly-A tail, at tire 3’ end of the positive-sense RNA; and (iv) a m7G-ribonucleotide or analog capping group at tire 5’ end of the positive- or negative-sense RNA encoding the one or more non-viral polypeptides; and(v) any combination of (i), (ii), (iii) and (iv).
37. The composition of claim 36, further comprising an immune evasion protein V gene of a nonsegmented negative- sense RNA virus, and wherein the V gene is operably linked to one or more of the N, P and RdRp L genes through a ribosome skipping element.
38. The composition of claim 36 or 37, wherein the ribosome skipping element is T2A (Thosea asigna virus 2 A).ISB-153.01WO Attorney Reference No. 9929-113741-02 39. The composition of claim 37, wherein the N, V, P and RdRp L genes are each independently present or absent on a given positive sense RNA molecule, and when present, are operably linked in any position XI through X4 in die 5’ to 3’ direction of the formula 5’-W-Xl-Yl-X2-Y2-X3-Y3-X4-Z-3’, wherein:(a) W is a 7mG ribonucleotide or analog capping group or contains an IRES group;(b) XI through X4 are each individually present or absent, with the proviso that at least two of the N, V, P and L genes are present;(c) Y 1 through Y3 are each individually a ribosome skipping element that is present or absent, with the proviso that at least one ribosome skipping element is present; and(d) Z is present or absent, and when present, is one or more genes of interest encoding the one or more non- viral polypeptides.
40. The composition of claim 39, wherein the RdRp L gene is encoded on a first positive sense RNA molecule, and tire N, V and P genes are encoded on a second positive-sense RNA molecule and operably linked through at least one ribosome skipping element.
41. The composition of claim 39, wherein the RdRp L gene is encoded on a first positive sense RNA molecule, and tire N and P genes are encoded on a second positive-sense RNA molecule and operably linked through the ribosome skipping element.
42. The composition of claim 39 or claim 40, wherein Z is encoded on a separate negative-sense RNA molecule.
43. The composition of claim 36, wherein the naked RNA comprises a combination of the modifications comprising Nl-methyl-pseudouridinylation, one or more ribosome skipping elements operably linking one or more genes encoding the N, P, RdRp L, and non-viral polypeptides, an IRES element, or an m7G-ribonucleotide or analog capping group, at the 5’ end of tire positive-sense RNA, and exonuclease resistant group at tire 3’end.
44. The composition of claim 36, wherein the non-viral polypeptide is selected from a therapeutic, and a biomarker.ISB-153.01WO Attorney Reference No. 9929-113741-0245. A composition comprising a positive-sense RNA molecule encoding a viral RNA-dependent RNA polymerase protein (RdRp) derived from either positive-sense or negative-sense RNA virus, wherein the RNA molecule encoding the RdRp comprises a 5’ end, a 3’ end, or both a 5’end and a 3’ end modified with one or more exonuclease-resistant hairpins.
46. The composition of claim 45, wherein the RNA molecule encoding the RdRp further comprises an internal ribosomal entry site (IRES) for initiating translation.
47. The composition of claim 45, wherein the RNA molecule comprises pseudo-ribonucleotides.
48. The composition of claim 36 or claim 45, wherein the RNA virus is Newcastle Disease virus.
49. The composition of claim 36 or claim 45, wherein the RNA is encapsulated in non-viral nanoparticle delivery vehicle.
50. A method of treatment, comprising:administering to a subject in need thereof a composition according to any of the preceding claims.
51. The method of claim 50, wherein the composition is formulated for intramuscular', intravenous, or oral administration.
52. A method of producing a trans-amplifying RNA (taRNA), the method comprising:(a) providing a DNA template comprising a sequence encoding a nonsegmented negative-sense RNA virus-derived trans-amplifying RNA and operably linked to a T7 RNA polymerase promoter of Class II;(b) linearizing the DNA template; and(c) synthesizing tire taRNA by in vitro transcription using T7 RNA polymerase, optionally in the presence of modified nucleotides comprising N1 -methylpseudouridine (ml'P),ISB-153.01WO Attorney Reference No. 9929-113741-02 thereby producing a taRNA suitable for expression in a host cell.
53. The method of claim 52, wherein the T7 RNA polymerase promoter comprises a phi2.5 promoter.
54. The method of claim 52, wherein tire taRNA is synthesized with about 80% to 100% substitution of uridine with ml'P.
55. The method of claim 52, further comprising combining the taRNA with one or more RNA molecules encoding viral replication proteins selected from N, P, V, and L proteins of a nonsegmented negative-sense RNA virus.
56. The method of claim 55, further comprising encapsulating tire taRNA in a lipid nanoparticle.
57. The method of claim 52, wherein the DNA template further comprises a ribozyme sequence operably linked to the 3’ end of the taRNA configured to generate a defined 3’ terminus of the taRNA upon autocatalytic cleavage following in vitro transcription.
58. The method of claim 57, wherein the ribozyme comprises a hepatitis delta virus (HDV) ribozyme.
59. The method of claim 58, wherein the HDV ribozyme is selected from an antigenomic HDV ribozyme, a genomic HDV ribozyme, a minimal HDV ribozyme variant, and a Twister ribozyme.
60. The method of claim 57, wherein tire ribozyme autocatalytic cleavage generates a 2’,3’-cyclic phosphate at the 3’ end of the taRNA, and optionally, a 5’ hydroxyl at the 5’ end of the taRNA.
61. A composition comprising an RNA molecule having 5’ and 3’ ends, the RNA molecule comprising (a) a 2’,3’-cyclic phosphate at tire 3’ end of the RNA, and (b) one or more pseudo-ISB-153.01WO Attorney Reference No. 9929-113741-02 ribonucleotides incorporated into the RNA, such as pseudouridine, Nl-methyl-pseudouridine, 5-methoxyuridine, 5 -methylcytidine, 5-hydroxymethylcytidine, or methyluridine.
62. The composition of claim 61, comprised in a non- viral nanoparticle delivery vehicle encapsulating:(a) positive-sense RNA encoding RNA-dependent RNA polymerase L (RdRp L) protein and nucleoprotein N and virus phosphoprotein P derived from nonsegmented negative-sense RNA virus and under control of a ribosome recruitment element; and(b) positive- or negative-sense RNA encoding one or more non- viral polypeptides under control of a subgenomic promoter for the RdRp L;wherein the RdRp L, N, and P proteins and the one or more non- viral polypeptides are each individually encoded on the same or different RNA molecules, with the proviso that when on the same molecule, the RNA is positive-sense, and wherein the RNA molecule comprising the 2’,3’-cyclic phosphate at the 3’ end encodes the one or more non-viral polypeptides.
63. The composition of claim 1, 36, or 61, wherein (a) tire RNA encoding the viral proteins are paramyxoviridae N, V, P and RdRp L proteins, (b) the N, V, and P proteins are encoded by a first RNA molecule, the RdRp L protein is encoded by a second RNA molecule, and the one or more non-viral therapeutic polypeptides is encoded by a third RNA molecule, and (c) the first, second, and third RNA molecules are provided in the composition at a mass ratio of about 2:1:1, respectively.
64. The composition of claim 1, 36, or 61, wherein the viral protein comprises, or is selected from Nucleoprotein (N) NDV Strain Ulster (SEQ ID NO:33), Phosphoprotein (P) NDV Strain Ulster (SEQ ID NO: 34), RNA-dependent RNA Polymerase (L) NDV Strain Bl (SEQ ID NO: 35), Interferon-Suppressor (V) Measles Strain Ichinose-B95A (SEQ ID NO:36), Nucleoprotein (N) SeV Strain Ohita (SEQ ID NO: 37), Phosphoprotein (P) SeV Strain Ohita (SEQ ID NO:38), RNA-dependent RNA Polymerase (L) SeV Strain Ohita (SEQ ID NO:39), Nucleoprotein (N) PIV5 Strain W3A (SEQ ID NO:40), Phosphoprotein (P) PIV5 Strain W3A (SEQ ID NO:41), Interferon-Suppressor (V) PIV5 Strain W3A (SEQ ID NO:42), RNA-dependent RNA Polymerase (L) PIV5 Strain W3A (SEQ ID NO:43), Nucleoprotein (N) NDV Strain LaSota (SEQ ID NO:44), Phosphoprotein (P) NDV Strain LaSota (SEQ ID NO:45), RNA-dependent RNA Polymerase (L) NDV Strain LaSota (SEQ ID NO:46), Interferon-Suppressor (V) NDV Strain LaSota (SEQ ID NO: 104), Interferon-Suppressor (V) PIV5 Strain W3A (N100D) (SEQ ID NO: 105), RNA-dependent RNA Polymerase (L) NDV Strain Ulster (SEQ ID NO: 105), or derivatives thereof.ISB-153.01WO Attorney Reference No. 9929-113741-0265. The composition of claim 1, 36, or 61, wherein the RNA comprises, or is selected from mEGFP + tagBFP2 + mCherry (SEQ ID NO:48), Etanercept (SEQ ID NO:49), Cemiplimab LC + HC (SEQ ID NO:50), Adalimumab LC + HC (SEQ ID NO:51), Erythropoietin (SEQ ID NO:52), GCSF (SEQ ID NO:53), Ustekinumab LC + HC + Hyaluronidase (SEQ ID NO:54), Dulaglutide (SEQ ID NO:55), Exenatide (SEQ ID NO:56), Fuzeon (SEQ ID NO:57), Denosumab LC + HC (SEQ ID NO:58), hCEACAM5-hCD3 di-scFv BiTE (SEQ ID NO:59), COVID19 A*02:01 TCR BiTE (a-CD3 + B) (SEQ ID NO:60), Gamma Delta BiTE (52-CD3 + y9) (SEQ ID NO:61), Pembrolizumab LC + HC (SEQ ID NO:62), PDL1-CD3 di-scFv BiTE (SEQ ID NO:63), Colorectal Cancer Neoantigen Vaccine (HLA-A*ll:01 Targeted), neoantigens KRAS G12D, PIK3CA E545K, TP53 R248Q, BRAF V600E, FBXW7 R479Q (SEQ ID NO:64), Adalimumab LC + HC (Alternate Signal Sequence) (SEQ ID NO: 107), Ustekinumab LC + HC (SEQ ID NQ:108), FGF21 (L98R, P171G, A180E) + GLP1 [7-37] (A8G) (SEQ ID NO:109), FGF21 (L98R, P171G, A180E) + GLP1 [7-37] (A8G) (SEQ ID NQ:110), GLP2 (A8G) (SEQ ID NO:111), F-Luc (SEQ ID NO:112), F-Luc (Capped) (SEQ ID NO:113), AkaLuciferase (Capped) (SEQ ID NO: 114), mScarlet3 (Capped) (SEQ ID NO: 115), Flag-tagged Albumin (Capped) (SEQ ID NO:116), mEGFP (SEQ ID NO:117), mEGFP (Capped) (SEQ ID NO:118), and mEGFP (Ribozyme) (SEQ ID NO: 119), 5’UTR-N(NDV)-T2A-V(Measles)-T2A-P(NDV)-3'UTR-polyA (SEQ ID NO:65), 5'UTR-L(NDV)-3’UTR-polyA (SEQ ID NO:66), 5'UTR-N(NDV)-T2A-V(Measles)-T2A-P(NDV)-T2A-L(NDV)-3'UTR-polyA (SEQ ID NO:67), 5'Hairpin-IRES-N(NDV)-T2A-V(Measles)-T2A-P(NDV)-3'Hairpin (SEQ ID NO:68), 5'Hairpin-IRES-N(NDV)-T2A-V(Measles)-T2A-P (NDV)-T2A-L (NDV)-3'Hairpin (SEQ ID NO:69), 5'UTR-N(NDV)-T2A-V(PIV5)-T2A-P(NDV)-3'UTR-polyA (SEQ ID NO: 120), 5'UTR-N(NDV)-T2A-V(PIV5[N100D])-T2A-P(NDV)-3'UTR-polyA (SEQ ID NO: 121), 5'UTR-L(NDV Ulster)-3'UTR-polyA (SEQ ID NO: 122), Adalimumab LC + HC (AC) (SEQ ID NOVO), Adalimumab LC + HC (AG) (SEQ ID NO:71), Adalimumab LC + HC (AU) (SEQ ID NO:72), Adalimumab LC + HC (AG Pentamer) (SEQ ID NO:73), Adalimumab LC + HC (AG Hexamer) (SEQ ID NO:74), Adalimumab LC + HC (IRES-driven) (SEQ ID NO:75), Firefly Luciferase (SEQ ID NO:76), CEACAM5 scFv (Transmembrane Anchored) (SEQ ID NO:77), CA-19 scFv (SEQ ID NO:78), CD19 scFv (Transmembrane Anchored) (SEQ ID NO:79), CEACAM5 TM-scFv - T2A - PDL1-CD3 di-scFv BiTE (SEQ ID NQ:80), CA-19 TM-scFv + PDL1-CD3 di-scFv BiTE (SEQ ID NO:81), CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (AC) (SEQ ID NO:82), CEACAM5 TM-scFv -T2A - PDLL CD3 di-scFv BiTE (AG) (SEQ ID NO:83), CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (AU) (SEQ ID NO:84), CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (AG Pentamer) (SEQ ID NO:85), CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (AG Hexamer) (SEQ ID NO:86), CEACAM5 TM-scFv -T2A- PDL1-CD3 di-scFv BiTE (IRES-driven) (SEQ ID NO:87), Adalimumab LC + HC (SEQ ID NO:88), Human Parainfluenza Virus 5 [PIV5] - Adalimumab LC + HC (SEQ ID NO:89), Human Parainfluenza Virus 5 [PIV5] - mEGFP (SEQ ID NO: 123), Murine Respirovirus (Sendai Virus) [SeV] - mEGFP (SEQ ID NO: 124), 5’UTR-N(SeV)-T2A-V(Measles)-T2A-P(SeV)-3'UTR-polyA (SEQISB-153.01WO Attorney Reference No. 9929-113741-02 ID NO:90), 5'UTR-L(SeV)-3'UTR-polyA (SEQ ID NO:91), 5'UTR-N(PIV5)-T2A-V(PIV5)-T2A- P(PIV5)-3'UTR-polyA (SEQ ID NO:92), 5’UTR-L(PIV5)-3’UTR-polyA (SEQ ID NO:93), and derivatives thereof.
